drug1_db
stringlengths 7
7
| drug2_db
stringlengths 7
7
| drug1_id
int64 0
1.71k
| drug2_id
int64 1
1.71k
| drug1_name
stringlengths 4
31
| drug2_name
stringlengths 4
31
| drug1_desc
stringlengths 27
1.09k
⌀ | drug2_desc
stringlengths 27
1.06k
⌀ | label
stringlengths 58
191
| label_idx
int64 0
85
| all_paths
listlengths 1
10
| all_paths_str
listlengths 1
10
| path_str
stringlengths 0
2.58k
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|
DB01365
|
DB00752
| 707 | 63 |
Mephentermine
|
Tranylcypromine
|
A sympathomimetic agent with mainly indirect effects on adrenergic receptors. It is used to maintain blood pressure in hypotensive states, for example, following spinal anesthesia. Although the central stimulant effects of mephentermine are much less than those of amphetamine, its use may lead to amphetamine-type dependence. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1248)
|
A propylamine formed from the cyclization of the side chain of amphetamine. This monoamine oxidase inhibitor is effective in the treatment of major depression, dysthymic disorder, and atypical depression. It also is useful in panic and phobic disorders (From AMA Drug Evaluations Annual, 1994, p311). Tranylcypromine is a racemate comprising equal amounts of (1R,2S)- and (1S,2R)-2-phenylcyclopropan-1-amine with the chiral centers both located on the cylopropane ring. An irreversible monoamine oxidase inhibitor that is used as an antidepressant (INN tranylcypromine).
|
Mephentermine may increase the hypertensive activities of Tranylcypromine.
| 70 |
[
[
[
707,
93,
63
]
],
[
[
707,
155,
1298
],
[
1298,
155,
63
]
],
[
[
707,
83,
915
],
[
915,
225,
63
]
],
[
[
707,
93,
53
],
[
53,
225,
63
]
],
[
[
707,
1,
151
],
[
151,
69,
63
]
],
[
[
707,
155,
16933
],
[
16933,
1,
63
]
],
[
[
707,
225,
712
],
[
712,
225,
63
]
],
[
[
707,
225,
1464
],
[
1464,
1,
63
]
],
[
[
707,
1,
34
],
[
34,
155,
63
]
],
[
[
707,
98,
41
],
[
41,
24,
63
]
]
] |
[
[
[
"Mephentermine",
"{u} may increase the hypertensive activities of {v}",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Dextroamphetamine"
],
[
"Dextroamphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} may decrease the stimulatory activities of {v}",
"Fencamfamin"
],
[
"Fencamfamin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} may increase the hypertensive activities of {v}",
"Phenelzine"
],
[
"Phenelzine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Phenol"
],
[
"Phenol",
"{u} (Compound) resembles {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenylpropanolamine"
],
[
"Phenylpropanolamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenmetrazine"
],
[
"Phenmetrazine",
"{u} (Compound) resembles {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Amphetamine"
],
[
"Amphetamine",
"{u} (Compound) resembles {v} (Compound)",
"Tranylcypromine"
]
],
[
[
"Mephentermine",
"{u} may decrease the sedative activities of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may increase the anticholinergic activities of {v}",
"Tranylcypromine"
]
]
] |
Mephentermine (Compound) resembles Dextroamphetamine (Compound) and Dextroamphetamine (Compound) resembles Tranylcypromine (Compound)
Mephentermine may decrease the stimulatory activities of Fencamfamin and Fencamfamin may increase the severity of adverse effects when combined with Tranylcypromine
Mephentermine may increase the hypertensive activities of Phenelzine and Phenelzine may increase the severity of adverse effects when combined with Tranylcypromine
Mephentermine (Compound) resembles Benzyl alcohol (Compound) and Benzyl alcohol may decrease the metabolism of Tranylcypromine
Mephentermine (Compound) resembles Phenol (Compound) and Phenol (Compound) resembles Tranylcypromine (Compound)
Mephentermine may increase the severity of adverse effects when combined with Phenylpropanolamine and Phenylpropanolamine may increase the severity of adverse effects when combined with Tranylcypromine
Mephentermine may increase the severity of adverse effects when combined with Phenmetrazine and Phenmetrazine (Compound) resembles Tranylcypromine (Compound)
Mephentermine (Compound) resembles Amphetamine (Compound) and Amphetamine (Compound) resembles Tranylcypromine (Compound)
Mephentermine may decrease the sedative activities of Clemastine and Clemastine may increase the anticholinergic activities of Tranylcypromine
|
DB00373
|
DB00472
| 647 | 394 |
Timolol
|
Fluoxetine
|
Timolol is a nonselective beta-adrenergic antagonist given in an eye drop solution to reduce intraocular pressure, or pressure in the eyes. It is also used in tablet form as a drug to treat hypertension. Timolol was first approved by the FDA in 1978. This drug is marketed by several manufacturers and is an effective agent for the management of conditions such as open-angle glaucoma and hypertension.
|
Fluoxetine is a 2nd generation antidepressant categorized as a selective serotonin reuptake inhibitor (SSRI). It gained FDA approval in 1987 and although it was initially intended for the treatment of depression, today it is commonly prescribed to manage depression in addition to various other pathologies.
|
The metabolism of Fluoxetine can be decreased when combined with Timolol.
| 46 |
[
[
[
647,
69,
394
]
],
[
[
647,
69,
547
],
[
547,
223,
394
]
],
[
[
647,
71,
733
],
[
733,
1,
394
]
],
[
[
647,
52,
828
],
[
828,
95,
394
]
],
[
[
647,
6,
10999
],
[
10999,
160,
394
]
],
[
[
647,
21,
28384
],
[
28384,
175,
394
]
],
[
[
647,
69,
173
],
[
173,
26,
394
]
],
[
[
647,
180,
147
],
[
147,
26,
394
]
],
[
[
647,
236,
161
],
[
161,
26,
394
]
],
[
[
647,
251,
177
],
[
177,
26,
394
]
]
] |
[
[
[
"Timolol",
"{u} may decrease the metabolism of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may decrease the metabolism of {v}",
"Cinacalcet"
],
[
"Cinacalcet",
"{u} may decrease the metabolism of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoxsuprine"
],
[
"Isoxsuprine",
"{u} (Compound) resembles {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the serum concentration of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may decrease the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may increase the hypotensive activities of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fluoxetine"
]
],
[
[
"Timolol",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Fluoxetine"
]
]
] |
Timolol may decrease the metabolism of Cinacalcet and Cinacalcet may decrease the metabolism of Fluoxetine
Timolol may increase the severity of adverse effects when combined with Isoxsuprine and Isoxsuprine (Compound) resembles Fluoxetine (Compound)
Timolol may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the serum concentration of Fluoxetine
Timolol (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Fluoxetine (Compound)
Timolol (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Fluoxetine (Compound)
Timolol may decrease the metabolism of Nevirapine and Nevirapine can increase the metabolism of Fluoxetine
Timolol can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Fluoxetine
Timolol may increase the hypotensive activities of Primidone and Primidone can increase the metabolism of Fluoxetine
Timolol may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Fluoxetine
|
DB01421
|
DB09216
| 904 | 449 |
Paromomycin
|
Tolfenamic acid
|
An oligosaccharide antibiotic produced by various streptomyces. [PubChem]
|
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.
|
Paromomycin may decrease the excretion rate of Tolfenamic acid which could result in a higher serum level.
| 71 |
[
[
[
904,
94,
449
]
],
[
[
904,
94,
687
],
[
687,
28,
449
]
],
[
[
904,
225,
894
],
[
894,
205,
449
]
],
[
[
904,
200,
1343
],
[
1343,
225,
449
]
],
[
[
904,
94,
628
],
[
628,
71,
449
]
],
[
[
904,
79,
1151
],
[
1151,
71,
449
]
],
[
[
904,
94,
789
],
[
789,
225,
449
]
],
[
[
904,
94,
798
],
[
798,
79,
449
]
],
[
[
904,
233,
198
],
[
198,
79,
449
]
],
[
[
904,
155,
902
],
[
902,
94,
449
]
]
] |
[
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may increase the hypocalcemic activities of {v}",
"Clodronic acid"
],
[
"Clodronic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Suprofen"
],
[
"Suprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may increase the nephrotoxic activities of {v}",
"Amphotericin B"
],
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Benzydamine"
],
[
"Benzydamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may decrease the excretion rate {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the nephrotoxic activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} may increase the nephrotoxic activities of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Paromomycin",
"{u} (Compound) resembles {v} (Compound)",
"Arbekacin"
],
[
"Arbekacin",
"{u} may decrease the excretion rate {v}",
"Tolfenamic acid"
]
]
] |
Paromomycin may decrease the excretion rate Nafamostat and Nafamostat may increase the anticoagulant activities of Tolfenamic acid
Paromomycin may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Tolfenamic acid
Paromomycin may increase the hypocalcemic activities of Clodronic acid and Clodronic acid may increase the severity of adverse effects when combined with Tolfenamic acid
Paromomycin may decrease the excretion rate Suprofen and Suprofen may increase the severity of adverse effects when combined with Tolfenamic acid
Paromomycin may increase the nephrotoxic activities of Amphotericin B and Amphotericin B may increase the severity of adverse effects when combined with Tolfenamic acid
Paromomycin may decrease the excretion rate Benzydamine and Benzydamine may increase the severity of adverse effects when combined with Tolfenamic acid
Paromomycin may decrease the excretion rate Balsalazide and Balsalazide may increase the nephrotoxic activities of Tolfenamic acid
Paromomycin may increase the nephrotoxic activities of Cyclosporine and Cyclosporine may increase the nephrotoxic activities of Tolfenamic acid
Paromomycin (Compound) resembles Arbekacin (Compound) and Arbekacin may decrease the excretion rate Tolfenamic acid
|
DB01355
|
DB01158
| 298 | 1,044 |
Hexobarbital
|
Bretylium
|
A barbiturate that is effective as a hypnotic and sedative.
|
Bretylium blocks the release of noradrenaline from the peripheral sympathetic nervous system, and is used in emergency medicine, cardiology, and other specialties for the acute management of ventricular tachycardia and ventricular fibrillation. The primary mode of action for bretylium is thought to be inhibition of voltage-gated K(+) channels. Recent evidence has shown that bretylium may also inhibit the Na,K-ATPase by binding to the extracellular K-site.
|
Hexobarbital may increase the hypotensive activities of Bretylium.
| 59 |
[
[
[
298,
82,
1044
]
],
[
[
298,
69,
615
],
[
615,
32,
1044
]
],
[
[
298,
38,
702
],
[
702,
32,
1044
]
],
[
[
298,
82,
662
],
[
662,
225,
1044
]
],
[
[
298,
225,
214
],
[
214,
71,
1044
]
],
[
[
298,
82,
315
],
[
315,
71,
1044
]
],
[
[
298,
71,
975
],
[
975,
71,
1044
]
],
[
[
298,
69,
227
],
[
227,
71,
1044
]
],
[
[
298,
26,
146
],
[
146,
71,
1044
]
],
[
[
298,
225,
955
],
[
955,
225,
1044
]
]
] |
[
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Clevidipine"
],
[
"Clevidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
],
[
"Levobupivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Enalapril"
],
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
],
[
"Tolcapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} can increase the metabolism of {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bretylium"
]
]
] |
Hexobarbital may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Bretylium
Hexobarbital may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Bretylium
Hexobarbital may increase the hypotensive activities of Clevidipine and Clevidipine may increase the severity of adverse effects when combined with Bretylium
Hexobarbital may increase the severity of adverse effects when combined with Levobupivacaine and Levobupivacaine may increase the severity of adverse effects when combined with Bretylium
Hexobarbital may increase the hypotensive activities of Enalapril and Enalapril may increase the severity of adverse effects when combined with Bretylium
Hexobarbital may increase the severity of adverse effects when combined with Tolcapone and Tolcapone may increase the severity of adverse effects when combined with Bretylium
Hexobarbital may decrease the metabolism of Bortezomib and Bortezomib may increase the severity of adverse effects when combined with Bretylium
Hexobarbital can increase the metabolism of Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Bretylium
Hexobarbital may increase the severity of adverse effects when combined with Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Bretylium
|
DB04839
|
DB06216
| 1,224 | 494 |
Cyproterone acetate
|
Asenapine
|
An anti-androgen that, in the form of its acetate (cyproterone acetate), also has progestational properties. It is used in the treatment of hypersexuality in males, as a palliative in prostatic carcinoma, and, in combination with estrogen, for the therapy of severe acne and hirsutism in females.
|
Developed by Schering-Plough after its merger with Organon International, asenapine is a sublingually administered, atypical antipsychotic for treatment of schizophrenia and acute mania associated with bipolar disorder. Asenapine also belongs to the dibenzo-oxepino pyrrole class. It is also for severe post-traumatic stress disorder nightmares in soldiers as an off-label use. FDA approved on August 13, 2009.
|
The serum concentration of Asenapine can be decreased when it is combined with Cyproterone acetate.
| 74 |
[
[
[
1224,
97,
494
]
],
[
[
1224,
21,
28769
],
[
28769,
175,
494
]
],
[
[
1224,
97,
156
],
[
156,
26,
494
]
],
[
[
1224,
246,
587
],
[
587,
38,
494
]
],
[
[
1224,
97,
543
],
[
543,
38,
494
]
],
[
[
1224,
97,
987
],
[
987,
196,
494
]
],
[
[
1224,
97,
471
],
[
471,
208,
494
]
],
[
[
1224,
97,
370
],
[
370,
55,
494
]
],
[
[
1224,
97,
528
],
[
528,
223,
494
]
],
[
[
1224,
249,
267
],
[
267,
223,
494
]
]
] |
[
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} (Compound) causes {v} (Side Effect)",
"Loss of consciousness"
],
[
"Loss of consciousness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the therapeutic efficacy of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Maprotiline"
],
[
"Maprotiline",
"{u} may increase the QTc prolonging activities of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Domperidone"
],
[
"Domperidone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may decrease the serum concentration of {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may decrease the metabolism of {v}",
"Asenapine"
]
],
[
[
"Cyproterone acetate",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Asenapine"
]
]
] |
Cyproterone acetate (Compound) causes Loss of consciousness (Side Effect) and Loss of consciousness (Side Effect) is caused by Asenapine (Compound)
Cyproterone acetate may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Asenapine
Cyproterone acetate may decrease the therapeutic efficacy of Ethanol and Ethanol may increase the central nervous system depressant activities of Asenapine
Cyproterone acetate may decrease the serum concentration of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Asenapine
Cyproterone acetate may decrease the serum concentration of Maprotiline and Maprotiline may increase the QTc prolonging activities of Asenapine
Cyproterone acetate may decrease the serum concentration of Rotigotine and Rotigotine may increase the sedative activities of Asenapine
Cyproterone acetate may decrease the serum concentration of Domperidone and Domperidone may increase the severity of QTc prolonging effects when combined with Asenapine
Cyproterone acetate may decrease the serum concentration of Telithromycin and Telithromycin may decrease the metabolism of Asenapine
Cyproterone acetate may increase the serum concentration of Lovastatin and Lovastatin may decrease the metabolism of Asenapine
|
DB01355
|
DB00325
| 298 | 1,050 |
Hexobarbital
|
Nitroprusside
|
A barbiturate that is effective as a hypnotic and sedative.
|
Nitroprusside serves as a source of nitric oxide, a potent peripheral vasodilator that affects both arterioles and venules (venules more than arterioles). Nitroprusside is often administered intravenously to patients who are experiencing a hypertensive emergency.
|
Hexobarbital may increase the hypotensive activities of Nitroprusside.
| 59 |
[
[
[
298,
82,
1050
]
],
[
[
298,
6,
12128
],
[
12128,
160,
1050
]
],
[
[
298,
69,
615
],
[
615,
32,
1050
]
],
[
[
298,
38,
702
],
[
702,
32,
1050
]
],
[
[
298,
82,
1357
],
[
1357,
225,
1050
]
],
[
[
298,
82,
1361
],
[
1361,
71,
1050
]
],
[
[
298,
54,
1365
],
[
1365,
71,
1050
]
],
[
[
298,
38,
1265
],
[
1265,
71,
1050
]
],
[
[
298,
225,
354
],
[
354,
71,
1050
]
],
[
[
298,
52,
183
],
[
183,
225,
1050
]
]
] |
[
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP1A2"
],
[
"CYP1A2",
"{u} (Gene) is bound by {v} (Compound)",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the antihypertensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Diclofenamide"
],
[
"Diclofenamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the hypotensive activities of {v}",
"Levosimendan"
],
[
"Levosimendan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
],
[
[
"Hexobarbital",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroprusside"
]
]
] |
Hexobarbital (Compound) binds CYP1A2 (Gene) and CYP1A2 (Gene) is bound by Nitroprusside (Compound)
Hexobarbital may decrease the metabolism of Sildenafil and Sildenafil may increase the antihypertensive activities of Nitroprusside
Hexobarbital may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Nitroprusside
Hexobarbital may increase the hypotensive activities of Diclofenamide and Diclofenamide may increase the severity of adverse effects when combined with Nitroprusside
Hexobarbital may increase the hypotensive activities of Levosimendan and Levosimendan may increase the severity of adverse effects when combined with Nitroprusside
Hexobarbital may increase the sedative activities of Pramipexole and Pramipexole may increase the severity of adverse effects when combined with Nitroprusside
Hexobarbital may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the severity of adverse effects when combined with Nitroprusside
Hexobarbital may increase the severity of adverse effects when combined with Sevoflurane and Sevoflurane may increase the severity of adverse effects when combined with Nitroprusside
Hexobarbital may increase the orthostatic hypotensive activities of Indapamide and Indapamide may increase the severity of adverse effects when combined with Nitroprusside
|
DB01551
|
DB00196
| 184 | 1,076 |
Dihydrocodeine
|
Fluconazole
|
Dihydrocodeine is an opioid analgesic used as an alternative or adjunct to codeine to treat moderate to severe pain, severe dyspnea, and cough. It is semi-synthetic, and was developed in Germany in 1908 during an international search to find a more effective antitussive agent to help reduce the spread of airborne infectious diseases such as tuburculosis. It was marketed in 1911.
|
Fluconazole, commonly known as _Diflucan_, is an antifungal drug used for the treatment of both systemic and superficial fungal infections in a variety of tissues. It was initially approved by the FDA in 1990. This drug is an _azole_ antifungal, in the same drug family as [ketoconazole] and [itraconazole]. Fluconazole has many advantages over the other antifungal drugs including the option of oral administration. The side effect profile of this drug is minimal. It has been demonstrated as an efficacious treatment for vaginal yeast infections in one single dose.
|
The metabolism of Fluconazole can be decreased when combined with Dihydrocodeine.
| 46 |
[
[
[
184,
69,
1076
]
],
[
[
184,
69,
657
],
[
657,
155,
1076
]
],
[
[
184,
6,
4590
],
[
4590,
160,
1076
]
],
[
[
184,
21,
28408
],
[
28408,
175,
1076
]
],
[
[
184,
225,
1007
],
[
1007,
42,
1076
]
],
[
[
184,
240,
324
],
[
324,
42,
1076
]
],
[
[
184,
69,
1091
],
[
1091,
42,
1076
]
],
[
[
184,
71,
956
],
[
956,
42,
1076
]
],
[
[
184,
95,
1324
],
[
1324,
42,
1076
]
],
[
[
184,
95,
1019
],
[
1019,
196,
1076
]
]
] |
[
[
[
"Dihydrocodeine",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may decrease the metabolism of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} (Compound) resembles {v} (Compound)",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} (Compound) causes {v} (Side Effect)",
"Convulsion"
],
[
"Convulsion",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the serotonergic activities of {v}",
"Escitalopram"
],
[
"Escitalopram",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may decrease the metabolism of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
],
[
[
"Dihydrocodeine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Fluconazole"
]
]
] |
Dihydrocodeine may decrease the metabolism of Voriconazole and Voriconazole (Compound) resembles Fluconazole (Compound)
Dihydrocodeine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Fluconazole (Compound)
Dihydrocodeine (Compound) causes Convulsion (Side Effect) and Convulsion (Side Effect) is caused by Fluconazole (Compound)
Dihydrocodeine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Fluconazole
Dihydrocodeine may increase the serotonergic activities of Escitalopram and Escitalopram may increase the QTc prolonging activities of Fluconazole
Dihydrocodeine may decrease the metabolism of Dronedarone and Dronedarone may increase the QTc prolonging activities of Fluconazole
Dihydrocodeine may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Fluconazole
Dihydrocodeine may increase the serum concentration of Ceritinib and Ceritinib may increase the QTc prolonging activities of Fluconazole
Dihydrocodeine may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Fluconazole
|
DB09224
|
DB00323
| 988 | 975 |
Melperone
|
Tolcapone
|
Melperone is an atypical antipsychotic of the butyrophenone chemical class, making it structurally related to the typical antipsychotic haloperidol. Melperone has been used for a span of greater than 30 years in the European Union. It has been well established in the treatment of confusion, anxiety, restlessness (particularly in the elderly) and schizophrenia as It is known to be well-tolerated with an excellent safety profile. Recently, it has been studied as a treatment of psychosis related to Parkinson's disease.
|
Tolcapone is a drug that inhibits the enzyme catechol-O-methyl transferase (COMT). It is used in the treatment of Parkinson's disease as an adjunct to levodopa/carbidopa medication. It is a yellow, odorless, non-hygroscopic, crystalline compound. Tolcapone is associated with a risk of hepatotoxicity.
|
The risk or severity of adverse effects can be increased when Melperone is combined with Tolcapone.
| 48 |
[
[
[
988,
71,
975
]
],
[
[
988,
184,
674
],
[
674,
30,
975
]
],
[
[
988,
192,
543
],
[
543,
38,
975
]
],
[
[
988,
38,
702
],
[
702,
192,
975
]
],
[
[
988,
54,
1365
],
[
1365,
208,
975
]
],
[
[
988,
225,
1439
],
[
1439,
71,
975
]
],
[
[
988,
71,
941
],
[
941,
225,
975
]
],
[
[
988,
225,
878
],
[
878,
225,
975
]
],
[
[
988,
71,
996
],
[
996,
71,
975
]
],
[
[
988,
92,
247
],
[
247,
71,
975
]
]
] |
[
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rufinamide"
],
[
"Rufinamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
],
[
"Clidinium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Propoxycaine"
],
[
"Propoxycaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
],
[
[
"Melperone",
"{u} may decrease the therapeutic efficacy of {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolcapone"
]
]
] |
Melperone can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Tolcapone
Melperone may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Tolcapone
Melperone may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Tolcapone
Melperone may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Tolcapone
Melperone may increase the severity of adverse effects when combined with Rufinamide and Rufinamide may increase the severity of adverse effects when combined with Tolcapone
Melperone may increase the severity of adverse effects when combined with Clidinium and Clidinium may increase the severity of adverse effects when combined with Tolcapone
Melperone may increase the severity of adverse effects when combined with Paroxetine and Paroxetine may increase the severity of adverse effects when combined with Tolcapone
Melperone may increase the severity of adverse effects when combined with Propoxycaine and Propoxycaine may increase the severity of adverse effects when combined with Tolcapone
Melperone may decrease the therapeutic efficacy of Bromocriptine and Bromocriptine may increase the severity of adverse effects when combined with Tolcapone
|
DB00298
|
DB13323
| 933 | 927 |
Dapiprazole
|
Trichloroethylene
|
Dapiprazole (U.S. trade name Rev-Eyes) is an alpha blocker. It is found in ophthalmic solutions used to reverse mydriasis after an eye examination.
|
Trichloroethylene is a halocarbon commonly used as an industrial solvent, not to be confused with the similar 1,1,1-trichloroethane, also known as chlorothene. It has been sold under a variety of trade names including Trimar and Trilene and used as a volatile anesthetic and as an inhaled obstetrical analgesic. Environmental exposure, particularly groundwater and drinking water contamination from industrial discharge, is a major concern for human health and has been the subject of numerous incidents and lawsuits.
|
The risk or severity of adverse effects can be increased when Dapiprazole is combined with Trichloroethylene.
| 48 |
[
[
[
933,
71,
927
]
],
[
[
933,
184,
674
],
[
674,
30,
927
]
],
[
[
933,
192,
587
],
[
587,
38,
927
]
],
[
[
933,
38,
405
],
[
405,
192,
927
]
],
[
[
933,
54,
1046
],
[
1046,
208,
927
]
],
[
[
933,
71,
639
],
[
639,
71,
927
]
],
[
[
933,
225,
156
],
[
156,
71,
927
]
],
[
[
933,
71,
965
],
[
965,
225,
927
]
],
[
[
933,
212,
980
],
[
980,
71,
927
]
],
[
[
933,
211,
997
],
[
997,
71,
927
]
]
] |
[
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valproic acid"
],
[
"Valproic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the severity of adverse effects when combined with {v}",
"Entacapone"
],
[
"Entacapone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the antipsychotic activities of {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
],
[
[
"Dapiprazole",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trichloroethylene"
]
]
] |
Dapiprazole can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Trichloroethylene
Dapiprazole may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Trichloroethylene
Dapiprazole may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Trichloroethylene
Dapiprazole may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Trichloroethylene
Dapiprazole may increase the severity of adverse effects when combined with Valproic acid and Valproic acid may increase the severity of adverse effects when combined with Trichloroethylene
Dapiprazole may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine may increase the severity of adverse effects when combined with Trichloroethylene
Dapiprazole may increase the severity of adverse effects when combined with Entacapone and Entacapone may increase the severity of adverse effects when combined with Trichloroethylene
Dapiprazole may increase the antipsychotic activities of Amisulpride and Amisulpride may increase the severity of adverse effects when combined with Trichloroethylene
Dapiprazole may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the severity of adverse effects when combined with Trichloroethylene
|
DB00216
|
DB00908
| 558 | 59 |
Eletriptan
|
Quinidine
|
Eletriptan is a second generation triptan drug developed by Pfizer Inc for the treatment of migraine headaches.
|
Quinidine is a D-isomer of [quinine] present in the bark of the Cinchona tree and similar plant species. This alkaloid was first described in 1848 and has a long history as an antiarrhythmic medication.[A38016,A250050] Quinidine is considered the first antiarrhythmic drug (class Ia) and is moderately efficacious in the acute conversion of atrial fibrillation to normal sinus rhythm. It prolongs cellular action potential by blocking sodium and potassium currents. A phenomenon known as “quinidine syncope” was first described in the 1950s, characterized by syncopal attacks and ventricular fibrillation in patients treated with this drug. Due to its side effects and increased risk of mortality, the use of quinidine was reduced over the next few decades. However, it continues to be used in the treatment of Brugada syndrome, short QT syndrome and idiopathic ventricular fibrillation.
|
The metabolism of Quinidine can be decreased when combined with Eletriptan.
| 46 |
[
[
[
558,
69,
59
]
],
[
[
558,
69,
640
],
[
640,
1,
59
]
],
[
[
558,
6,
7128
],
[
7128,
160,
59
]
],
[
[
558,
21,
28671
],
[
28671,
175,
59
]
],
[
[
558,
71,
18
],
[
18,
24,
59
]
],
[
[
558,
180,
171
],
[
171,
26,
59
]
],
[
[
558,
95,
173
],
[
173,
26,
59
]
],
[
[
558,
71,
486
],
[
486,
196,
59
]
],
[
[
558,
69,
501
],
[
501,
196,
59
]
],
[
[
558,
95,
1079
],
[
1079,
196,
59
]
]
] |
[
[
[
"Eletriptan",
"{u} may decrease the metabolism of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may decrease the metabolism of {v}",
"Quinine"
],
[
"Quinine",
"{u} (Compound) resembles {v} (Compound)",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} (Compound) causes {v} (Side Effect)",
"Confusional state"
],
[
"Confusional state",
"{u} (Side Effect) is caused by {v} (Compound)",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the anticholinergic activities of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may decrease the metabolism of {v}",
"Saquinavir"
],
[
"Saquinavir",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
],
[
[
"Eletriptan",
"{u} may increase the serum concentration of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Quinidine"
]
]
] |
Eletriptan may decrease the metabolism of Quinine and Quinine (Compound) resembles Quinidine (Compound)
Eletriptan (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Quinidine (Compound)
Eletriptan (Compound) causes Confusional state (Side Effect) and Confusional state (Side Effect) is caused by Quinidine (Compound)
Eletriptan may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the anticholinergic activities of Quinidine
Eletriptan can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Quinidine
Eletriptan may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Quinidine
Eletriptan may increase the severity of adverse effects when combined with Doxepin and Doxepin may increase the QTc prolonging activities of Quinidine
Eletriptan may decrease the metabolism of Saquinavir and Saquinavir may increase the QTc prolonging activities of Quinidine
Eletriptan may increase the serum concentration of Crizotinib and Crizotinib may increase the QTc prolonging activities of Quinidine
|
DB01452
|
DB00852
| 1,012 | 718 |
Diamorphine
|
Pseudoephedrine
|
Diamorphine (heroin) is a narcotic analgesic that may be habit-forming. It is a controlled substance (opium derivative) listed in the U.S. Code of Federal Regulations, Title 21 Parts 329.1, 1308.11 (1987). Sale is forbidden in the United States by Federal statute. (Merck Index, 11th ed) Internationally, diamorphine is controlled under Schedules I and IV of the Single Convention on Narcotic Drugs. As heroin, it is illegal to manufacture, possess, or sell in the United States and the UK. However, under the name diamorphine, heroin is a legal prescription drug in the United Kingdom.
|
Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927.
|
Diamorphine may increase the analgesic activities of Pseudoephedrine.
| 68 |
[
[
[
1012,
91,
718
]
],
[
[
1012,
225,
916
],
[
916,
155,
718
]
],
[
[
1012,
91,
707
],
[
707,
71,
718
]
],
[
[
1012,
91,
1335
],
[
1335,
155,
718
]
],
[
[
1012,
71,
151
],
[
151,
155,
718
]
],
[
[
1012,
71,
224
],
[
224,
213,
718
]
],
[
[
1012,
225,
195
],
[
195,
213,
718
]
],
[
[
1012,
192,
543
],
[
543,
213,
718
]
],
[
[
1012,
71,
1269
],
[
1269,
223,
718
]
],
[
[
1012,
225,
200
],
[
200,
223,
718
]
]
] |
[
[
[
"Diamorphine",
"{u} may increase the analgesic activities of {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etomidate"
],
[
"Etomidate",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the analgesic activities of {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the analgesic activities of {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benzyl alcohol"
],
[
"Benzyl alcohol",
"{u} (Compound) resembles {v} (Compound)",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amoxapine"
],
[
"Amoxapine",
"{u} may decrease the antihypertensive activities of {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} may decrease the antihypertensive activities of {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may decrease the antihypertensive activities of {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may decrease the metabolism of {v}",
"Pseudoephedrine"
]
],
[
[
"Diamorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
],
[
"Cocaine",
"{u} may decrease the metabolism of {v}",
"Pseudoephedrine"
]
]
] |
Diamorphine may increase the severity of adverse effects when combined with Etomidate and Etomidate (Compound) resembles Pseudoephedrine (Compound)
Diamorphine may increase the analgesic activities of Mephentermine and Mephentermine may increase the severity of adverse effects when combined with Pseudoephedrine
Diamorphine may increase the analgesic activities of Phentermine and Phentermine (Compound) resembles Pseudoephedrine (Compound)
Diamorphine may increase the severity of adverse effects when combined with Benzyl alcohol and Benzyl alcohol (Compound) resembles Pseudoephedrine (Compound)
Diamorphine may increase the severity of adverse effects when combined with Amoxapine and Amoxapine may decrease the antihypertensive activities of Pseudoephedrine
Diamorphine may increase the severity of adverse effects when combined with Cyclobenzaprine and Cyclobenzaprine may decrease the antihypertensive activities of Pseudoephedrine
Diamorphine may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may decrease the antihypertensive activities of Pseudoephedrine
Diamorphine may increase the severity of adverse effects when combined with Stiripentol and Stiripentol may decrease the metabolism of Pseudoephedrine
Diamorphine may increase the severity of adverse effects when combined with Cocaine and Cocaine may decrease the metabolism of Pseudoephedrine
|
DB06725
|
DB00443
| 286 | 103 |
Lornoxicam
|
Betamethasone
|
Lornoxicam (chlortenoxicam) is a new nonsteroidal anti-inflammatory drug (NSAID) of the oxicam class with analgesic, anti-inflammatory and antipyretic properties. Lornoxicam differs from other oxicam compounds in its potent inhibition of prostaglandin biosynthesis, a property that explains the particularly pronounced efficacy of the drug. Lornoxicam is approved for use in Japan.
|
Betamethasone is a long-acting corticosteroid with immunosuppressive and antiinflammatory properties. It can be used topically to manage inflammatory skin conditions such as eczema, and parenterally to manage several disease states including autoimmune disorders. Betamethasone has potent glucocorticoid activity and negligible mineralocorticoid activity.
|
The risk or severity of adverse effects can be increased when Lornoxicam is combined with Betamethasone.
| 48 |
[
[
[
286,
71,
103
]
],
[
[
286,
71,
96
],
[
96,
155,
103
]
],
[
[
286,
71,
134
],
[
134,
1,
103
]
],
[
[
286,
6,
7784
],
[
7784,
160,
103
]
],
[
[
286,
225,
4
],
[
4,
71,
103
]
],
[
[
286,
49,
884
],
[
884,
225,
103
]
],
[
[
286,
233,
798
],
[
798,
71,
103
]
],
[
[
286,
71,
783
],
[
783,
71,
103
]
],
[
[
286,
270,
584
],
[
584,
71,
103
]
],
[
[
286,
182,
687
],
[
687,
71,
103
]
]
] |
[
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clocortolone"
],
[
"Clocortolone",
"{u} (Compound) resembles {v} (Compound)",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is bound by {v} (Compound)",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tiaprofenic acid"
],
[
"Tiaprofenic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the neuroexcitatory activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Droxicam"
],
[
"Droxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Tenoxicam"
],
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
],
[
[
"Lornoxicam",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betamethasone"
]
]
] |
Lornoxicam may increase the severity of adverse effects when combined with Methylprednisolone and Methylprednisolone (Compound) resembles Betamethasone (Compound)
Lornoxicam may increase the severity of adverse effects when combined with Clocortolone and Clocortolone (Compound) resembles Betamethasone (Compound)
Lornoxicam (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is bound by Betamethasone (Compound)
Lornoxicam may increase the severity of adverse effects when combined with Tiaprofenic acid and Tiaprofenic acid may increase the severity of adverse effects when combined with Betamethasone
Lornoxicam may increase the neuroexcitatory activities of Levofloxacin and Levofloxacin may increase the severity of adverse effects when combined with Betamethasone
Lornoxicam may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the severity of adverse effects when combined with Betamethasone
Lornoxicam may increase the severity of adverse effects when combined with Droxicam and Droxicam may increase the severity of adverse effects when combined with Betamethasone
Lornoxicam (Compound) resembles Tenoxicam (Compound) and Lornoxicam may increase the severity of adverse effects when combined with Tenoxicam and Tenoxicam may increase the severity of adverse effects when combined with Betamethasone
Lornoxicam may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Betamethasone
|
DB09285
|
DB01050
| 1,462 | 334 |
Morniflumate
|
Ibuprofen
|
Morniflumate is a non-steroidal anti-inflammatory drug with antipyretic properties. It is the morpholinoethyl ester of niflumic acid. In one study, post morniflumate ingestion, physical examination and clinical symptoms of those with bronchitis showed improvement.
|
Ibuprofen is a non-steroidal anti-inflammatory drug (NSAID) derived from propionic acid and it is considered the first of the propionics. The formula of ibuprofen is 2-(4-isobutylphenyl) propionic acid and its initial development was in 1960 while researching for a safer alternative for aspirin. Ibuprofen was finally patented in 1961 and this drug was first launched against rheumatoid arthritis in the UK in 1969 and USA in 1974. It was the first available over-the-counter NSAID. On the available products, ibuprofen is administered as a racemic mixture. Once administered, the R-enantiomer undergoes extensive interconversion to the S-enantiomer _in vivo_ by the activity of the alpha-methylacyl-CoA racemase. In particular, it is generally proposed that the S-enantiomer is capable of eliciting stronger pharmacological activity than
|
The risk or severity of adverse effects can be increased when Morniflumate is combined with Ibuprofen.
| 48 |
[
[
[
1462,
71,
334
]
],
[
[
1462,
71,
687
],
[
687,
28,
334
]
],
[
[
1462,
71,
582
],
[
582,
223,
334
]
],
[
[
1462,
71,
166
],
[
166,
225,
334
]
],
[
[
1462,
71,
460
],
[
460,
71,
334
]
],
[
[
1462,
71,
11
],
[
11,
116,
334
]
],
[
[
1462,
71,
687
],
[
687,
180,
156
],
[
156,
26,
334
]
],
[
[
1462,
71,
582
],
[
582,
213,
1034
],
[
1034,
1,
334
]
],
[
[
1462,
71,
742
],
[
742,
182,
677
],
[
677,
28,
334
]
],
[
[
1462,
71,
770
],
[
770,
225,
1034
],
[
1034,
1,
334
]
]
] |
[
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the metabolism of {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zaltoprofen"
],
[
"Zaltoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etodolac"
],
[
"Etodolac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
],
[
"Carprofen",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may decrease the antihypertensive activities of {v}",
"Esmolol"
],
[
"Esmolol",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clonixin"
],
[
"Clonixin",
"{u} may increase the anticoagulant activities of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Ibuprofen"
]
],
[
[
"Morniflumate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} (Compound) resembles {v} (Compound)",
"Ibuprofen"
]
]
] |
Morniflumate may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activities of Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may decrease the metabolism of Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Zaltoprofen and Zaltoprofen may increase the severity of adverse effects when combined with Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Etodolac and Etodolac may increase the severity of adverse effects when combined with Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Carprofen and Carprofen (Compound) resembles Ibuprofen (Compound) and Carprofen may increase the severity of adverse effects when combined with Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Nafamostat and Nafamostat can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may decrease the antihypertensive activities of Esmolol and Esmolol (Compound) resembles Ibuprofen (Compound)
Morniflumate may increase the severity of adverse effects when combined with Clonixin and Clonixin may increase the anticoagulant activities of Dabigatran etexilate and Dabigatran etexilate may increase the anticoagulant activities of Ibuprofen
Morniflumate may increase the severity of adverse effects when combined with Floctafenine and Floctafenine may increase the severity of adverse effects when combined with Esmolol and Esmolol (Compound) resembles Ibuprofen (Compound)
|
DB01169
|
DB00177
| 1,208 | 239 |
Arsenic trioxide
|
Valsartan
|
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
|
Valsartan belongs to the angiotensin II receptor blocker (ARB) family of drugs, which also includes [telmisartan], [candesartan], [losartan], [olmesartan], and [irbesartan]. ARBs selectively bind to angiotensin receptor 1 (AT1) and prevent the protein angiotensin II from binding and exerting its hypertensive effects, which include vasoconstriction, stimulation and synthesis of aldosterone and ADH, cardiac stimulation, and renal reabsorption of sodium, among others. Overall, valsartan's physiologic effects lead to reduced blood pressure, lower aldosterone levels, reduced cardiac activity, and increased excretion of sodium. Valsartan also affects the renin-angiotensin aldosterone system (RAAS), which plays an important role in hemostasis and regulation of kidney, vascular, and cardiac functions. Pharmacological blockade of RAAS via
|
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Valsartan.
| 48 |
[
[
[
1208,
71,
239
]
],
[
[
1208,
71,
1054
],
[
1054,
225,
239
]
],
[
[
1208,
236,
164
],
[
164,
26,
239
]
],
[
[
1208,
42,
154
],
[
154,
32,
239
]
],
[
[
1208,
71,
702
],
[
702,
32,
239
]
],
[
[
1208,
52,
828
],
[
828,
206,
239
]
],
[
[
1208,
42,
158
],
[
158,
223,
239
]
],
[
[
1208,
209,
394
],
[
394,
69,
239
]
],
[
[
1208,
92,
514
],
[
514,
69,
239
]
],
[
[
1208,
42,
296
],
[
296,
69,
239
]
]
] |
[
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may decrease the therapeutic efficacy of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Dolasetron"
],
[
"Dolasetron",
"{u} may decrease the metabolism of {v}",
"Valsartan"
]
]
] |
Arsenic trioxide may increase the severity of adverse effects when combined with Olmesartan and Olmesartan may increase the severity of adverse effects when combined with Valsartan
Arsenic trioxide may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Valsartan
Arsenic trioxide may increase the QTc prolonging activities of Vardenafil and Vardenafil may increase the antihypertensive activities of Valsartan
Arsenic trioxide may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Valsartan
Arsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Valsartan
Arsenic trioxide may increase the QTc prolonging activities of Nicardipine and Nicardipine may decrease the metabolism of Valsartan
Arsenic trioxide may increase the severity of QTc prolonging effects when combined with Fluoxetine and Fluoxetine may decrease the metabolism of Valsartan
Arsenic trioxide may decrease the therapeutic efficacy of Rosiglitazone and Rosiglitazone may decrease the metabolism of Valsartan
Arsenic trioxide may increase the QTc prolonging activities of Dolasetron and Dolasetron may decrease the metabolism of Valsartan
|
DB01424
|
DB00907
| 374 | 200 |
Aminophenazone
|
Cocaine
|
Aminophenazone is a pyrazolone with analgesic, anti-inflammatory, and antipyretic properties that carries a risk of agranulocytosis. In biomedical applications, radiolabelled (13C-labeled) aminophenazone has been used in breath tests to measure the cytochrome P-450 metabolic activity in liver function tests. The FDA suspended the use of aminophenazone due to its association with agranulocytosis, a life-threatening side effect.[A254242,L43942]
|
An alkaloid ester extracted from the leaves of plants including coca. It is a local anesthetic and vasoconstrictor and is clinically used for that purpose, particularly in the eye, ear, nose, and throat. It also has powerful central nervous system effects similar to the amphetamines and is a drug of abuse. Cocaine, like amphetamines, acts by multiple mechanisms on brain catecholaminergic neurons; the mechanism of its reinforcing effects is thought to involve inhibition of dopamine uptake.
|
The metabolism of Cocaine can be decreased when combined with Aminophenazone.
| 46 |
[
[
[
374,
69,
200
]
],
[
[
374,
6,
4590
],
[
4590,
160,
200
]
],
[
[
374,
180,
161
],
[
161,
26,
200
]
],
[
[
374,
69,
1086
],
[
1086,
223,
200
]
],
[
[
374,
69,
499
],
[
499,
69,
200
]
],
[
[
374,
95,
1095
],
[
1095,
223,
200
]
],
[
[
374,
1,
552
],
[
552,
225,
200
]
],
[
[
374,
69,
63
],
[
63,
71,
200
]
],
[
[
374,
69,
1108
],
[
1108,
225,
200
]
],
[
[
374,
95,
1394
],
[
1394,
249,
200
]
]
] |
[
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may increase the serum concentration of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may decrease the metabolism of {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} (Compound) resembles {v} (Compound)",
"Methsuximide"
],
[
"Methsuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may decrease the metabolism of {v}",
"Topiramate"
],
[
"Topiramate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cocaine"
]
],
[
[
"Aminophenazone",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may increase the serum concentration of {v}",
"Cocaine"
]
]
] |
Aminophenazone (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Cocaine (Compound)
Aminophenazone can increase the metabolism of Primidone and Primidone can increase the metabolism of Cocaine
Aminophenazone may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Cocaine
Aminophenazone may decrease the metabolism of Clomipramine and Clomipramine may decrease the metabolism of Cocaine
Aminophenazone may increase the serum concentration of Cobicistat and Cobicistat may decrease the metabolism of Cocaine
Aminophenazone (Compound) resembles Methsuximide (Compound) and Methsuximide may increase the severity of adverse effects when combined with Cocaine
Aminophenazone may decrease the metabolism of Tranylcypromine and Tranylcypromine may increase the severity of adverse effects when combined with Cocaine
Aminophenazone may decrease the metabolism of Topiramate and Topiramate may increase the severity of adverse effects when combined with Cocaine
Aminophenazone may increase the serum concentration of Palbociclib and Palbociclib may increase the serum concentration of Cocaine
|
DB00865
|
DB06152
| 149 | 701 |
Benzphetamine
|
Nylidrin
|
A sympathomimetic agent with properties similar to dextroamphetamine. It is used in the treatment of obesity. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1222)
|
Nylidrin, also known as _buphenine_ belongs to the category of drugs called _vasodilators_, which relax blood vessels and increase blood flow. Nylidrin is a peripheral vasodilator. Some studies show the evidence of improving cognitive impairment in selected individuals, such as geriatric patients with mild to moderate symptoms of cognitive, emotional and physical impairment. Nylidrin is utilized to treat several disorders that may benefit from increased blood flow (for example, certain mental disorders, blood vessel disease due to diabetes, frostbite, night leg cramps, and certain types of ulcers). This medication works by dilating (widening) blood vessels to help increase blood flow (improving circulation) throughout the body, including the extremities and central nervous system. This effect may help to improve memory/judgment, improve walking ability, and support the healing of frostbite/ulcers. FDA has considered nylidrin as "lacking
|
The risk or severity of adverse effects can be increased when Benzphetamine is combined with Nylidrin.
| 48 |
[
[
[
149,
71,
701
]
],
[
[
149,
225,
728
],
[
728,
71,
701
]
],
[
[
149,
71,
707
],
[
707,
71,
701
]
],
[
[
149,
71,
733
],
[
733,
225,
701
]
],
[
[
149,
47,
1026
],
[
1026,
71,
701
]
],
[
[
149,
93,
1451
],
[
1451,
247,
701
]
],
[
[
149,
59,
193
],
[
193,
107,
701
]
],
[
[
149,
261,
1261
],
[
1261,
107,
701
]
],
[
[
149,
225,
728
],
[
728,
181,
509
],
[
509,
27,
701
]
],
[
[
149,
71,
707
],
[
707,
181,
509
],
[
509,
27,
701
]
]
] |
[
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaraminol"
],
[
"Metaraminol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isoxsuprine"
],
[
"Isoxsuprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Acebutolol"
],
[
"Acebutolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the hypertensive activities of {v}",
"Linezolid"
],
[
"Linezolid",
"{u} may increase the hypertensive activities of {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may decrease the antihypertensive activities of {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may increase the tachycardic activities of {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the tachycardic activities of {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metaraminol"
],
[
"Metaraminol",
"{u} may decrease the vasoconstricting activities of {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Nylidrin"
]
],
[
[
"Benzphetamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} may decrease the vasoconstricting activities of {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Nylidrin"
]
]
] |
Benzphetamine may increase the severity of adverse effects when combined with Metaraminol and Metaraminol may increase the severity of adverse effects when combined with Nylidrin
Benzphetamine may increase the severity of adverse effects when combined with Mephentermine and Mephentermine may increase the severity of adverse effects when combined with Nylidrin
Benzphetamine may increase the severity of adverse effects when combined with Isoxsuprine and Isoxsuprine may increase the severity of adverse effects when combined with Nylidrin
Benzphetamine may increase the atrioventricular blocking activities of Acebutolol and Acebutolol may increase the severity of adverse effects when combined with Nylidrin
Benzphetamine may increase the hypertensive activities of Linezolid and Linezolid may increase the hypertensive activities of Nylidrin
Benzphetamine may decrease the antihypertensive activities of Levomilnacipran and Levomilnacipran may increase the tachycardic activities of Nylidrin
Benzphetamine may increase the tachycardic activities of Dronabinol and Dronabinol may increase the tachycardic activities of Nylidrin
Benzphetamine may increase the severity of adverse effects when combined with Metaraminol and Metaraminol may decrease the vasoconstricting activities of Tamsulosin and Tamsulosin may decrease the vasoconstricting activities of Nylidrin
Benzphetamine may increase the severity of adverse effects when combined with Mephentermine and Mephentermine may decrease the vasoconstricting activities of Tamsulosin and Tamsulosin may decrease the vasoconstricting activities of Nylidrin
|
DB09396
|
DB00254
| 325 | 755 |
Dextropropoxyphene
|
Doxycycline
|
Dextropropoxyphene is an opioid analgesic manufactured by Eli Lilly and Company. It is used in the symptomatic treatment of mild pain. It displays antitussive and local anaesthetic actions. Due to the risk of cardiac arrhythmias and overdose, possibly leading to death, dextropropoxyphene has been withdrawn from the market in Europe and the United States. The drug is often referred to as the general form, "propoxyphene", however only the dextro-isomer (dextropropoxyphene) has any analgesic effect. The levo-isomer appears to exhibit a very limited antitussive effect.
|
Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
|
The metabolism of Doxycycline can be decreased when combined with Dextropropoxyphene.
| 46 |
[
[
[
325,
69,
755
]
],
[
[
325,
69,
613
],
[
613,
69,
755
]
],
[
[
325,
95,
191
],
[
191,
69,
755
]
],
[
[
325,
180,
173
],
[
173,
69,
755
]
],
[
[
325,
99,
35
],
[
35,
69,
755
]
],
[
[
325,
251,
684
],
[
684,
69,
755
]
],
[
[
325,
249,
531
],
[
531,
69,
755
]
],
[
[
325,
249,
1240
],
[
1240,
95,
755
]
],
[
[
325,
69,
1085
],
[
1085,
95,
755
]
],
[
[
325,
251,
225
],
[
225,
95,
755
]
]
] |
[
[
[
"Dextropropoxyphene napsylate",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Fesoterodine"
],
[
"Fesoterodine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may decrease the serum concentration of {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may increase the serum concentration of {v}",
"Bosutinib"
],
[
"Bosutinib",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may decrease the metabolism of {v}",
"Olaparib"
],
[
"Olaparib",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Dextropropoxyphene napsylate",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
]
] |
Dextropropoxyphene napsylate may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may decrease the metabolism of Ticlopidine and Ticlopidine may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may increase the serum concentration of Aprepitant and Aprepitant may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate can increase the metabolism of Nevirapine and Nevirapine may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may increase the serum concentration of the active metabolites of Fesoterodine and Fesoterodine may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may decrease the serum concentration of Dabrafenib and Dabrafenib may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may increase the serum concentration of Conivaptan and Conivaptan may decrease the metabolism of Doxycycline
Dextropropoxyphene napsylate may increase the serum concentration of Bosutinib and Bosutinib may increase the serum concentration of Doxycycline
Dextropropoxyphene napsylate may decrease the metabolism of Olaparib and Olaparib may increase the serum concentration of Doxycycline
Dextropropoxyphene napsylate may decrease the serum concentration of Bosentan and Bosentan may increase the serum concentration of Doxycycline
|
DB00469
|
DB00588
| 584 | 84 |
Tenoxicam
|
Fluticasone propionate
|
Tenoxicam, an antiinflammatory agent with analgesic and antipyretic properties, is used to treat osteoarthritis and control acute pain.
|
Fluticasone propionate is a synthetic glucocorticoid[F4355,F4358][FDA Label]. These drugs are available as inhalers, nasal, sprays, and topical treatments for various inflammatory indications[F4355,F4358][FDA Label]. Fluticasone propionate was first approved in 1990.
|
The risk or severity of adverse effects can be increased when Tenoxicam is combined with Fluticasone propionate.
| 48 |
[
[
[
584,
71,
84
]
],
[
[
584,
71,
113
],
[
113,
155,
84
]
],
[
[
584,
71,
117
],
[
117,
1,
84
]
],
[
[
584,
6,
7784
],
[
7784,
172,
84
]
],
[
[
584,
21,
28704
],
[
28704,
175,
84
]
],
[
[
584,
180,
161
],
[
161,
26,
84
]
],
[
[
584,
69,
1076
],
[
1076,
223,
84
]
],
[
[
584,
71,
783
],
[
783,
71,
84
]
],
[
[
584,
49,
884
],
[
884,
225,
84
]
],
[
[
584,
233,
798
],
[
798,
71,
84
]
]
] |
[
[
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diflorasone"
],
[
"Diflorasone",
"{u} (Compound) resembles {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rimexolone"
],
[
"Rimexolone",
"{u} (Compound) resembles {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} (Compound) binds {v} (Gene)",
"PTGS2"
],
[
"PTGS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} (Compound) causes {v} (Side Effect)",
"Mental disorder"
],
[
"Mental disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Droxicam"
],
[
"Droxicam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may increase the neuroexcitatory activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
],
[
[
"Tenoxicam",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluticasone propionate"
]
]
] |
Tenoxicam may increase the severity of adverse effects when combined with Diflorasone and Diflorasone (Compound) resembles Fluticasone propionate (Compound)
Tenoxicam may increase the severity of adverse effects when combined with Rimexolone and Rimexolone (Compound) resembles Fluticasone propionate (Compound)
Tenoxicam (Compound) binds PTGS2 (Gene) and PTGS2 (Gene) is downregulated by Fluticasone propionate (Compound)
Tenoxicam (Compound) causes Mental disorder (Side Effect) and Mental disorder (Side Effect) is caused by Fluticasone propionate (Compound)
Tenoxicam can increase the metabolism of Primidone and Primidone can increase the metabolism of Fluticasone propionate
Tenoxicam may decrease the metabolism of Fluconazole and Fluconazole may decrease the metabolism of Fluticasone propionate
Tenoxicam may increase the severity of adverse effects when combined with Droxicam and Droxicam may increase the severity of adverse effects when combined with Fluticasone propionate
Tenoxicam may increase the neuroexcitatory activities of Levofloxacin and Levofloxacin may increase the severity of adverse effects when combined with Fluticasone propionate
Tenoxicam may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the severity of adverse effects when combined with Fluticasone propionate
|
DB00826
|
DB06712
| 1,150 | 435 |
Natamycin
|
Nilvadipine
|
Amphoteric macrolide antifungal antibiotic from Streptomyces natalensis or S. chattanoogensis. It is used for a variety of fungal infections, mainly topically. [PubChem]
|
Nilvadipine is a calcium channel blocker (CCB) for the treatment of hypertension.
|
The risk or severity of adverse effects can be increased when Natamycin is combined with Nilvadipine.
| 48 |
[
[
[
1150,
71,
435
]
],
[
[
1150,
71,
329
],
[
329,
155,
435
]
],
[
[
1150,
71,
158
],
[
158,
82,
435
]
],
[
[
1150,
71,
482
],
[
482,
223,
435
]
],
[
[
1150,
249,
379
],
[
379,
223,
435
]
],
[
[
1150,
1,
1152
],
[
1152,
71,
435
]
],
[
[
1150,
71,
146
],
[
146,
71,
435
]
],
[
[
1150,
223,
198
],
[
198,
71,
435
]
],
[
[
1150,
71,
185
],
[
185,
236,
435
]
],
[
[
1150,
249,
142
],
[
142,
95,
435
]
]
] |
[
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitrendipine"
],
[
"Nitrendipine",
"{u} (Compound) resembles {v} (Compound)",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicardipine"
],
[
"Nicardipine",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may decrease the metabolism of {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} (Compound) resembles {v} (Compound)",
"Nystatin"
],
[
"Nystatin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Barnidipine"
],
[
"Barnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lacidipine"
],
[
"Lacidipine",
"{u} may increase the hypotensive activities of {v}",
"Nilvadipine"
]
],
[
[
"Natamycin",
"{u} may increase the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may increase the serum concentration of {v}",
"Nilvadipine"
]
]
] |
Natamycin may increase the severity of adverse effects when combined with Nitrendipine and Nitrendipine (Compound) resembles Nilvadipine (Compound)
Natamycin may increase the severity of adverse effects when combined with Nicardipine and Nicardipine may increase the hypotensive activities of Nilvadipine
Natamycin may increase the severity of adverse effects when combined with Verapamil and Verapamil may decrease the metabolism of Nilvadipine
Natamycin may increase the serum concentration of Ranolazine and Ranolazine may decrease the metabolism of Nilvadipine
Natamycin (Compound) resembles Nystatin (Compound) and Nystatin may increase the severity of adverse effects when combined with Nilvadipine
Natamycin may increase the severity of adverse effects when combined with Barnidipine and Barnidipine may increase the severity of adverse effects when combined with Nilvadipine
Natamycin may decrease the metabolism of Cyclosporine and Cyclosporine may increase the severity of adverse effects when combined with Nilvadipine
Natamycin may increase the severity of adverse effects when combined with Lacidipine and Lacidipine may increase the hypotensive activities of Nilvadipine
Natamycin may increase the serum concentration of Phenytoin and Phenytoin may increase the serum concentration of Nilvadipine
|
DB09048
|
DB06603
| 476 | 1,098 |
Netupitant
|
Panobinostat
|
Netupitant is an antiemitic drug approved by the FDA in October 2014 for use in combination with palonosetron for the prevention of acute and delayed vomiting and nausea associated with cancer chemotherapy including highly emetogenic chemotherapy. Netupitant is a neurokinin 1 receptor antagonist. The combination drug is marketed by Eisai Inc. and Helsinn Therapeutics (U.S.) Inc. under the brand Akynzeo.
|
Panobinostat is an oral deacetylace (DAC) inhibitor approved on February 23, 2015 by the FDA for the treatment of multiple myeloma. The approval was accelerated based on progression-free survival, therefore confirmatory trials by the sponsor to demonstrate clinical efficacy in multiple myeloma treatment are in progress of being conducted. Panobinostat is marketed by Novartis under the brand name Farydak. Panobinostat acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor) and it is the most potent DAC inhibiting agent available on the market.
|
The serum concentration of Panobinostat can be increased when it is combined with Netupitant.
| 72 |
[
[
[
476,
95,
1098
]
],
[
[
476,
249,
568
],
[
568,
187,
1098
]
],
[
[
476,
249,
645
],
[
645,
196,
1098
]
],
[
[
476,
249,
413
],
[
413,
42,
1098
]
],
[
[
476,
69,
575
],
[
575,
196,
1098
]
],
[
[
476,
249,
340
],
[
340,
210,
1098
]
],
[
[
476,
249,
267
],
[
267,
223,
1098
]
],
[
[
476,
69,
41
],
[
41,
223,
1098
]
],
[
[
476,
249,
292
],
[
292,
71,
1098
]
],
[
[
476,
249,
1084
],
[
1084,
249,
1098
]
]
] |
[
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Pimozide"
],
[
"Pimozide",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may increase the QTc prolonging activities of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the immunosuppressive activities of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Lovastatin"
],
[
"Lovastatin",
"{u} may decrease the metabolism of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may decrease the metabolism of {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Panobinostat"
]
],
[
[
"Netupitant",
"{u} may increase the serum concentration of {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
]
]
] |
Netupitant may increase the serum concentration of Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Panobinostat
Netupitant may increase the serum concentration of Azithromycin and Azithromycin may increase the QTc prolonging activities of Panobinostat
Netupitant may increase the serum concentration of Pimozide and Pimozide may increase the QTc prolonging activities of Panobinostat
Netupitant may decrease the metabolism of Sulfisoxazole and Sulfisoxazole may increase the QTc prolonging activities of Panobinostat
Netupitant may increase the serum concentration of Fingolimod and Fingolimod may increase the immunosuppressive activities of Panobinostat
Netupitant may increase the serum concentration of Lovastatin and Lovastatin may decrease the metabolism of Panobinostat
Netupitant may decrease the metabolism of Clemastine and Clemastine may decrease the metabolism of Panobinostat
Netupitant may increase the serum concentration of Paclitaxel and Paclitaxel may increase the severity of adverse effects when combined with Panobinostat
Netupitant may increase the serum concentration of Itraconazole and Itraconazole may increase the serum concentration of Panobinostat
|
DB00829
|
DB01176
| 407 | 989 |
Diazepam
|
Cyclizine
|
A benzodiazepine with anticonvulsant, anxiolytic, sedative, muscle relaxant, and amnesic properties and a long duration of action. Its actions are mediated by enhancement of gamma-aminobutyric acid activity. It is used in the treatment of severe anxiety disorders, as a hypnotic in the short-term management of insomnia, as a sedative and premedicant, as an anticonvulsant, and in the management of alcohol withdrawal syndrome. (From Martindale, The Extra Pharmacopoeia, 30th ed, p589) Given diazepam's storied history as a commonly used and effective medication for a variety of indications, contemporary advancements in the formulation and administration of the agent include the development and US FDA approval of an auto-injectable formulation for the rapid treatment of uncontrolled seizures in 2015-2016. Combining diazepam, a proven effective therapy for acute repetitive seizures
|
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
|
The risk or severity of adverse effects can be increased when Diazepam is combined with Cyclizine.
| 48 |
[
[
[
407,
71,
989
]
],
[
[
407,
246,
16
],
[
16,
1,
989
]
],
[
[
407,
38,
1262
],
[
1262,
155,
989
]
],
[
[
407,
225,
270
],
[
270,
71,
989
]
],
[
[
407,
192,
72
],
[
72,
38,
989
]
],
[
[
407,
116,
681
],
[
681,
71,
989
]
],
[
[
407,
69,
488
],
[
488,
1,
989
]
],
[
[
407,
71,
976
],
[
976,
71,
989
]
],
[
[
407,
71,
434
],
[
434,
225,
989
]
],
[
[
407,
6,
7128
],
[
7128,
160,
989
]
]
] |
[
[
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may decrease the therapeutic efficacy of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may decrease the metabolism of {v}",
"Modafinil"
],
[
"Modafinil",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dimenhydrinate"
],
[
"Dimenhydrinate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Diazepam",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclizine"
]
]
] |
Diazepam may decrease the therapeutic efficacy of Mianserin and Mianserin (Compound) resembles Cyclizine (Compound)
Diazepam may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine (Compound) resembles Cyclizine (Compound)
Diazepam may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Cyclizine
Diazepam may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Cyclizine
Diazepam (Compound) resembles Clozapine (Compound) and Diazepam may increase the severity of adverse effects when combined with Clozapine and Clozapine may increase the severity of adverse effects when combined with Cyclizine
Diazepam may decrease the metabolism of Modafinil and Modafinil (Compound) resembles Cyclizine (Compound)
Diazepam may increase the severity of adverse effects when combined with Dimenhydrinate and Dimenhydrinate may increase the severity of adverse effects when combined with Cyclizine
Diazepam may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Cyclizine
Diazepam (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Cyclizine (Compound)
|
DB01118
|
DB00983
| 137 | 253 |
Amiodarone
|
Formoterol
|
Amiodarone is a benzofuran derivative, anti-arrhythmic drug used commonly in a variety of settings. Most known for its approved indication in life-threatening ventricular arrhythmias, it is also used off-label in the outpatient and inpatient setting for atrial fibrillation. Because of its ability to cause serious toxicity and possibly death, amiodarone use should be reserved for its approved indications, according to prescribing information.[L3561,L11265,L11286]
|
Formoterol is an inhaled beta<sub>2</sub>-agonist used in the management of COPD and asthma that was first approved for use in the United States in 2001. It acts on bronchial smooth muscle to dilate and relax airways, and is administered as a racemic mixture of its active (R;R)- and inactive (S;S)-enantiomers. A major clinical advantage of formoterol over other inhaled beta-agonists is its rapid onset of action (2-3 minutes), which is at least as fast as [salbutamol], combined with a long duration of action (12 hours) - for this reason, treatment guidelines for asthma recommend its use as both a reliever and maintenance medication. It is available as a single-entity product [L10986,L11223] and in several formulations in combination with both inhaled corticosteroids [L10995,L10619] and long-acting
|
Amiodarone may increase the QTc-prolonging activities of Formoterol.
| 19 |
[
[
[
137,
42,
253
]
],
[
[
137,
6,
18777
],
[
18777,
160,
253
]
],
[
[
137,
7,
3107
],
[
3107,
161,
253
]
],
[
[
137,
21,
29392
],
[
29392,
175,
253
]
],
[
[
137,
180,
171
],
[
171,
26,
253
]
],
[
[
137,
187,
147
],
[
147,
26,
253
]
],
[
[
137,
251,
142
],
[
142,
26,
253
]
],
[
[
137,
249,
248
],
[
248,
27,
253
]
],
[
[
137,
76,
1032
],
[
1032,
36,
253
]
],
[
[
137,
249,
1079
],
[
1079,
42,
253
]
]
] |
[
[
[
"Amiodarone",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} (Compound) upregulates {v} (Gene)",
"HMOX1"
],
[
"HMOX1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} (Compound) causes {v} (Side Effect)",
"Hypokinesia"
],
[
"Hypokinesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} may increase the serum concentration of {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may decrease the vasoconstricting activities of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} may increase the bradycardic activities of {v}",
"Bopindolol"
],
[
"Bopindolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Formoterol"
]
],
[
[
"Amiodarone",
"{u} may increase the serum concentration of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Formoterol"
]
]
] |
Amiodarone (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Formoterol (Compound)
Amiodarone (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is upregulated by Formoterol (Compound)
Amiodarone (Compound) causes Hypokinesia (Side Effect) and Hypokinesia (Side Effect) is caused by Formoterol (Compound)
Amiodarone can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Formoterol
Amiodarone may reduce the serum concentration of the active metabolites of Rifampicin and Rifampicin can increase the metabolism of Formoterol
Amiodarone may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Formoterol
Amiodarone may increase the serum concentration of Carvedilol and Carvedilol may decrease the vasoconstricting activities of Formoterol
Amiodarone may increase the bradycardic activities of Bopindolol and Bopindolol may decrease the bronchodilatory activities of Formoterol
Amiodarone may increase the serum concentration of Crizotinib and Crizotinib may increase the QTc prolonging activities of Formoterol
|
DB01169
|
DB00703
| 1,208 | 1,367 |
Arsenic trioxide
|
Methazolamide
|
Arsenic trioxide is a chemotherapeutic agent of idiopathic function used to treat leukemia that is unresponsive to first line agents. It is suspected that arsenic trisulfide induces cancer cells to undergo apoptosis. In general, arsenic is known to be a naturally toxic substance capable of eliciting a variety of dangerous adverse effects. The enzyme thioredoxin reductase has recently been identified as a target for arsenic trioxide.
|
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
|
The risk or severity of adverse effects can be increased when Arsenic trioxide is combined with Methazolamide.
| 48 |
[
[
[
1208,
71,
1367
]
],
[
[
1208,
6,
4590
],
[
4590,
160,
1367
]
],
[
[
1208,
52,
828
],
[
828,
206,
1367
]
],
[
[
1208,
71,
1354
],
[
1354,
225,
1367
]
],
[
[
1208,
42,
499
],
[
499,
71,
1367
]
],
[
[
1208,
71,
1326
],
[
1326,
71,
1367
]
],
[
[
1208,
225,
1303
],
[
1303,
71,
1367
]
],
[
[
1208,
236,
161
],
[
161,
225,
1367
]
],
[
[
1208,
71,
304
],
[
304,
78,
1367
]
],
[
[
1208,
236,
932
],
[
932,
82,
1367
]
]
] |
[
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
],
[
"Nitroglycerin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methylergometrine"
],
[
"Methylergometrine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the hypotensive activities of {v}",
"Primidone"
],
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Candesartan cilexetil"
],
[
"Candesartan cilexetil",
"{u} may increase the hypotensive effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Arsenic trioxide",
"{u} may increase the hypotensive activities of {v}",
"Aripiprazole"
],
[
"Aripiprazole",
"{u} may increase the hypotensive activities of {v}",
"Methazolamide"
]
]
] |
Arsenic trioxide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Methazolamide (Compound)
Arsenic trioxide may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Methazolamide
Arsenic trioxide may increase the severity of adverse effects when combined with Nitroglycerin and Nitroglycerin may increase the severity of adverse effects when combined with Methazolamide
Arsenic trioxide may increase the QTc prolonging activities of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Methazolamide
Arsenic trioxide may increase the severity of adverse effects when combined with Methyclothiazide and Methyclothiazide may increase the severity of adverse effects when combined with Methazolamide
Arsenic trioxide may increase the severity of adverse effects when combined with Methylergometrine and Methylergometrine may increase the severity of adverse effects when combined with Methazolamide
Arsenic trioxide may increase the hypotensive activities of Primidone and Primidone may increase the severity of adverse effects when combined with Methazolamide
Arsenic trioxide may increase the severity of adverse effects when combined with Candesartan cilexetil and Candesartan cilexetil may increase the hypotensive effects when combined with Methazolamide
Arsenic trioxide may increase the hypotensive activities of Aripiprazole and Aripiprazole may increase the hypotensive activities of Methazolamide
|
DB00542
|
DB01250
| 642 | 768 |
Benazepril
|
Olsalazine
|
Benazepril, brand name Lotensin, is a medication used to treat high blood pressure (hypertension), congestive heart failure, and chronic renal failure[A838,A837]. Upon cleavage of its ester group by the liver, benazepril is converted into its active form benazeprilat, a non-sulfhydryl angiotensin-converting enzyme (ACE) inhibitor.
|
Olsalazine is an aminosalicylate and a prodrug of [mesalamine] (5-aminosalicylic acid, 5-ASA). It was first developed for delivering mesalamine to the colon without the use of [sulfapyridine]. Olsalazine comprises two mesalamine molecules joined by an azo bridge, which is cleaved in the colon. Olsalazine is an anti-inflammatory agent that works by inhibiting cyclooxygenase and lipoxygenase, subsequently reducing the production of pro-inflammatory factors like prostaglandin and leukotriene. Olsalazine is used in the treatment of ulcerative colitis.[L45023,L45151]
|
The risk or severity of adverse effects can be increased when Benazepril is combined with Olsalazine.
| 48 |
[
[
[
642,
71,
768
]
],
[
[
642,
223,
461
],
[
461,
182,
768
]
],
[
[
642,
59,
790
],
[
790,
28,
768
]
],
[
[
642,
71,
426
],
[
426,
31,
768
]
],
[
[
642,
236,
640
],
[
640,
31,
768
]
],
[
[
642,
225,
247
],
[
247,
31,
768
]
],
[
[
642,
71,
894
],
[
894,
205,
768
]
],
[
[
642,
225,
557
],
[
557,
205,
768
]
],
[
[
642,
225,
1359
],
[
1359,
59,
768
]
],
[
[
642,
71,
1038
],
[
1038,
59,
768
]
]
] |
[
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the anticoagulant activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may decrease the antihypertensive activities of {v}",
"Trolamine salicylate"
],
[
"Trolamine salicylate",
"{u} may increase the anticoagulant activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dapagliflozin"
],
[
"Dapagliflozin",
"{u} may increase the hypoglycemic activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the hypotensive activities of {v}",
"Quinine"
],
[
"Quinine",
"{u} may increase the hypoglycemic activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the hypoglycemic activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triamterene"
],
[
"Triamterene",
"{u} may decrease the antihypertensive activities of {v}",
"Olsalazine"
]
],
[
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may decrease the antihypertensive activities of {v}",
"Olsalazine"
]
]
] |
Benazepril may decrease the metabolism of Diltiazem and Diltiazem may increase the anticoagulant activities of Olsalazine
Benazepril may decrease the antihypertensive activities of Trolamine salicylate and Trolamine salicylate may increase the anticoagulant activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Dapagliflozin and Dapagliflozin may increase the hypoglycemic activities of Olsalazine
Benazepril may increase the hypotensive activities of Quinine and Quinine may increase the hypoglycemic activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Bromocriptine and Bromocriptine may increase the hypoglycemic activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Triamterene and Triamterene may decrease the antihypertensive activities of Olsalazine
Benazepril may increase the severity of adverse effects when combined with Nadolol and Nadolol may decrease the antihypertensive activities of Olsalazine
|
DB00250
|
DB09063
| 314 | 1,324 |
Dapsone
|
Ceritinib
|
A sulfone active against a wide range of bacteria but mainly employed for its actions against mycobacterium leprae. Its mechanism of action is probably similar to that of the sulfonamides which involves inhibition of folic acid synthesis in susceptible organisms. It is also used with pyrimethamine in the treatment of malaria. (From Martindale, The Extra Pharmacopoeia, 30th ed, p157-8)
|
Ceritinib is used for the treatment of adults with anaplastic lymphoma kinase (ALK)-positive metastatic non-small cell lung cancer (NSCLC) following failure (secondary to resistance or intolerance) of prior crizotinib therapy. About 4% of patients with NSCLC have a chromosomal rearrangement that generates a fusion gene between EML4 (echinoderm microtubule-associated protein-like 4) and ALK (anaplastic lymphoma kinase), which results in constitutive kinase activity that contributes to carcinogenesis and seems to drive the malignant phenotype. Ceritinib exerts its therapeutic effect by inhibiting autophosphorylation of ALK, ALK-mediated phosphorylation of the downstream signaling protein STAT3, and proliferation of ALK-dependent cancer cells. Following treatment with crizotinib (a first-generation ALK inhibitor), most tumours develop drug resistance due to mutations in key "gatekeeper" residues of the
|
The serum concentration of Ceritinib can be increased when it is combined with Dapsone.
| 72 |
[
[
[
314,
95,
1324
]
],
[
[
314,
95,
1019
],
[
1019,
95,
1324
]
],
[
[
314,
69,
1076
],
[
1076,
196,
1324
]
],
[
[
314,
71,
1293
],
[
1293,
196,
1324
]
],
[
[
314,
116,
284
],
[
284,
95,
1324
]
],
[
[
314,
180,
173
],
[
173,
95,
1324
]
],
[
[
314,
225,
539
],
[
539,
95,
1324
]
],
[
[
314,
71,
534
],
[
534,
95,
1324
]
],
[
[
314,
249,
270
],
[
270,
95,
1324
]
],
[
[
314,
69,
227
],
[
227,
95,
1324
]
]
] |
[
[
[
"Dapsone",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may increase the QTc prolonging activities of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Isosorbide mononitrate"
],
[
"Isosorbide mononitrate",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may increase the serum concentration of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
],
[
[
"Dapsone",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
]
]
] |
Dapsone may increase the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Ceritinib
Dapsone may decrease the metabolism of Fluconazole and Fluconazole may increase the QTc prolonging activities of Ceritinib
Dapsone may increase the severity of adverse effects when combined with Metoclopramide and Metoclopramide may increase the QTc prolonging activities of Ceritinib
Dapsone (Compound) resembles Sulfadiazine (Compound) and Dapsone may increase the severity of adverse effects when combined with Sulfadiazine and Sulfadiazine may increase the serum concentration of Ceritinib
Dapsone can increase the metabolism of Nevirapine and Nevirapine may increase the serum concentration of Ceritinib
Dapsone may increase the severity of adverse effects when combined with Artemether and Artemether may increase the serum concentration of Ceritinib
Dapsone may increase the severity of adverse effects when combined with Isosorbide mononitrate and Isosorbide mononitrate may increase the serum concentration of Ceritinib
Dapsone may increase the serum concentration of Prochlorperazine and Prochlorperazine may increase the serum concentration of Ceritinib
Dapsone may decrease the metabolism of Bortezomib and Bortezomib may increase the serum concentration of Ceritinib
|
DB01201
|
DB11560
| 177 | 427 |
Rifapentine
|
Lesinurad
|
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
|
Lesinurad is an oral uric acid transporter 1 (URAT1) inhibitor indicated for the treatment of hyperuricemia associated with gout. It reduces serum uric acid concentration through the inhibition of URAT1, an enzyme responsible for reuptake of uric acid from the renal tubule, and OAT4, another uric acid transporter associated with diuretic-induced hyperuricemia. Marketed as the product Zurampic, it is indicated for use in combination with a xanthine oxidase inhibitor for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a xanthine oxidase inhibitor alone. In August 2017, a combination oral therapy consisting of lesinurad and was FDA-approved under the brand name Duzallo indicated for the treatment of gout-related hyperuricemia in patients with uncontrolled gout.
|
The metabolism of Lesinurad can be increased when combined with Rifapentine.
| 3 |
[
[
[
177,
26,
427
]
],
[
[
177,
26,
142
],
[
142,
26,
427
]
],
[
[
177,
26,
307
],
[
307,
223,
427
]
],
[
[
177,
95,
1076
],
[
1076,
223,
427
]
],
[
[
177,
97,
1019
],
[
1019,
249,
427
]
],
[
[
177,
26,
684
],
[
684,
97,
427
]
],
[
[
177,
26,
142
],
[
142,
137,
161
],
[
161,
26,
427
]
],
[
[
177,
26,
161
],
[
161,
291,
142
],
[
142,
26,
427
]
],
[
[
177,
26,
147
],
[
147,
180,
161
],
[
161,
26,
427
]
],
[
[
177,
26,
156
],
[
156,
97,
142
],
[
142,
26,
427
]
]
] |
[
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} may decrease the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Dabrafenib"
],
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} (Compound) resembles {v} (Compound) and {u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Lesinurad"
]
]
] |
Rifapentine can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Lesinurad
Rifapentine can increase the metabolism of Fluvastatin and Fluvastatin may decrease the metabolism of Lesinurad
Rifapentine may increase the serum concentration of Fluconazole and Fluconazole may decrease the metabolism of Lesinurad
Rifapentine may decrease the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Lesinurad
Rifapentine can increase the metabolism of Dabrafenib and Dabrafenib may decrease the serum concentration of Lesinurad
Rifapentine can increase the metabolism of Phenytoin and Phenytoin (Compound) resembles Primidone (Compound) and Phenytoin can increase the metabolism of Primidone and Primidone can increase the metabolism of Lesinurad
Rifapentine can increase the metabolism of Primidone and Primidone (Compound) resembles Phenytoin (Compound) and Primidone can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Lesinurad
Rifapentine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Primidone and Primidone can increase the metabolism of Lesinurad
Rifapentine can increase the metabolism of Carbamazepine and Carbamazepine may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Lesinurad
|
DB00492
|
DB00821
| 656 | 11 |
Fosinopril
|
Carprofen
|
Fosinopril is a phosphinic acid-containing ester prodrug that belongs to the angiotensin-converting enzyme (ACE) inhibitor class of medications. It is rapidly hydrolyzed to fosinoprilat, its principle active metabolite. Fosinoprilat inhibits ACE, the enzyme responsible for the conversion of angiotensin I (ATI) to angiotensin II (ATII). ATII regulates blood pressure and is a key component of the renin-angiotensin-aldosterone system (RAAS). Fosinopril may be used to treat mild to moderate hypertension, as an adjunct in the treatment of congestive heart failure, and to slow the rate of progression of renal disease in hypertensive individuals with diabetes mellitus and microalbuminuria or overt nephropathy.
|
Carprofen is a non-steroidal anti-inflammatory drug (NSAID) that is used by veterinarians as a supportive treatment for the relief of arthritic symptoms in geriatric dogs. Carprofen was previously used in human medicine for over 10 years (1985-1995). It was generally well tolerated, with the majority of adverse effects being mild, such as gastro-intestinal pain and nausea, similar to those recorded with aspirin and other non-steroidal anti-inflammatory drugs. It is no longer marketed for human usage, after being withdrawn on commercial grounds.
|
The risk or severity of adverse effects can be increased when Fosinopril is combined with Carprofen.
| 48 |
[
[
[
656,
71,
11
]
],
[
[
656,
71,
211
],
[
211,
225,
11
]
],
[
[
656,
71,
388
],
[
388,
1,
11
]
],
[
[
656,
225,
557
],
[
557,
205,
11
]
],
[
[
656,
71,
894
],
[
894,
205,
11
]
],
[
[
656,
90,
306
],
[
306,
59,
11
]
],
[
[
656,
225,
139
],
[
139,
59,
11
]
],
[
[
656,
71,
1022
],
[
1022,
59,
11
]
],
[
[
656,
82,
911
],
[
911,
59,
11
]
],
[
[
656,
71,
642
],
[
642,
71,
11
]
]
] |
[
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flurbiprofen"
],
[
"Flurbiprofen",
"{u} (Compound) resembles {v} (Compound)",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the hyperkalemic activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may decrease the antihypertensive activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Atenolol"
],
[
"Atenolol",
"{u} may decrease the antihypertensive activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pindolol"
],
[
"Pindolol",
"{u} may decrease the antihypertensive activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the hypotensive activities of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may decrease the antihypertensive activities of {v}",
"Carprofen"
]
],
[
[
"Fosinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
],
[
"Benazepril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carprofen"
]
]
] |
Fosinopril may increase the severity of adverse effects when combined with Ketoprofen and Ketoprofen may increase the severity of adverse effects when combined with Carprofen
Fosinopril may increase the severity of adverse effects when combined with Flurbiprofen and Flurbiprofen (Compound) resembles Carprofen (Compound)
Fosinopril may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Carprofen
Fosinopril may increase the severity of adverse effects when combined with Furosemide and Furosemide may decrease the diuretic activities of Carprofen
Fosinopril may increase the hyperkalemic activities of Aliskiren and Aliskiren may decrease the antihypertensive activities of Carprofen
Fosinopril may increase the severity of adverse effects when combined with Atenolol and Atenolol may decrease the antihypertensive activities of Carprofen
Fosinopril may increase the severity of adverse effects when combined with Pindolol and Pindolol may decrease the antihypertensive activities of Carprofen
Fosinopril may increase the hypotensive activities of Oxprenolol and Oxprenolol may decrease the antihypertensive activities of Carprofen
Fosinopril may increase the severity of adverse effects when combined with Benazepril and Benazepril may increase the severity of adverse effects when combined with Carprofen
|
DB00572
|
DB01339
| 47 | 40 |
Atropine
|
Vecuronium
|
Atropine is an alkaloid originally synthesized from Atropa belladonna. It is a racemic mixture of d-and l-hyoscyamine, of which only l-hyoscyamine is pharmacologically active.[A251670,L42835] Atropine is generally available as a sulfate salt and can be administered by intravenous, subcutaneous, intramuscular, intraosseous, endotracheal and ophthalmic methods. Oral atropine is only available in combination products.[A251660,L42840] Atropine is a competitive, reversible antagonist of muscarinic receptors that blocks the effects of acetylcholine and other choline esters.[A251660,L42815,L42825,L42835] It has a variety of therapeutic applications, including pupil dilation and the treatment of anticholinergic poisoning and symptomatic bradycardia in the absence of reversible causes. Atropine is a relatively inexpensive drug and
|
Monoquaternary homolog of pancuronium. A non-depolarizing neuromuscular blocking agent with shorter duration of action than pancuronium. Its lack of significant cardiovascular effects and lack of dependence on good kidney function for elimination as well as its short duration of action and easy reversibility provide advantages over, or alternatives to, other established neuromuscular blocking agents.
|
The risk or severity of adverse effects can be increased when Atropine is combined with Vecuronium.
| 48 |
[
[
[
47,
71,
40
]
],
[
[
47,
71,
73
],
[
73,
71,
40
]
],
[
[
47,
21,
28614
],
[
28614,
175,
40
]
],
[
[
47,
24,
16
],
[
16,
178,
40
]
],
[
[
47,
178,
20
],
[
20,
24,
40
]
],
[
[
47,
71,
59
],
[
59,
197,
40
]
],
[
[
47,
61,
1399
],
[
1399,
215,
40
]
],
[
[
47,
71,
64
],
[
64,
225,
40
]
],
[
[
47,
225,
43
],
[
43,
71,
40
]
],
[
[
47,
246,
1279
],
[
1279,
92,
40
]
]
] |
[
[
[
"Atropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pancuronium"
],
[
"Pancuronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} (Compound) causes {v} (Side Effect)",
"Hypotension"
],
[
"Hypotension",
"{u} (Side Effect) is caused by {v} (Compound)",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the anticholinergic activities of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} may increase the anticholinergic activities of {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the anticholinergic activities of {v}",
"Umeclidinium"
],
[
"Umeclidinium",
"{u} may increase the anticholinergic activities of {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the neuromuscular blocking activities of {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the constipating activities of {v}",
"Ramosetron"
],
[
"Ramosetron",
"{u} may increase the constipating activities of {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metixene"
],
[
"Metixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procyclidine"
],
[
"Procyclidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Vecuronium"
]
],
[
[
"Atropine",
"{u} may decrease the therapeutic efficacy of {v}",
"Decamethonium"
],
[
"Decamethonium",
"{u} may decrease the therapeutic efficacy of {v}",
"Vecuronium"
]
]
] |
Atropine may increase the severity of adverse effects when combined with Pancuronium and Pancuronium may increase the severity of adverse effects when combined with Vecuronium
Atropine (Compound) causes Hypotension (Side Effect) and Hypotension (Side Effect) is caused by Vecuronium (Compound)
Atropine may increase the anticholinergic activities of Mianserin and Mianserin may increase the anticholinergic activities of Vecuronium
Atropine may increase the anticholinergic activities of Umeclidinium and Umeclidinium may increase the anticholinergic activities of Vecuronium
Atropine may increase the severity of adverse effects when combined with Quinidine and Quinidine may increase the neuromuscular blocking activities of Vecuronium
Atropine may increase the constipating activities of Ramosetron and Ramosetron may increase the constipating activities of Vecuronium
Atropine may increase the severity of adverse effects when combined with Metixene and Metixene may increase the severity of adverse effects when combined with Vecuronium
Atropine may increase the severity of adverse effects when combined with Procyclidine and Procyclidine may increase the severity of adverse effects when combined with Vecuronium
Atropine may decrease the therapeutic efficacy of Decamethonium and Decamethonium may decrease the therapeutic efficacy of Vecuronium
|
DB00741
|
DB00091
| 92 | 198 |
Hydrocortisone
|
Cyclosporine
|
Hydrocortisone, or cortisol, is a glucocorticoid secreted by the adrenal cortex. Hydrocortisone is used to treat immune, inflammatory, and neoplastic conditions.[L10529,L10532,L10535,L10538,L7772,L7321] It was discovered in the 1930s by Edward Kendall and named Compound F, or 17-hydroxycorticosterone. Hydrocortisone was granted FDA approval on 5 August 1952.
|
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
|
The metabolism of Cyclosporine can be decreased when combined with Hydrocortisone.
| 46 |
[
[
[
92,
69,
198
]
],
[
[
92,
5,
17020
],
[
17020,
159,
198
]
],
[
[
92,
6,
15658
],
[
15658,
160,
198
]
],
[
[
92,
18,
8514
],
[
8514,
161,
198
]
],
[
[
92,
7,
8526
],
[
8526,
161,
198
]
],
[
[
92,
7,
4471
],
[
4471,
172,
198
]
],
[
[
92,
21,
28466
],
[
28466,
175,
198
]
],
[
[
92,
251,
161
],
[
161,
26,
198
]
],
[
[
92,
1,
458
],
[
458,
189,
198
]
],
[
[
92,
71,
1293
],
[
1293,
40,
198
]
]
] |
[
[
[
"Hydrocortisone",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) treats {v} (Disease)",
"rheumatoid arthritis"
],
[
"rheumatoid arthritis",
"{u} (Disease) is treated by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) downregulates {v} (Gene)",
"RAP1GAP"
],
[
"RAP1GAP",
"{u} (Gene) is upregulated by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) upregulates {v} (Gene)",
"TSC22D3"
],
[
"TSC22D3",
"{u} (Gene) is upregulated by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) upregulates {v} (Gene)",
"RGS2"
],
[
"RGS2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) causes {v} (Side Effect)",
"Neuropathy peripheral"
],
[
"Neuropathy peripheral",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} (Compound) resembles {v} (Compound)",
"Progesterone"
],
[
"Progesterone",
"{u} may decrease the absorption of {v}",
"Cyclosporine"
]
],
[
[
"Hydrocortisone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} can increase the absorption and serum concentration of {v}",
"Cyclosporine"
]
]
] |
Hydrocortisone (Compound) treats rheumatoid arthritis (Disease) and rheumatoid arthritis (Disease) is treated by Cyclosporine (Compound)
Hydrocortisone (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Cyclosporine (Compound)
Hydrocortisone (Compound) downregulates RAP1GAP (Gene) and RAP1GAP (Gene) is upregulated by Cyclosporine (Compound)
Hydrocortisone (Compound) upregulates TSC22D3 (Gene) and TSC22D3 (Gene) is upregulated by Cyclosporine (Compound)
Hydrocortisone (Compound) upregulates RGS2 (Gene) and RGS2 (Gene) is downregulated by Cyclosporine (Compound)
Hydrocortisone (Compound) causes Neuropathy peripheral (Side Effect) and Neuropathy peripheral (Side Effect) is caused by Cyclosporine (Compound)
Hydrocortisone may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Cyclosporine
Hydrocortisone (Compound) resembles Progesterone (Compound) and Progesterone may decrease the absorption of Cyclosporine
Hydrocortisone may increase the severity of adverse effects when combined with Metoclopramide and Metoclopramide can increase the absorption and serum concentration of Cyclosporine
|
DB00458
|
DB00227
| 438 | 267 |
Imipramine
|
Lovastatin
|
Imipramine, the prototypical tricyclic antidepressant (TCA), is a dibenzazepine-derivative TCA. TCAs are structurally similar to phenothiazines. They contain a tricyclic ring system with an alkyl amine substituent on the central ring. In non-depressed individuals, imipramine does not affect mood or arousal, but may cause sedation. In depressed individuals, imipramine exerts a positive effect on mood. TCAs are potent inhibitors of serotonin and norepinephrine reuptake. Tertiary amine TCAs, such as imipramine and amitriptyline, are more potent inhibitors of serotonin reuptake than secondary amine TCAs, such as nortriptyline and desipramine. TCAs also block histamine H<sub>1</sub> receptors, α<sub>1</sub>-adrenergic
|
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
|
The metabolism of Lovastatin can be decreased when combined with Imipramine.
| 46 |
[
[
[
438,
69,
267
]
],
[
[
438,
223,
439
],
[
439,
69,
267
]
],
[
[
438,
6,
4590
],
[
4590,
160,
267
]
],
[
[
438,
21,
28622
],
[
28622,
175,
267
]
],
[
[
438,
180,
147
],
[
147,
26,
267
]
],
[
[
438,
251,
225
],
[
225,
26,
267
]
],
[
[
438,
38,
1257
],
[
1257,
69,
267
]
],
[
[
438,
69,
615
],
[
615,
69,
267
]
],
[
[
438,
225,
469
],
[
469,
69,
267
]
],
[
[
438,
95,
1098
],
[
1098,
69,
267
]
]
] |
[
[
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Simvastatin"
],
[
"Simvastatin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} (Compound) causes {v} (Side Effect)",
"Decreased appetite"
],
[
"Decreased appetite",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Dextropropoxyphene"
],
[
"Dextropropoxyphene",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Imipramine",
"{u} may increase the serum concentration of {v}",
"Panobinostat"
],
[
"Panobinostat",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
]
] |
Imipramine may decrease the metabolism of Simvastatin and Simvastatin may decrease the metabolism of Lovastatin
Imipramine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lovastatin (Compound)
Imipramine (Compound) causes Decreased appetite (Side Effect) and Decreased appetite (Side Effect) is caused by Lovastatin (Compound)
Imipramine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Lovastatin
Imipramine may decrease the serum concentration of Bosentan and Bosentan can increase the metabolism of Lovastatin
Imipramine may increase the central nervous system depressant activities of Perampanel and Perampanel may decrease the metabolism of Lovastatin
Imipramine may decrease the metabolism of Sildenafil and Sildenafil may decrease the metabolism of Lovastatin
Imipramine may increase the severity of adverse effects when combined with Dextropropoxyphene and Dextropropoxyphene may decrease the metabolism of Lovastatin
Imipramine may increase the serum concentration of Panobinostat and Panobinostat may decrease the metabolism of Lovastatin
|
DB00266
|
DB00817
| 498 | 776 |
Dicoumarol
|
Rosoxacin
|
Dicoumarol is an oral anticoagulant agent that works by interfering with the metabolism of vitamin K. In addition to its clinical use, it is also used in biochemical experiments as an inhibitor of reductases.
|
Rosoxacin is a quinolone derivative antibiotic for the treatment of bacterial infection of respiratory tract, urinary tract, GI, CNS and immuno compromised patients. Rosoxacin is known to be effective against penicillin resistant strains and is a single dose orally administered drug, which avoids all complications of parenteral administration seen with penicillin, especially anaphylactic shock.
|
Dicoumarol may increase the anticoagulant activities of Rosoxacin.
| 5 |
[
[
[
498,
28,
776
]
],
[
[
498,
28,
850
],
[
850,
155,
776
]
],
[
[
498,
182,
169
],
[
169,
28,
776
]
],
[
[
498,
285,
219
],
[
219,
28,
776
]
],
[
[
498,
28,
326
],
[
326,
31,
776
]
],
[
[
498,
69,
284
],
[
284,
31,
776
]
],
[
[
498,
28,
334
],
[
334,
49,
776
]
],
[
[
498,
88,
1351
],
[
1351,
49,
776
]
],
[
[
498,
34,
124
],
[
124,
71,
776
]
],
[
[
498,
28,
808
],
[
808,
97,
776
]
]
] |
[
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Enoxacin"
],
[
"Enoxacin",
"{u} (Compound) resembles {v} (Compound)",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may increase the hypoglycemic activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may increase the hypoglycemic activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Ibuprofen"
],
[
"Ibuprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase bleeding risks when combined with {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may decrease the anticoagulant activities of {v}",
"Estrone"
],
[
"Estrone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rosoxacin"
]
],
[
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may decrease the serum concentration of {v}",
"Rosoxacin"
]
]
] |
Dicoumarol may increase the anticoagulant activities of Enoxacin and Enoxacin (Compound) resembles Rosoxacin (Compound)
Dicoumarol may increase the anticoagulant activities of Phenindione and Phenindione may increase the anticoagulant activities of Rosoxacin
Dicoumarol (Compound) resembles Warfarin (Compound) and Dicoumarol may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Rosoxacin
Dicoumarol may increase the anticoagulant activities of Glipizide and Glipizide may increase the hypoglycemic activities of Rosoxacin
Dicoumarol may decrease the metabolism of Sulfadiazine and Sulfadiazine may increase the hypoglycemic activities of Rosoxacin
Dicoumarol may increase the anticoagulant activities of Ibuprofen and Ibuprofen may increase the neuroexcitatory activities of Rosoxacin
Dicoumarol may increase bleeding risks when combined with Acemetacin and Acemetacin may increase the neuroexcitatory activities of Rosoxacin
Dicoumarol may decrease the anticoagulant activities of Estrone and Estrone may increase the severity of adverse effects when combined with Rosoxacin
Dicoumarol may increase the anticoagulant activities of Magnesium salicylate and Magnesium salicylate may decrease the serum concentration of Rosoxacin
|
DB00264
|
DB09080
| 576 | 638 |
Metoprolol
|
Olodaterol
|
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
|
Olodaterol is a novel, long-acting beta2-adrenergic agonist (LABA) that exerts its pharmacological effect by binding and activating beta2-adrenergic receptors located primarily in the lungs. Beta2-adrenergic receptors are membrane-bound receptors that are normally activated by endogenous epinephrine whose signalling, via a downstream L-type calcium channel interaction, mediates smooth muscle relaxation and bronchodilation. Activation of the receptor stimulates an associated G protein which then activates adenylate cyclase, catalyzing the formation of cyclic adenosine monophosphate (cAMP) and protein kinase A (PKA). Elevation of these two molecules induces bronchodilation by relaxation of airway smooth muscles. It is by this mechanism that olodaterol is used for the treatment of chronic obstructive pulmonary disease (COPD) and the progressive airflow obstruction that is characteristic of it. Treatment with bronchodilators helps to mitigate associated
|
Metoprolol may decrease the bronchodilatory activities of Olodaterol.
| 13 |
[
[
[
576,
36,
638
]
],
[
[
576,
236,
164
],
[
164,
26,
638
]
],
[
[
576,
251,
177
],
[
177,
26,
638
]
],
[
[
576,
180,
156
],
[
156,
26,
638
]
],
[
[
576,
52,
509
],
[
509,
27,
638
]
],
[
[
576,
236,
278
],
[
278,
27,
638
]
],
[
[
576,
36,
519
],
[
519,
36,
638
]
],
[
[
576,
119,
911
],
[
911,
36,
638
]
],
[
[
576,
82,
1033
],
[
1033,
36,
638
]
],
[
[
576,
225,
1034
],
[
1034,
36,
638
]
]
] |
[
[
[
"Metoprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may increase the hypotensive activities of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Tamsulosin"
],
[
"Tamsulosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may increase the hypotensive activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may decrease the vasoconstricting activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Celiprolol"
],
[
"Celiprolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Oxprenolol"
],
[
"Oxprenolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may increase the hypotensive activities of {v}",
"Bupranolol"
],
[
"Bupranolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
],
[
[
"Metoprolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may decrease the bronchodilatory activities of {v}",
"Olodaterol"
]
]
] |
Metoprolol may increase the hypotensive activities of Phenobarbital and Phenobarbital can increase the metabolism of Olodaterol
Metoprolol may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Olodaterol
Metoprolol can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Olodaterol
Metoprolol may increase the orthostatic hypotensive activities of Tamsulosin and Tamsulosin may decrease the vasoconstricting activities of Olodaterol
Metoprolol may increase the hypotensive activities of Alfuzosin and Alfuzosin may decrease the vasoconstricting activities of Olodaterol
Metoprolol may decrease the bronchodilatory activities of Celiprolol and Celiprolol may decrease the bronchodilatory activities of Olodaterol
Metoprolol (Compound) resembles Oxprenolol (Compound) and Metoprolol may increase the serum concentration of Oxprenolol and Oxprenolol may decrease the bronchodilatory activities of Olodaterol
Metoprolol may increase the hypotensive activities of Bupranolol and Bupranolol may decrease the bronchodilatory activities of Olodaterol
Metoprolol may increase the severity of adverse effects when combined with Esmolol and Esmolol may decrease the bronchodilatory activities of Olodaterol
|
DB00661
|
DB00705
| 482 | 508 |
Verapamil
|
Delavirdine
|
Verapamil is a phenylalkylamine calcium channel blocker used in the treatment of high blood pressure, heart arrhythmias, and angina, and was the first calcium channel antagonist to be introduced into therapy in the early 1960s. It is a member of the non-dihydropyridine class of calcium channel blockers, which includes drugs like [diltiazem] and [flunarizine], but is chemically unrelated to other cardioactive medications. Verapamil is administered as a racemic mixture containing equal amounts of the S- and R-enantiomer, each of which is pharmacologically distinct - the S-enantiomer carries approximately 20-fold greater potency than the R-enantiomer, but is metabolized at a higher rate.
|
A potent, non-nucleoside reverse transcriptase inhibitor with activity specific for HIV-1.
|
The metabolism of Delavirdine can be decreased when combined with Verapamil.
| 46 |
[
[
[
482,
69,
508
]
],
[
[
482,
6,
15658
],
[
15658,
160,
508
]
],
[
[
482,
21,
28515
],
[
28515,
175,
508
]
],
[
[
482,
180,
173
],
[
173,
26,
508
]
],
[
[
482,
33,
680
],
[
680,
187,
508
]
],
[
[
482,
92,
597
],
[
597,
187,
508
]
],
[
[
482,
223,
307
],
[
307,
69,
508
]
],
[
[
482,
69,
544
],
[
544,
69,
508
]
],
[
[
482,
69,
1084
],
[
1084,
223,
508
]
],
[
[
482,
76,
137
],
[
137,
223,
508
]
]
] |
[
[
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A7"
],
[
"CYP3A7",
"{u} (Gene) is bound by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ifosfamide"
],
[
"Ifosfamide",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may decrease the therapeutic efficacy of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Mexiletine"
],
[
"Mexiletine",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Itraconazole"
],
[
"Itraconazole",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
],
[
[
"Verapamil",
"{u} may increase the bradycardic activities of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may decrease the metabolism of {v}",
"Delavirdine"
]
]
] |
Verapamil (Compound) binds CYP3A7 (Gene) and CYP3A7 (Gene) is bound by Delavirdine (Compound)
Verapamil (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Delavirdine (Compound)
Verapamil can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Delavirdine
Verapamil may reduce the serum concentration of the active metabolites of Ifosfamide and Ifosfamide may reduce the serum concentration of the active metabolites of Delavirdine
Verapamil may decrease the therapeutic efficacy of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Delavirdine
Verapamil may decrease the metabolism of Fluvastatin and Fluvastatin may decrease the metabolism of Delavirdine
Verapamil may decrease the metabolism of Mexiletine and Mexiletine may decrease the metabolism of Delavirdine
Verapamil may decrease the metabolism of Itraconazole and Itraconazole may decrease the metabolism of Delavirdine
Verapamil may increase the bradycardic activities of Amiodarone and Amiodarone may decrease the metabolism of Delavirdine
|
DB04552
|
DB00524
| 774 | 1,059 |
Niflumic acid
|
Metolazone
|
Niflumic acid is an analgesic and anti-inflammatory agent used in the treatment of rheumatoid arthritis.
|
A quinazoline-sulfonamide that is considered a thiazide-like diuretic which is long-acting so useful in chronic renal failure. It also tends to lower blood pressure and increase potassium loss.
|
The therapeutic efficacy of Metolazone can be decreased when used in combination with Niflumic acid.
| 69 |
[
[
[
774,
92,
1059
]
],
[
[
774,
92,
1325
],
[
1325,
1,
1059
]
],
[
[
774,
213,
139
],
[
139,
71,
1059
]
],
[
[
774,
213,
306
],
[
306,
225,
1059
]
],
[
[
774,
225,
1071
],
[
1071,
225,
1059
]
],
[
[
774,
92,
1049
],
[
1049,
71,
1059
]
],
[
[
774,
51,
557
],
[
557,
71,
1059
]
],
[
[
774,
92,
1069
],
[
1069,
225,
1059
]
],
[
[
774,
51,
893
],
[
893,
225,
1059
]
],
[
[
774,
225,
239
],
[
239,
71,
1059
]
]
] |
[
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Quinethazone"
],
[
"Quinethazone",
"{u} (Compound) resembles {v} (Compound)",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Atenolol"
],
[
"Atenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the antihypertensive activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the diuretic activities of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the therapeutic efficacy of {v}",
"Hydrochlorothiazide"
],
[
"Hydrochlorothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may decrease the diuretic activities of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
],
[
[
"Niflumic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Valsartan"
],
[
"Valsartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metolazone"
]
]
] |
Niflumic acid may decrease the therapeutic efficacy of Quinethazone and Quinethazone (Compound) resembles Metolazone (Compound)
Niflumic acid may decrease the antihypertensive activities of Atenolol and Atenolol may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may decrease the antihypertensive activities of Aliskiren and Aliskiren may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may increase the severity of adverse effects when combined with Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may decrease the therapeutic efficacy of Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may decrease the diuretic activities of Torasemide and Torasemide may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may decrease the therapeutic efficacy of Hydrochlorothiazide and Hydrochlorothiazide may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may decrease the diuretic activities of Etacrynic acid and Etacrynic acid may increase the severity of adverse effects when combined with Metolazone
Niflumic acid may increase the severity of adverse effects when combined with Valsartan and Valsartan may increase the severity of adverse effects when combined with Metolazone
|
DB00593
|
DB01104
| 572 | 411 |
Ethosuximide
|
Sertraline
|
An anticonvulsant especially useful in the treatment of absence seizures unaccompanied by other types of seizures.
|
Sertraline is a popular antidepressant medication commonly known as a selective serotonin reuptake inhibitor (SSRI), and is similar to drugs such as [Citalopram] and [Fluoxetine]. Despite marked structural differences between compounds in this drug class, SSRIs exert similar pharmacological effects. Several weeks of therapy with sertraline may be required before beneficial effects are noticed. Sertraline displays enhanced safety or tolerability than other classes of antidepressants, which frequently cause high levels of drowsiness, dizziness, blurred vision, and other undesirable effects.[A1846,A187075,T28]
|
The risk or severity of adverse effects can be increased when Ethosuximide is combined with Sertraline.
| 48 |
[
[
[
572,
71,
411
]
],
[
[
572,
71,
987
],
[
987,
71,
411
]
],
[
[
572,
6,
4590
],
[
4590,
160,
411
]
],
[
[
572,
21,
28833
],
[
28833,
175,
411
]
],
[
[
572,
180,
173
],
[
173,
26,
411
]
],
[
[
572,
225,
392
],
[
392,
42,
411
]
],
[
[
572,
69,
1079
],
[
1079,
42,
411
]
],
[
[
572,
71,
956
],
[
956,
42,
411
]
],
[
[
572,
180,
156
],
[
156,
69,
411
]
],
[
[
572,
69,
1088
],
[
1088,
223,
411
]
]
] |
[
[
[
"Ethosuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Maprotiline"
],
[
"Maprotiline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} (Compound) causes {v} (Side Effect)",
"Urethral disorder"
],
[
"Urethral disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} may increase the QTc prolonging activities of {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tetrabenazine"
],
[
"Tetrabenazine",
"{u} may increase the QTc prolonging activities of {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} may decrease the metabolism of {v}",
"Sertraline"
]
],
[
[
"Ethosuximide",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may decrease the metabolism of {v}",
"Sertraline"
]
]
] |
Ethosuximide may increase the severity of adverse effects when combined with Maprotiline and Maprotiline may increase the severity of adverse effects when combined with Sertraline
Ethosuximide (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Sertraline (Compound)
Ethosuximide (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Sertraline (Compound)
Ethosuximide can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Sertraline
Ethosuximide may increase the severity of adverse effects when combined with Chlorpromazine and Chlorpromazine may increase the QTc prolonging activities of Sertraline
Ethosuximide may decrease the metabolism of Crizotinib and Crizotinib may increase the QTc prolonging activities of Sertraline
Ethosuximide may increase the severity of adverse effects when combined with Tetrabenazine and Tetrabenazine may increase the QTc prolonging activities of Sertraline
Ethosuximide can increase the metabolism of Carbamazepine and Carbamazepine may decrease the metabolism of Sertraline
Ethosuximide may decrease the metabolism of Clarithromycin and Clarithromycin may decrease the metabolism of Sertraline
|
DB00906
|
DB00980
| 201 | 250 |
Tiagabine
|
Ramelteon
|
Tiagabine is an anti-convulsive medication. It is also used in the treatment for panic disorder as are a few other anticonvulsants. Though the exact mechanism by which tiagabine exerts its effect on the human body is unknown, it does appear to operate as a selective GABA reuptake inhibitor.
|
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
|
The risk or severity of adverse effects can be increased when Tiagabine is combined with Ramelteon.
| 48 |
[
[
[
201,
71,
250
]
],
[
[
201,
6,
4590
],
[
4590,
160,
250
]
],
[
[
201,
21,
28575
],
[
28575,
175,
250
]
],
[
[
201,
180,
164
],
[
164,
26,
250
]
],
[
[
201,
192,
72
],
[
72,
38,
250
]
],
[
[
201,
38,
1261
],
[
1261,
192,
250
]
],
[
[
201,
54,
471
],
[
471,
208,
250
]
],
[
[
201,
69,
1077
],
[
1077,
223,
250
]
],
[
[
201,
225,
611
],
[
611,
223,
250
]
],
[
[
201,
71,
394
],
[
394,
223,
250
]
]
] |
[
[
[
"Tiagabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} (Compound) causes {v} (Side Effect)",
"Influenza"
],
[
"Influenza",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may decrease the metabolism of {v}",
"Isavuconazonium"
],
[
"Isavuconazonium",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lidocaine"
],
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Tiagabine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may decrease the metabolism of {v}",
"Ramelteon"
]
]
] |
Tiagabine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ramelteon (Compound)
Tiagabine (Compound) causes Influenza (Side Effect) and Influenza (Side Effect) is caused by Ramelteon (Compound)
Tiagabine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Ramelteon
Tiagabine may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Ramelteon
Tiagabine may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Ramelteon
Tiagabine may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Ramelteon
Tiagabine may decrease the metabolism of Isavuconazonium and Isavuconazonium may decrease the metabolism of Ramelteon
Tiagabine may increase the severity of adverse effects when combined with Lidocaine and Lidocaine may decrease the metabolism of Ramelteon
Tiagabine may increase the severity of adverse effects when combined with Fluoxetine and Fluoxetine may decrease the metabolism of Ramelteon
|
DB01590
|
DB00701
| 1,392 | 431 |
Everolimus
|
Amprenavir
|
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
|
Amprenavir is a protease inhibitor used to treat HIV infection.
|
The serum concentration of Amprenavir can be increased when it is combined with Everolimus.
| 72 |
[
[
[
1392,
95,
431
]
],
[
[
1392,
6,
4590
],
[
4590,
160,
431
]
],
[
[
1392,
169,
24710
],
[
24710,
15,
431
]
],
[
[
1392,
21,
28501
],
[
28501,
175,
431
]
],
[
[
1392,
251,
161
],
[
161,
26,
431
]
],
[
[
1392,
95,
173
],
[
173,
26,
431
]
],
[
[
1392,
95,
657
],
[
657,
223,
431
]
],
[
[
1392,
95,
482
],
[
482,
69,
431
]
],
[
[
1392,
92,
297
],
[
297,
223,
431
]
],
[
[
1392,
119,
513
],
[
513,
225,
431
]
]
] |
[
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Cytochrome P450 3A4 Inhibitors"
],
[
"Cytochrome P450 3A4 Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} (Compound) causes {v} (Side Effect)",
"Gastrointestinal pain"
],
[
"Gastrointestinal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} may decrease the serum concentration of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Voriconazole"
],
[
"Voriconazole",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} may increase the serum concentration of {v}",
"Verapamil"
],
[
"Verapamil",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} may decrease the therapeutic efficacy of {v}",
"Tolbutamide"
],
[
"Tolbutamide",
"{u} may decrease the metabolism of {v}",
"Amprenavir"
]
],
[
[
"Everolimus",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the serum concentration of {v}",
"Temsirolimus"
],
[
"Temsirolimus",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amprenavir"
]
]
] |
Everolimus (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Amprenavir (Compound)
Everolimus (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Amprenavir (Compound)
Everolimus (Compound) causes Gastrointestinal pain (Side Effect) and Gastrointestinal pain (Side Effect) is caused by Amprenavir (Compound)
Everolimus may decrease the serum concentration of Primidone and Primidone can increase the metabolism of Amprenavir
Everolimus may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Amprenavir
Everolimus may increase the serum concentration of Voriconazole and Voriconazole may decrease the metabolism of Amprenavir
Everolimus may increase the serum concentration of Verapamil and Verapamil may decrease the metabolism of Amprenavir
Everolimus may decrease the therapeutic efficacy of Tolbutamide and Tolbutamide may decrease the metabolism of Amprenavir
Everolimus (Compound) resembles Temsirolimus (Compound) and Everolimus may increase the serum concentration of Temsirolimus and Temsirolimus may increase the severity of adverse effects when combined with Amprenavir
|
DB00924
|
DB00343
| 195 | 461 |
Cyclobenzaprine
|
Diltiazem
|
Cyclobenzaprine, a centrally-acting muscle relaxant, was first synthesized in 1961 and has been available for human use since 1977. It was initially studied for use as antidepressant given its structural similarity to tricyclic antidepressants - it differs from [Amitriptyline] by only a single double bond.[A185039,A184982] Since its approval, it has remained relatively popular as an adjunctive, short-term treatment for acute skeletal muscle spasms secondary to musculoskeletal injury.
|
Diltiazem is a benzothiazepine derivative with antihypertensive and vasodilating properties. Approved in 1982 by the FDA, it is a member of the non-dihydropyridine calcium channel blockers drug class. It works through various mechanisms of action, but it primarily works by inhibiting the calcium influx into cardiac and vascular smooth muscle during depolarization. Compared to dihydropyridine drugs, such as [nifedipine], that preferentially act on vascular smooth muscle and [verapamil] that directly acts on the heart muscle, diltiazem displays an intermediate specificity to target both the cardiac and vascular smooth muscle. Being a potent vasodilator, diltiazem is used clinically as an antihypertensive, anti-arrhythmic, and as an anti-anginal agent for the management of cardiovascular conditions such as hypertension, chronic stable angina, atrial fibrillation,
|
The metabolism of Diltiazem can be decreased when combined with Cyclobenzaprine.
| 46 |
[
[
[
195,
69,
461
]
],
[
[
195,
155,
317
],
[
317,
1,
461
]
],
[
[
195,
6,
4590
],
[
4590,
160,
461
]
],
[
[
195,
21,
28782
],
[
28782,
175,
461
]
],
[
[
195,
180,
164
],
[
164,
26,
461
]
],
[
[
195,
38,
702
],
[
702,
32,
461
]
],
[
[
195,
69,
1091
],
[
1091,
201,
461
]
],
[
[
195,
71,
968
],
[
968,
206,
461
]
],
[
[
195,
211,
997
],
[
997,
211,
461
]
],
[
[
195,
249,
230
],
[
230,
213,
461
]
]
] |
[
[
[
"Cyclobenzaprine",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Promethazine"
],
[
"Promethazine",
"{u} (Compound) resembles {v} (Compound)",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} (Compound) causes {v} (Side Effect)",
"Dry mouth"
],
[
"Dry mouth",
"{u} (Side Effect) is caused by {v} (Compound)",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} may decrease the metabolism of {v}",
"Dronedarone"
],
[
"Dronedarone",
"{u} may increase the atrioventricular blocking activities of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Diltiazem"
]
],
[
[
"Cyclobenzaprine",
"{u} may increase the serum concentration of {v}",
"Yohimbine"
],
[
"Yohimbine",
"{u} may decrease the antihypertensive activities of {v}",
"Diltiazem"
]
]
] |
Cyclobenzaprine (Compound) resembles Promethazine (Compound) and Promethazine (Compound) resembles Diltiazem (Compound)
Cyclobenzaprine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Diltiazem (Compound)
Cyclobenzaprine (Compound) causes Dry mouth (Side Effect) and Dry mouth (Side Effect) is caused by Diltiazem (Compound)
Cyclobenzaprine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Diltiazem
Cyclobenzaprine may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the antihypertensive activities of Diltiazem
Cyclobenzaprine may decrease the metabolism of Dronedarone and Dronedarone may increase the atrioventricular blocking activities of Diltiazem
Cyclobenzaprine may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Diltiazem
Cyclobenzaprine may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the neurotoxic activities of Diltiazem
Cyclobenzaprine may increase the serum concentration of Yohimbine and Yohimbine may decrease the antihypertensive activities of Diltiazem
|
DB00852
|
DB01142
| 718 | 486 |
Pseudoephedrine
|
Doxepin
|
Pseudoephedrine is structurally related to [ephedrine] but exerts a weaker effect on the sympathetic nervous system.[A188820,A188823] Both drugs naturally occur in in ephedra plant which have a history of use in traditional Eastern medicine and were first researched in the west in 1889. The decongestant effect of pseudoephedrine was described in dogs in 1927.
|
Doxepin is a psychotropic agent with antidepressant and anxiolytic properties. It is a tertiary amine that can be presented as (E) and (Z) stereoisomers with the (Z) stereoisomer corresponding to [cidoxepin]. Doxepin commonly produces a 5:1 (E):(Z) racemic mixture. In a strict sense, doxepin is not a tricyclic antidepressant but it is commonly associated with the class since it shares a lot of properties with members of the drug family including [amitriptyline], [clomipramine], [desipramine], [imipramine], [nortriptyline], [protriptyline] and [trimipramine]. Doxepin was developed by Pfizer and FDA approved in 1969 as an antidepressant. However, in 2010 it was approved for the treatment of insomnia. The latter
|
Pseudoephedrine may decrease the antihypertensive activities of Doxepin.
| 36 |
[
[
[
718,
59,
486
]
],
[
[
718,
83,
967
],
[
967,
71,
486
]
],
[
[
718,
59,
221
],
[
221,
71,
486
]
],
[
[
718,
98,
478
],
[
478,
71,
486
]
],
[
[
718,
98,
1650
],
[
1650,
155,
486
]
],
[
[
718,
98,
1637
],
[
1637,
1,
486
]
],
[
[
718,
69,
288
],
[
288,
155,
486
]
],
[
[
718,
6,
11891
],
[
11891,
160,
486
]
],
[
[
718,
21,
28446
],
[
28446,
175,
486
]
],
[
[
718,
97,
164
],
[
164,
26,
486
]
]
] |
[
[
[
"Pseudoephedrine",
"{u} may decrease the antihypertensive activities of {v}",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the stimulatory activities of {v}",
"Chlorprothixene"
],
[
"Chlorprothixene",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the antihypertensive activities of {v}",
"Nortriptyline"
],
[
"Nortriptyline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the sedative activities of {v}",
"Olopatadine"
],
[
"Olopatadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the sedative activities of {v}",
"Dimetindene"
],
[
"Dimetindene",
"{u} (Compound) resembles {v} (Compound)",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the sedative activities of {v}",
"Pheniramine"
],
[
"Pheniramine",
"{u} (Compound) resembles {v} (Compound)",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the metabolism of {v}",
"Promazine"
],
[
"Promazine",
"{u} (Compound) resembles {v} (Compound)",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) binds {v} (Gene)",
"ADRA1A"
],
[
"ADRA1A",
"{u} (Gene) is bound by {v} (Compound)",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} (Compound) causes {v} (Side Effect)",
"Anorexia"
],
[
"Anorexia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Doxepin"
]
],
[
[
"Pseudoephedrine",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Doxepin"
]
]
] |
Pseudoephedrine may decrease the stimulatory activities of Chlorprothixene and Chlorprothixene may increase the severity of adverse effects when combined with Doxepin
Pseudoephedrine may decrease the antihypertensive activities of Nortriptyline and Nortriptyline may increase the severity of adverse effects when combined with Doxepin
Pseudoephedrine may decrease the sedative activities of Olopatadine and Olopatadine may increase the severity of adverse effects when combined with Doxepin
Pseudoephedrine may decrease the sedative activities of Dimetindene and Dimetindene (Compound) resembles Doxepin (Compound)
Pseudoephedrine may decrease the sedative activities of Pheniramine and Pheniramine (Compound) resembles Doxepin (Compound)
Pseudoephedrine may decrease the metabolism of Promazine and Promazine (Compound) resembles Doxepin (Compound)
Pseudoephedrine (Compound) binds ADRA1A (Gene) and ADRA1A (Gene) is bound by Doxepin (Compound)
Pseudoephedrine (Compound) causes Anorexia (Side Effect) and Anorexia (Side Effect) is caused by Doxepin (Compound)
Pseudoephedrine may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Doxepin
|
DB04855
|
DB01026
| 1,091 | 496 |
Dronedarone
|
Ketoconazole
|
Dronedarone is a Class III antiarrhythmic drug that works to restore the normal sinus rhythm in patients with paroxysmal or persistent atrial fibrillation. Atrial fibrillation is a common sustained arrhythmia where the treatment primarily focuses on stroke prevention and symptom management. It is managed by rate control, rhythm control, prevention of thromboembolic events, and treatment of the underlying disease. Similar to [amiodarone], dronedarone is a multichannel blocker that works to control rhythm and rate in atrial fibrillation. It meets criteria of all four Vaughan Williams antiarrhythmic drug classes by blocking sodium, potassium, and calcium ion channels and inhibiting β-adrenergic receptors.[A34604,L8699] Dronedarone is a related benzofuran compound to amiodarone but its chemical structure lacks iodine moieties which are associated with amiodarone-induced thyroid problems.[A34604,T28] Additionally
|
Ketoconazole is an imidazole antifungal agent used in the prevention and treatment of a variety of fungal infections.[FDA Label] It functions by preventing the synthesis of ergosterol, the fungal equivalent of cholesterol, thereby increasing membrane fluidity and preventing growth of the fungus.[A181802,T116] Ketoconazole was first approved in an oral formulation for systemic use by the FDA in 1981. At this time it was considered a significant improvement over previous antifungals, [miconazole] and [clotrimazole], due to its broad spectrum and good absorption. However, it was discovered that ketoconazole produces frequent gastrointestinal side effects and dose-related hepatitis.[A188054,A188057] These effects combined with waning efficacy led to its eventual replacement by triazole agents, [fluconazole], [itraconazole], [voriconazole], and [posaconazole]. Ketoconazole and its predecessor [clotrimazole] continue
|
The serum concentration of Ketoconazole can be increased when it is combined with Dronedarone.
| 72 |
[
[
[
1091,
95,
496
]
],
[
[
1091,
95,
479
],
[
479,
69,
496
]
],
[
[
1091,
6,
8339
],
[
8339,
160,
496
]
],
[
[
1091,
21,
28474
],
[
28474,
175,
496
]
],
[
[
1091,
251,
177
],
[
177,
26,
496
]
],
[
[
1091,
33,
568
],
[
568,
187,
496
]
],
[
[
1091,
223,
597
],
[
597,
187,
496
]
],
[
[
1091,
209,
1208
],
[
1208,
42,
496
]
],
[
[
1091,
42,
863
],
[
863,
42,
496
]
],
[
[
1091,
76,
1027
],
[
1027,
42,
496
]
]
] |
[
[
[
"Dronedarone",
"{u} may increase the serum concentration of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may increase the serum concentration of {v}",
"Posaconazole"
],
[
"Posaconazole",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} (Compound) causes {v} (Side Effect)",
"Dermatitis"
],
[
"Dermatitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Tamoxifen"
],
[
"Tamoxifen",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may decrease the metabolism of {v}",
"Clopidogrel"
],
[
"Clopidogrel",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Arsenic trioxide"
],
[
"Arsenic trioxide",
"{u} may increase the QTc prolonging activities of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the QTc prolonging activities of {v}",
"Ketoconazole"
]
],
[
[
"Dronedarone",
"{u} may increase the bradycardic activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the QTc prolonging activities of {v}",
"Ketoconazole"
]
]
] |
Dronedarone may increase the serum concentration of Posaconazole and Posaconazole may decrease the metabolism of Ketoconazole
Dronedarone (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Ketoconazole (Compound)
Dronedarone (Compound) causes Dermatitis (Side Effect) and Dermatitis (Side Effect) is caused by Ketoconazole (Compound)
Dronedarone may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Ketoconazole
Dronedarone may reduce the serum concentration of the active metabolites of Tamoxifen and Tamoxifen may reduce the serum concentration of the active metabolites of Ketoconazole
Dronedarone may decrease the metabolism of Clopidogrel and Clopidogrel may reduce the serum concentration of the active metabolites of Ketoconazole
Dronedarone may increase the severity of QTc prolonging effects when combined with Arsenic trioxide and Arsenic trioxide may increase the QTc prolonging activities of Ketoconazole
Dronedarone may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the QTc prolonging activities of Ketoconazole
Dronedarone may increase the bradycardic activities of Sotalol and Sotalol may increase the QTc prolonging activities of Ketoconazole
|
DB06788
|
DB00912
| 1,319 | 423 |
Histrelin
|
Repaglinide
|
Histrelin is a gonadotropin-releasing hormone (GnRH) agonist that acts as a potent inhibitor of gonadotropin when administered as an implant delivering continuous therapeutic doses. This drug is a synthetic analog of naturally occurring GnRH with a higher potency. Histrelin implants are non-biodegradable, diffusion-controlled, hydrogel polymer reservoirs containing histrelin acetate that need to be replaced every 52 weeks.[L41700,L41715,L41755] Initially, histrelin implants were developed to reduce testosterone to castration levels in patients with advanced prostate cancer. The Vantas product was approved by the FDA in October 2004 for the palliative treatment of this condition. Vantas was later discontinued by Endo Pharmaceuticals Inc. on September 21, 2021. GnRH agonists are the first line of treatment for children with central precocious puberty (CPP) due to their capacity to reduce LH levels and the concentration of
|
Repaglinide is an oral antihyperglycemic agent used for the treatment of non-insulin-dependent diabetes mellitus (NIDDM). It belongs to the meglitinide class of short-acting insulin secretagogues, which act by binding to β cells of the pancreas to stimulate insulin release. Repaglinide induces an early insulin response to meals decreasing postprandial blood glucose levels. It should only be taken with meals and meal-time doses should be skipped with any skipped meal. Approximately one month of therapy is required before a decrease in fasting blood glucose is seen. Meglitnides may have a neutral effect on weight or cause a slight increase in weight. The average weight gain caused by meglitinides appears to be lower than that caused by sulfonylureas and insulin and appears to occur only in those naïve to oral antidiabetic agents. Due to their mechanism of action, meglitinides may cause hypoglycemia
|
The therapeutic efficacy of Repaglinide can be decreased when used in combination with Histrelin.
| 69 |
[
[
[
1319,
92,
423
]
],
[
[
1319,
92,
326
],
[
326,
31,
423
]
],
[
[
1319,
196,
863
],
[
863,
185,
423
]
],
[
[
1319,
92,
947
],
[
947,
185,
423
]
],
[
[
1319,
196,
1079
],
[
1079,
223,
423
]
],
[
[
1319,
92,
514
],
[
514,
223,
423
]
],
[
[
1319,
196,
1187
],
[
1187,
92,
423
]
],
[
[
1319,
196,
137
],
[
137,
249,
423
]
],
[
[
1319,
42,
1019
],
[
1019,
249,
423
]
],
[
[
1319,
196,
495
],
[
495,
97,
423
]
]
] |
[
[
[
"Histrelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Gemifloxacin"
],
[
"Gemifloxacin",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Acarbose"
],
[
"Acarbose",
"{u} may increase the hypoglycemic activities of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may decrease the metabolism of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may decrease the metabolism of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Goserelin"
],
[
"Goserelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may increase the serum concentration of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Repaglinide"
]
],
[
[
"Histrelin",
"{u} may increase the QTc prolonging activities of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may decrease the serum concentration of {v}",
"Repaglinide"
]
]
] |
Histrelin may decrease the therapeutic efficacy of Glipizide and Glipizide may increase the hypoglycemic activities of Repaglinide
Histrelin may increase the QTc prolonging activities of Gemifloxacin and Gemifloxacin may increase the hypoglycemic activities of Repaglinide
Histrelin may decrease the therapeutic efficacy of Acarbose and Acarbose may increase the hypoglycemic activities of Repaglinide
Histrelin may increase the QTc prolonging activities of Crizotinib and Crizotinib may decrease the metabolism of Repaglinide
Histrelin may decrease the therapeutic efficacy of Rosiglitazone and Rosiglitazone may decrease the metabolism of Repaglinide
Histrelin may increase the QTc prolonging activities of Goserelin and Goserelin may decrease the therapeutic efficacy of Repaglinide
Histrelin may increase the QTc prolonging activities of Amiodarone and Amiodarone may increase the serum concentration of Repaglinide
Histrelin may increase the QTc prolonging activities of Mifepristone and Mifepristone may increase the serum concentration of Repaglinide
Histrelin may increase the QTc prolonging activities of Vemurafenib and Vemurafenib may decrease the serum concentration of Repaglinide
|
DB01016
|
DB08880
| 526 | 814 |
Glyburide
|
Teriflunomide
|
Glyburide is a second generation sulfonylurea used to treat patients with diabetes mellitus type II. It is typically given to patients who cannot be managed with the standard first line therapy, [metformin]. Glyburide stimulates insulin secretion through the closure of ATP-sensitive potassium channels on beta cells, raising intracellular potassium and calcium ion concentrations. Glyburide was granted FDA approval on 1 May 1984. A formulation with metformin was granted FDA approval on on 31 July 2000.
|
Teriflunomide is the active metabolite of leflunomide, and it acts as an immunomodulatory agent by inhibiting pyrimidine synthesis. It is marketed under the name Aubagio® and is indicated for the treatment of multiple sclerosis, specifically relapsing forms. The FDA label states an important warning about the risk of hepatoxicity and teratogenicity for patients using teriflunomide.
|
The serum concentration of Teriflunomide can be increased when it is combined with Glyburide.
| 72 |
[
[
[
526,
95,
814
]
],
[
[
526,
182,
498
],
[
498,
28,
814
]
],
[
[
526,
249,
744
],
[
744,
28,
814
]
],
[
[
526,
31,
776
],
[
776,
203,
814
]
],
[
[
526,
246,
557
],
[
557,
205,
814
]
],
[
[
526,
31,
731
],
[
731,
59,
814
]
],
[
[
526,
69,
535
],
[
535,
69,
814
]
],
[
[
526,
180,
142
],
[
142,
69,
814
]
],
[
[
526,
251,
1110
],
[
1110,
69,
814
]
],
[
[
526,
246,
80
],
[
80,
225,
814
]
]
] |
[
[
[
"Glyburide",
"{u} may increase the serum concentration of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may increase the serum concentration of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may increase the anticoagulant activities of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Rosoxacin"
],
[
"Rosoxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may decrease the therapeutic efficacy of {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may decrease the antihypertensive activities of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may decrease the metabolism of {v}",
"Irbesartan"
],
[
"Irbesartan",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may decrease the serum concentration of {v}",
"Enzalutamide"
],
[
"Enzalutamide",
"{u} may decrease the metabolism of {v}",
"Teriflunomide"
]
],
[
[
"Glyburide",
"{u} may decrease the therapeutic efficacy of {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Teriflunomide"
]
]
] |
Glyburide may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Teriflunomide
Glyburide may increase the serum concentration of Edoxaban and Edoxaban may increase the anticoagulant activities of Teriflunomide
Glyburide may increase the hypoglycemic activities of Rosoxacin and Rosoxacin may increase the neuroexcitatory activities of Teriflunomide
Glyburide may decrease the therapeutic efficacy of Torasemide and Torasemide may decrease the diuretic activities of Teriflunomide
Glyburide may increase the hypoglycemic activities of Nebivolol and Nebivolol may decrease the antihypertensive activities of Teriflunomide
Glyburide may decrease the metabolism of Irbesartan and Irbesartan may decrease the metabolism of Teriflunomide
Glyburide can increase the metabolism of Phenytoin and Phenytoin may decrease the metabolism of Teriflunomide
Glyburide may decrease the serum concentration of Enzalutamide and Enzalutamide may decrease the metabolism of Teriflunomide
Glyburide may decrease the therapeutic efficacy of Prednisone and Prednisone may increase the severity of adverse effects when combined with Teriflunomide
|
DB01189
|
DB01210
| 914 | 1,029 |
Desflurane
|
Levobunolol
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
A nonselective beta-adrenoceptor antagonist used in the treatment of glaucoma.
|
The risk or severity of adverse effects can be increased when Desflurane is combined with Levobunolol.
| 48 |
[
[
[
914,
71,
1029
]
],
[
[
914,
71,
1035
],
[
1035,
155,
1029
]
],
[
[
914,
21,
28580
],
[
28580,
175,
1029
]
],
[
[
914,
225,
247
],
[
247,
41,
1029
]
],
[
[
914,
52,
968
],
[
968,
206,
1029
]
],
[
[
914,
71,
385
],
[
385,
71,
1029
]
],
[
[
914,
225,
605
],
[
605,
71,
1029
]
],
[
[
914,
196,
1027
],
[
1027,
71,
1029
]
],
[
[
914,
192,
679
],
[
679,
71,
1029
]
],
[
[
914,
196,
955
],
[
955,
225,
1029
]
]
] |
[
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carteolol"
],
[
"Carteolol",
"{u} (Compound) resembles {v} (Compound)",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Conjunctivitis"
],
[
"Conjunctivitis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may increase the vasoconstricting activities of {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amlodipine"
],
[
"Amlodipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cilnidipine"
],
[
"Cilnidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobunolol"
]
]
] |
Desflurane may increase the severity of adverse effects when combined with Carteolol and Carteolol (Compound) resembles Levobunolol (Compound)
Desflurane (Compound) causes Conjunctivitis (Side Effect) and Conjunctivitis (Side Effect) is caused by Levobunolol (Compound)
Desflurane may increase the severity of adverse effects when combined with Bromocriptine and Bromocriptine may increase the vasoconstricting activities of Levobunolol
Desflurane may increase the orthostatic hypotensive activities of Levodopa and Levodopa may increase the orthostatic hypotensive activities of Levobunolol
Desflurane may increase the severity of adverse effects when combined with Amlodipine and Amlodipine may increase the severity of adverse effects when combined with Levobunolol
Desflurane may increase the severity of adverse effects when combined with Cilnidipine and Cilnidipine may increase the severity of adverse effects when combined with Levobunolol
Desflurane may increase the QTc prolonging activities of Sotalol and Sotalol may increase the severity of adverse effects when combined with Levobunolol
Desflurane may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the severity of adverse effects when combined with Levobunolol
Desflurane may increase the QTc prolonging activities of Quetiapine and Quetiapine may increase the severity of adverse effects when combined with Levobunolol
|
DB00988
|
DB00264
| 415 | 576 |
Dopamine
|
Metoprolol
|
One of the catecholamine neurotransmitters in the brain. It is derived from tyrosine and is the precursor to norepinephrine and epinephrine. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (receptors, dopamine) mediate its action.
|
Metoprolol is a selective beta-1 blocker commonly employed as the succinate and tartrate derivatives depending if the formulation is designed to be of immediate release or extended release.[A175159, L5530] The possibility of the generation of these formulations comes from the lower systemic bioavailability of the succinate derivative. To this date, it is one of the preferred beta-blockers in general clinical guidelines and it is widely prescribed in the Netherlands, New Zealand, and the US. Metoprolol was developed since 1969 by US Pharmaceutical Holdings I and FDA approved in 1978.
|
The metabolism of Metoprolol can be decreased when combined with Dopamine.
| 46 |
[
[
[
415,
69,
576
]
],
[
[
415,
69,
1037
],
[
1037,
249,
576
]
],
[
[
415,
6,
18777
],
[
18777,
160,
576
]
],
[
[
415,
21,
28613
],
[
28613,
175,
576
]
],
[
[
415,
180,
147
],
[
147,
26,
576
]
],
[
[
415,
71,
710
],
[
710,
190,
576
]
],
[
[
415,
225,
725
],
[
725,
190,
576
]
],
[
[
415,
155,
727
],
[
727,
190,
576
]
],
[
[
415,
225,
720
],
[
720,
47,
576
]
],
[
[
415,
270,
721
],
[
721,
47,
576
]
]
] |
[
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} may decrease the metabolism of {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may increase the serum concentration of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} (Compound) causes {v} (Side Effect)",
"Vomiting"
],
[
"Vomiting",
"{u} (Side Effect) is caused by {v} (Compound)",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Procaterol"
],
[
"Procaterol",
"{u} may decrease the bronchodilatory activities of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Orciprenaline"
],
[
"Orciprenaline",
"{u} may decrease the bronchodilatory activities of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} (Compound) resembles {v} (Compound)",
"Isoetharine"
],
[
"Isoetharine",
"{u} may decrease the bronchodilatory activities of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxymetazoline"
],
[
"Oxymetazoline",
"{u} may increase the atrioventricular blocking activities of {v}",
"Metoprolol"
]
],
[
[
"Dopamine",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Norepinephrine"
],
[
"Norepinephrine",
"{u} may increase the atrioventricular blocking activities of {v}",
"Metoprolol"
]
]
] |
Dopamine may decrease the metabolism of Betaxolol and Betaxolol may increase the serum concentration of Metoprolol
Dopamine (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Metoprolol (Compound)
Dopamine (Compound) causes Vomiting (Side Effect) and Vomiting (Side Effect) is caused by Metoprolol (Compound)
Dopamine can increase the metabolism of Rifampicin and Rifampicin can increase the metabolism of Metoprolol
Dopamine may increase the severity of adverse effects when combined with Procaterol and Procaterol may decrease the bronchodilatory activities of Metoprolol
Dopamine may increase the severity of adverse effects when combined with Orciprenaline and Orciprenaline may decrease the bronchodilatory activities of Metoprolol
Dopamine (Compound) resembles Isoetharine (Compound) and Isoetharine may decrease the bronchodilatory activities of Metoprolol
Dopamine may increase the severity of adverse effects when combined with Oxymetazoline and Oxymetazoline may increase the atrioventricular blocking activities of Metoprolol
Dopamine (Compound) resembles Norepinephrine (Compound) and Dopamine may increase the severity of adverse effects when combined with Norepinephrine and Norepinephrine may increase the atrioventricular blocking activities of Metoprolol
|
DB01401
|
DB00288
| 805 | 114 |
Choline magnesium trisalicylate
|
Amcinonide
|
Choline magnesium trisalicylate is a non-acetylated salicylate used widely as a nonsteroidal anti-inflammatory drug. Trisalicylate significantly reduces methotrexate renal clearance, displacing methotrexate from protein, increasing the fraction unbound by 28% [A19653, A19654].
|
Amcinonide is a corticosteroid.
|
The risk or severity of adverse effects can be increased when Choline magnesium trisalicylate is combined with Amcinonide.
| 48 |
[
[
[
805,
71,
114
]
],
[
[
805,
71,
82
],
[
82,
155,
114
]
],
[
[
805,
71,
117
],
[
117,
1,
114
]
],
[
[
805,
21,
28633
],
[
28633,
175,
114
]
],
[
[
805,
182,
219
],
[
219,
28,
114
]
],
[
[
805,
92,
1351
],
[
1351,
71,
114
]
],
[
[
805,
225,
770
],
[
770,
71,
114
]
],
[
[
805,
49,
882
],
[
882,
225,
114
]
],
[
[
805,
71,
826
],
[
826,
71,
114
]
],
[
[
805,
182,
687
],
[
687,
71,
114
]
]
] |
[
[
[
"Choline magnesium trisalicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prednisolone"
],
[
"Prednisolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Rimexolone"
],
[
"Rimexolone",
"{u} (Compound) resembles {v} (Compound)",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} (Compound) causes {v} (Side Effect)",
"Pruritus"
],
[
"Pruritus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may decrease the therapeutic efficacy of {v}",
"Acemetacin"
],
[
"Acemetacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Floctafenine"
],
[
"Floctafenine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the neuroexcitatory activities of {v}",
"Gatifloxacin"
],
[
"Gatifloxacin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxyphenbutazone"
],
[
"Oxyphenbutazone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
],
[
[
"Choline magnesium trisalicylate",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amcinonide"
]
]
] |
Choline magnesium trisalicylate may increase the severity of adverse effects when combined with Prednisolone and Prednisolone (Compound) resembles Amcinonide (Compound)
Choline magnesium trisalicylate may increase the severity of adverse effects when combined with Rimexolone and Rimexolone (Compound) resembles Amcinonide (Compound)
Choline magnesium trisalicylate (Compound) causes Pruritus (Side Effect) and Pruritus (Side Effect) is caused by Amcinonide (Compound)
Choline magnesium trisalicylate may increase the anticoagulant activities of Warfarin and Warfarin may increase the anticoagulant activities of Amcinonide
Choline magnesium trisalicylate may decrease the therapeutic efficacy of Acemetacin and Acemetacin may increase the severity of adverse effects when combined with Amcinonide
Choline magnesium trisalicylate may increase the severity of adverse effects when combined with Floctafenine and Floctafenine may increase the severity of adverse effects when combined with Amcinonide
Choline magnesium trisalicylate may increase the neuroexcitatory activities of Gatifloxacin and Gatifloxacin may increase the severity of adverse effects when combined with Amcinonide
Choline magnesium trisalicylate may increase the severity of adverse effects when combined with Oxyphenbutazone and Oxyphenbutazone may increase the severity of adverse effects when combined with Amcinonide
Choline magnesium trisalicylate may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the severity of adverse effects when combined with Amcinonide
|
DB01043
|
DB00209
| 1,120 | 57 |
Memantine
|
Trospium
|
Initially approved by the FDA in 2013, memantine is an N-methyl-D-aspartate (NMDA) receptor antagonist used in the management of Alzheimer's Disease (AD). It is different from many other Alzheimer's Disease medications, as it works by a different mechanism than the cholinesterase enzyme inhibitors normally employed in the management of Alzheimer's disease. Memantine blocks the effects of glutamate, a neurotransmitter in the brain that leads to neuronal excitability and excessive stimulation in Alzheimer's Disease. In 2010, it was estimated that 36 million people worldwide live with Alzheimer's Disease. In 2013, this number increased to 44 million. Almost doubling every 20 years, the prevalence of Alzheimer's Disease is predicted to reach 66 million by 2030 and to 115 million by 2050. In December 2013, the G8 dementia summit concluded that dementia should be considered a global priority with the objective of developing a cure or
|
Trospium is an antispasmodic agent used to treat the symptoms of overactive bladder, a condition that causes the bladder muscles to contract uncontrollably. An overactive bladder leads to an increased urge to urinate, frequent urination, and sometimes, loss of control over urination. Trospium is manufactured by _Indevus Pharmaceutical Inc._ and was granted FDA approval in 2007.
|
The therapeutic efficacy of Trospium can be decreased when used in combination with Memantine.
| 69 |
[
[
[
1120,
92,
57
]
],
[
[
1120,
92,
76
],
[
76,
71,
57
]
],
[
[
1120,
92,
28
],
[
28,
24,
57
]
],
[
[
1120,
21,
29613
],
[
29613,
175,
57
]
],
[
[
1120,
92,
45
],
[
45,
225,
57
]
],
[
[
1120,
92,
12
],
[
12,
146,
57
]
],
[
[
1120,
92,
76
],
[
76,
1,
941
],
[
941,
155,
57
]
],
[
[
1120,
21,
29613
],
[
29613,
175,
961
],
[
961,
225,
57
]
],
[
[
1120,
21,
28833
],
[
28833,
175,
32
],
[
32,
155,
57
]
],
[
[
1120,
21,
28461
],
[
28461,
175,
29
],
[
29,
1,
57
]
]
] |
[
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Glycopyrronium"
],
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} (Compound) causes {v} (Side Effect)",
"Micturition disorder"
],
[
"Micturition disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Trospium"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Mecamylamine"
],
[
"Mecamylamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Aclidinium"
],
[
"Aclidinium",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticholinergic activities of {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} may decrease the therapeutic efficacy of {v}",
"Benzatropine"
],
[
"Benzatropine",
"{u} (Compound) resembles {v} (Compound)",
"Clidinium"
],
[
"Clidinium",
"{u} (Compound) resembles {v} (Compound)",
"Trospium"
]
],
[
[
"Memantine",
"{u} (Compound) causes {v} (Side Effect)",
"Micturition disorder"
],
[
"Micturition disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fentanyl"
],
[
"Fentanyl",
"{u} may increase the severity of adverse effects when combined with {v}",
"Trospium"
]
],
[
[
"Memantine",
"{u} (Compound) causes {v} (Side Effect)",
"Urethral disorder"
],
[
"Urethral disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Darifenacin"
],
[
"Darifenacin",
"{u} (Compound) resembles {v} (Compound)",
"Trospium"
]
],
[
[
"Memantine",
"{u} (Compound) causes {v} (Side Effect)",
"Fatigue"
],
[
"Fatigue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ipratropium"
],
[
"Ipratropium",
"{u} (Compound) resembles {v} (Compound)",
"Trospium"
]
]
] |
Memantine may decrease the therapeutic efficacy of Benzatropine and Benzatropine may increase the severity of adverse effects when combined with Trospium
Memantine may decrease the therapeutic efficacy of Glycopyrronium and Glycopyrronium may increase the anticholinergic activities of Trospium
Memantine (Compound) causes Micturition disorder (Side Effect) and Micturition disorder (Side Effect) is caused by Trospium (Compound)
Memantine may decrease the therapeutic efficacy of Mecamylamine and Mecamylamine may increase the severity of adverse effects when combined with Trospium
Memantine may decrease the therapeutic efficacy of Aclidinium and Aclidinium (Compound) resembles Trospium (Compound) and Aclidinium may increase the anticholinergic activities of Trospium
Memantine may decrease the therapeutic efficacy of Benzatropine and Benzatropine (Compound) resembles Clidinium (Compound) and Clidinium (Compound) resembles Trospium (Compound)
Memantine (Compound) causes Micturition disorder (Side Effect) and Micturition disorder (Side Effect) is caused by Fentanyl (Compound) and Fentanyl may increase the severity of adverse effects when combined with Trospium
Memantine (Compound) causes Urethral disorder (Side Effect) and Urethral disorder (Side Effect) is caused by Darifenacin (Compound) and Darifenacin (Compound) resembles Trospium (Compound)
Memantine (Compound) causes Fatigue (Side Effect) and Fatigue (Side Effect) is caused by Ipratropium (Compound) and Ipratropium (Compound) resembles Trospium (Compound)
|
DB01131
|
DB00834
| 251 | 1,019 |
Proguanil
|
Mifepristone
|
Proguanil is a prophylactic antimalarial drug, which works by stopping the malaria parasite, _Plasmodium falciparum_ and _Plasmodium vivax_, from reproducing once it is in the red blood cells. It does this by inhibiting the enzyme, dihydrofolate reductase, which is involved in the reproduction of the parasite.
|
Mifepristone is a progestational and glucocorticoid hormone antagonist. Its inhibition of progesterone induces bleeding during the luteal phase and in early pregnancy by releasing endogenous prostaglandins from the endometrium or decidua. As a glucocorticoid receptor antagonist, the drug has been used to treat hypercortisolism in patients with nonpituitary cushing syndrome. The two marketed forms of mifepristone are Mifeprex® (mifepristone 200mg) and Korlym™ (mifepristone 300mg). Currently under investigation for use in psychotic depression (phase 3 trials).
|
The serum concentration of Mifepristone can be increased when it is combined with Proguanil.
| 72 |
[
[
[
251,
95,
1019
]
],
[
[
251,
6,
4590
],
[
4590,
160,
1019
]
],
[
[
251,
21,
28445
],
[
28445,
175,
1019
]
],
[
[
251,
69,
63
],
[
63,
185,
1019
]
],
[
[
251,
251,
244
],
[
244,
42,
1019
]
],
[
[
251,
95,
1324
],
[
1324,
249,
1019
]
],
[
[
251,
69,
472
],
[
472,
42,
1019
]
],
[
[
251,
95,
764
],
[
764,
42,
1019
]
],
[
[
251,
69,
861
],
[
861,
223,
1019
]
],
[
[
251,
69,
266
],
[
266,
95,
1019
]
]
] |
[
[
[
"Proguanil",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Tranylcypromine"
],
[
"Tranylcypromine",
"{u} may increase the hypoglycemic activities of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may decrease the serum concentration of {v}",
"Ritonavir"
],
[
"Ritonavir",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
],
[
"Dasatinib",
"{u} may increase the QTc prolonging activities of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Fluvoxamine"
],
[
"Fluvoxamine",
"{u} may decrease the metabolism of {v}",
"Mifepristone"
]
],
[
[
"Proguanil",
"{u} may decrease the metabolism of {v}",
"Indinavir"
],
[
"Indinavir",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
]
]
] |
Proguanil (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Mifepristone (Compound)
Proguanil (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Mifepristone (Compound)
Proguanil may decrease the metabolism of Tranylcypromine and Tranylcypromine may increase the hypoglycemic activities of Mifepristone
Proguanil may decrease the serum concentration of Ritonavir and Ritonavir may increase the QTc prolonging activities of Mifepristone
Proguanil may increase the serum concentration of Ceritinib and Ceritinib may increase the serum concentration of Mifepristone
Proguanil may decrease the metabolism of Isradipine and Isradipine may increase the QTc prolonging activities of Mifepristone
Proguanil may increase the serum concentration of Dasatinib and Dasatinib may increase the QTc prolonging activities of Mifepristone
Proguanil may decrease the metabolism of Fluvoxamine and Fluvoxamine may decrease the metabolism of Mifepristone
Proguanil may decrease the metabolism of Indinavir and Indinavir may increase the serum concentration of Mifepristone
|
DB08875
|
DB00263
| 688 | 575 |
Cabozantinib
|
Sulfisoxazole
|
Cabozantinib was first approved in 2012 and is a non-specific tyrosine kinase inhibitor. It was initially approved in the US under the brand name Cometriq, which is indicated for the treatment of metastatic medullary thyroid cancer. In 2016, a capsule formulation (Cabometyx) was approved for the treatment of advanced renal cell carcinoma, and this same formulation gained additional approval in both the US and Canada in 2019 for the treatment of hepatocellular carcinoma in previously treated patients.[L15128,L15133]
|
A short-acting sulfonamide antibacterial with activity against a wide range of gram- negative and gram-positive organisms.
|
The metabolism of Sulfisoxazole can be decreased when combined with Cabozantinib.
| 46 |
[
[
[
688,
69,
575
]
],
[
[
688,
69,
284
],
[
284,
223,
575
]
],
[
[
688,
251,
177
],
[
177,
26,
575
]
],
[
[
688,
95,
191
],
[
191,
26,
575
]
],
[
[
688,
95,
528
],
[
528,
42,
575
]
],
[
[
688,
69,
143
],
[
143,
196,
575
]
],
[
[
688,
95,
496
],
[
496,
196,
575
]
],
[
[
688,
69,
1079
],
[
1079,
42,
575
]
],
[
[
688,
80,
232
],
[
232,
69,
575
]
],
[
[
688,
69,
530
],
[
530,
69,
575
]
]
] |
[
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Sulfadiazine"
],
[
"Sulfadiazine",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the serum concentration of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
],
[
"Aprepitant",
"{u} can increase the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Telithromycin"
],
[
"Telithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may increase the serum concentration of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
],
[
"Crizotinib",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
]
],
[
[
"Cabozantinib",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Sulfisoxazole"
]
]
] |
Cabozantinib may decrease the metabolism of Sulfadiazine and Sulfadiazine may decrease the metabolism of Sulfisoxazole
Cabozantinib may decrease the serum concentration of Rifapentine and Rifapentine can increase the metabolism of Sulfisoxazole
Cabozantinib may increase the serum concentration of Aprepitant and Aprepitant can increase the metabolism of Sulfisoxazole
Cabozantinib may increase the serum concentration of Telithromycin and Telithromycin may increase the QTc prolonging activities of Sulfisoxazole
Cabozantinib may decrease the metabolism of Erythromycin and Erythromycin may increase the QTc prolonging activities of Sulfisoxazole
Cabozantinib may increase the serum concentration of Ketoconazole and Ketoconazole may increase the QTc prolonging activities of Sulfisoxazole
Cabozantinib may decrease the metabolism of Crizotinib and Crizotinib may increase the QTc prolonging activities of Sulfisoxazole
Cabozantinib may decrease the cardiotoxic activities of Digitoxin and Digitoxin may decrease the metabolism of Sulfisoxazole
Cabozantinib may decrease the metabolism of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Sulfisoxazole
|
DB00277
|
DB01254
| 497 | 764 |
Theophylline
|
Dasatinib
|
A methylxanthine derivative from tea with diuretic, smooth muscle relaxant, bronchial dilation, cardiac and central nervous system stimulant activities. Mechanistically, theophylline acts as a phosphodiesterase inhibitor, adenosine receptor blocker, and histone deacetylase activator. Theophylline is marketed under several brand names such as Uniphyl and Theochron, and it is indicated mainly for asthma, bronchospasm, and COPD.
|
Dasatinib is an orally available multikinase inhibitor indicated for the treatment of Philadelphia chromosome (Ph)-positive leukemias.[A2224,L45171] Ph is a chromosomal abnormality found in patients with chronic myelogenous leukemia (CML) and acute lymphocytic leukemia (ALL), where the ABL tyrosine kinase and the breakpoint cluster region (BCR) gene transcribe the chimeric protein BCR-ABL. BCR-ABL is associated with the uncontrolled activity of the ABL tyrosine kinase and is involved in the pathogenesis of CML and 15-30% of ALL cases.[A11377,A33432] Dasatinib also inhibits a spectrum of kinases involved in cancer, including several SRC-family kinases. Unlike [imatinib], another tyrosine kinase used for the treatment of CML and Ph-positive ALL, dasatinib inhibits the active and inactive conformations of the ABL
|
The serum concentration of Dasatinib can be increased when it is combined with Theophylline.
| 72 |
[
[
[
497,
95,
764
]
],
[
[
497,
6,
4590
],
[
4590,
160,
764
]
],
[
[
497,
7,
7531
],
[
7531,
161,
764
]
],
[
[
497,
6,
4588
],
[
4588,
172,
764
]
],
[
[
497,
21,
28471
],
[
28471,
175,
764
]
],
[
[
497,
251,
665
],
[
665,
28,
764
]
],
[
[
497,
223,
219
],
[
219,
28,
764
]
],
[
[
497,
69,
613
],
[
613,
28,
764
]
],
[
[
497,
95,
1019
],
[
1019,
196,
764
]
],
[
[
497,
69,
653
],
[
653,
42,
764
]
]
] |
[
[
[
"Theophylline",
"{u} may increase the serum concentration of {v}",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} (Compound) upregulates {v} (Gene)",
"UBQLN2"
],
[
"UBQLN2",
"{u} (Gene) is upregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} (Compound) binds {v} (Gene)",
"HDAC2"
],
[
"HDAC2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} (Compound) causes {v} (Side Effect)",
"Tremor"
],
[
"Tremor",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} may decrease the serum concentration of {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Ticlopidine"
],
[
"Ticlopidine",
"{u} may increase the anticoagulant activities of {v}",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the QTc prolonging activities of {v}",
"Dasatinib"
]
],
[
[
"Theophylline",
"{u} may decrease the metabolism of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Dasatinib"
]
]
] |
Theophylline (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Dasatinib (Compound)
Theophylline (Compound) upregulates UBQLN2 (Gene) and UBQLN2 (Gene) is upregulated by Dasatinib (Compound)
Theophylline (Compound) binds HDAC2 (Gene) and HDAC2 (Gene) is downregulated by Dasatinib (Compound)
Theophylline (Compound) causes Tremor (Side Effect) and Tremor (Side Effect) is caused by Dasatinib (Compound)
Theophylline may decrease the serum concentration of Bivalirudin and Bivalirudin may increase the anticoagulant activities of Dasatinib
Theophylline may decrease the metabolism of Warfarin and Warfarin may increase the anticoagulant activities of Dasatinib
Theophylline may decrease the metabolism of Ticlopidine and Ticlopidine may increase the anticoagulant activities of Dasatinib
Theophylline may increase the serum concentration of Mifepristone and Mifepristone may increase the QTc prolonging activities of Dasatinib
Theophylline may decrease the metabolism of Thioridazine and Thioridazine may increase the QTc prolonging activities of Dasatinib
|
DB06605
|
DB00744
| 632 | 487 |
Apixaban
|
Zileuton
|
Apixaban is an oral, direct, and highly selective factor Xa (FXa) inhibitor of both free and bound FXa, as well as prothrombinase, independent of antithrombin III for the prevention and treatment of thromboembolic diseases[Label,A6897]. It is marketed under the name Eliquis[Label,L6043]. Apixaban was approved by the FDA on December 28, 2012.
|
Leukotrienes are substances that induce numerous biological effects including augmentation of neutrophil and eosinophil migration, neutrophil and monocyte aggregation, leukocyte adhesion, increased capillary permeability, and smooth muscle contraction. These effects contribute to inflammation, edema, mucus secretion, and bronchoconstriction in the airways of asthmatic patients. Zileuton relieves such symptoms through its selective inhibition of 5-lipoxygenase, the enzyme that catalyzes the formation of leukotrienes from arachidonic acid. Specifically, it inhibits leukotriene LTB4, LTC4, LTD4, and LTE4 formation. Both the R(+) and S(-) enantiomers are pharmacologically active as 5-lipoxygenase inhibitors in in vitro systems. The immediate release tablet of Zileuton has been withdrawn from the US market.
|
Apixaban may increase the anticoagulant activities of Zileuton.
| 5 |
[
[
[
632,
28,
487
]
],
[
[
632,
28,
4
],
[
4,
225,
487
]
],
[
[
632,
6,
4590
],
[
4590,
160,
487
]
],
[
[
632,
21,
28448
],
[
28448,
175,
487
]
],
[
[
632,
251,
164
],
[
164,
26,
487
]
],
[
[
632,
180,
156
],
[
156,
26,
487
]
],
[
[
632,
95,
173
],
[
173,
26,
487
]
],
[
[
632,
182,
498
],
[
498,
28,
487
]
],
[
[
632,
225,
475
],
[
475,
28,
487
]
],
[
[
632,
95,
461
],
[
461,
223,
487
]
]
] |
[
[
[
"Apixaban",
"{u} may increase the anticoagulant activities of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may increase the anticoagulant activities of {v}",
"Tiaprofenic acid"
],
[
"Tiaprofenic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} (Compound) causes {v} (Side Effect)",
"Hypersensitivity"
],
[
"Hypersensitivity",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may decrease the serum concentration of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may increase the severity of adverse effects when combined with {v}",
"Argatroban"
],
[
"Argatroban",
"{u} may increase the anticoagulant activities of {v}",
"Zileuton"
]
],
[
[
"Apixaban",
"{u} may increase the serum concentration of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Zileuton"
]
]
] |
Apixaban may increase the anticoagulant activities of Tiaprofenic acid and Tiaprofenic acid may increase the severity of adverse effects when combined with Zileuton
Apixaban (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Zileuton (Compound)
Apixaban (Compound) causes Hypersensitivity (Side Effect) and Hypersensitivity (Side Effect) is caused by Zileuton (Compound)
Apixaban may decrease the serum concentration of Phenobarbital and Phenobarbital can increase the metabolism of Zileuton
Apixaban can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Zileuton
Apixaban may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Zileuton
Apixaban may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Zileuton
Apixaban may increase the severity of adverse effects when combined with Argatroban and Argatroban may increase the anticoagulant activities of Zileuton
Apixaban may increase the serum concentration of Diltiazem and Diltiazem may decrease the metabolism of Zileuton
|
DB00986
|
DB00497
| 28 | 163 |
Glycopyrronium
|
Oxycodone
|
Glycopyrronium, also known as NVA237 or glycopyrrolate, is a racemic mixture of two enantiomers. They are both quaternary ammonium compounds and long acting muscarinic antagonists. It is one of the most commonly prescribed anticholinergic medications.[A233535,A233540] Early research into glycopyrronium use was for its indication as an adjunct therapy in the treatment of peptic ulcers.[A233570,L33090] Later research, taking advantage of the systemic distribution of muscarinic receptors through the body, found that glycopyrronium could also be used for reducing sweat gland, oral, airway, and gastric secretions; as well as reducing cardiac inhibitory reflexes; and reducing bronchoconstriction in COPD. Glycopyrronium is commonly prescribed as a first line treatment for a wide variety indications and is considered to have a wider therapeutic window than [tiotropium]. Glycopy
|
Oxycodone is a semisynthetic opioid analgesic derived from thebaine in Germany in 1917. It is currently indicated as an immediate release product for moderate to severe pain and as an extended release product for chronic moderate to severe pain requiring continuous opioid analgesics for an extended period.[Label] The first oxycodone containing product, Percodan, was approved by the FDA on April 12, 1950.
|
The risk or severity of adverse effects can be increased when Glycopyrronium is combined with Oxycodone.
| 48 |
[
[
[
28,
71,
163
]
],
[
[
28,
71,
921
],
[
921,
225,
163
]
],
[
[
28,
71,
1083
],
[
1083,
38,
163
]
],
[
[
28,
246,
264
],
[
264,
1,
163
]
],
[
[
28,
21,
28392
],
[
28392,
175,
163
]
],
[
[
28,
24,
72
],
[
72,
38,
163
]
],
[
[
28,
107,
1261
],
[
1261,
192,
163
]
],
[
[
28,
61,
1400
],
[
1400,
215,
163
]
],
[
[
28,
24,
59
],
[
59,
223,
163
]
],
[
[
28,
71,
237
],
[
237,
223,
163
]
]
] |
[
[
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nalbuphine"
],
[
"Nalbuphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may decrease the therapeutic efficacy of {v}",
"Galantamine"
],
[
"Galantamine",
"{u} (Compound) resembles {v} (Compound)",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the tachycardic activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the constipating activities of {v}",
"Eluxadoline"
],
[
"Eluxadoline",
"{u} may increase the constipating activities of {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the anticholinergic activities of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
],
[
[
"Glycopyrronium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may decrease the metabolism of {v}",
"Oxycodone"
]
]
] |
Glycopyrronium may increase the severity of adverse effects when combined with Nalbuphine and Nalbuphine may increase the severity of adverse effects when combined with Oxycodone
Glycopyrronium may increase the severity of adverse effects when combined with Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Oxycodone
Glycopyrronium may decrease the therapeutic efficacy of Galantamine and Galantamine (Compound) resembles Oxycodone (Compound)
Glycopyrronium (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Oxycodone (Compound)
Glycopyrronium may increase the anticholinergic activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Oxycodone
Glycopyrronium may increase the tachycardic activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Oxycodone
Glycopyrronium may increase the constipating activities of Eluxadoline and Eluxadoline may increase the constipating activities of Oxycodone
Glycopyrronium may increase the anticholinergic activities of Quinidine and Quinidine may decrease the metabolism of Oxycodone
Glycopyrronium may increase the severity of adverse effects when combined with Mirabegron and Mirabegron may decrease the metabolism of Oxycodone
|
DB01215
|
DB01176
| 275 | 989 |
Estazolam
|
Cyclizine
|
A benzodiazepine with anticonvulsant, hypnotic, and muscle relaxant properties. It has been shown in some cases to be more potent than diazepam or nitrazepam.
|
A histamine H1 antagonist given by mouth or parenterally for the control of postoperative and drug-induced vomiting and in motion sickness. (From Martindale, The Extra Pharmacopoeia, 30th ed, p935)
|
The risk or severity of adverse effects can be increased when Estazolam is combined with Cyclizine.
| 48 |
[
[
[
275,
71,
989
]
],
[
[
275,
246,
16
],
[
16,
1,
989
]
],
[
[
275,
38,
1262
],
[
1262,
155,
989
]
],
[
[
275,
225,
270
],
[
270,
71,
989
]
],
[
[
275,
192,
72
],
[
72,
38,
989
]
],
[
[
275,
71,
681
],
[
681,
71,
989
]
],
[
[
275,
71,
434
],
[
434,
225,
989
]
],
[
[
275,
69,
610
],
[
610,
1,
989
]
],
[
[
275,
21,
28384
],
[
28384,
175,
989
]
],
[
[
275,
38,
1261
],
[
1261,
192,
989
]
]
] |
[
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may decrease the therapeutic efficacy of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} (Compound) causes {v} (Side Effect)",
"Somnolence"
],
[
"Somnolence",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cyclizine"
]
],
[
[
"Estazolam",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Cyclizine"
]
]
] |
Estazolam may decrease the therapeutic efficacy of Mianserin and Mianserin (Compound) resembles Cyclizine (Compound)
Estazolam may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine (Compound) resembles Cyclizine (Compound)
Estazolam may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Cyclizine
Estazolam may increase the central nervous system depressant activities of Orphenadrine and Orphenadrine may increase the central nervous system depressant activities of Cyclizine
Estazolam may increase the severity of adverse effects when combined with Clozapine and Clozapine may increase the severity of adverse effects when combined with Cyclizine
Estazolam may increase the severity of adverse effects when combined with Flunarizine and Flunarizine may increase the severity of adverse effects when combined with Cyclizine
Estazolam may decrease the metabolism of Atomoxetine and Atomoxetine (Compound) resembles Cyclizine (Compound)
Estazolam (Compound) causes Somnolence (Side Effect) and Somnolence (Side Effect) is caused by Cyclizine (Compound)
Estazolam may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Cyclizine
|
DB01580
|
DB06702
| 911 | 35 |
Oxprenolol
|
Fesoterodine
|
A beta-adrenergic antagonist used in the treatment of hypertension, angina pectoris, arrhythmias, and anxiety.
|
Fesoterodine is an antimuscarinic prodrug for the treatment of overactive bladder syndrome.
|
The serum concentration of the active metabolites of Fesoterodine can be increased when Fesoterodine is used in combination with Oxprenolol.
| 76 |
[
[
[
911,
99,
35
]
],
[
[
911,
230,
589
],
[
589,
1,
35
]
],
[
[
911,
6,
18777
],
[
18777,
160,
35
]
],
[
[
911,
21,
28515
],
[
28515,
175,
35
]
],
[
[
911,
225,
18
],
[
18,
24,
35
]
],
[
[
911,
71,
161
],
[
161,
26,
35
]
],
[
[
911,
251,
147
],
[
147,
26,
35
]
],
[
[
911,
225,
171
],
[
171,
26,
35
]
],
[
[
911,
201,
530
],
[
530,
223,
35
]
],
[
[
911,
236,
472
],
[
472,
223,
35
]
]
] |
[
[
[
"Oxprenolol",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the bradycardic activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} (Compound) resembles {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} (Compound) causes {v} (Side Effect)",
"Dyspepsia"
],
[
"Dyspepsia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the anticholinergic activities of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dihydroergotamine"
],
[
"Dihydroergotamine",
"{u} may decrease the metabolism of {v}",
"Fesoterodine"
]
],
[
[
"Oxprenolol",
"{u} may increase the hypotensive activities of {v}",
"Isradipine"
],
[
"Isradipine",
"{u} may decrease the metabolism of {v}",
"Fesoterodine"
]
]
] |
Oxprenolol may increase the bradycardic activities of Disopyramide and Disopyramide (Compound) resembles Fesoterodine (Compound)
Oxprenolol (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Fesoterodine (Compound)
Oxprenolol (Compound) causes Dyspepsia (Side Effect) and Dyspepsia (Side Effect) is caused by Fesoterodine (Compound)
Oxprenolol may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the anticholinergic activities of Fesoterodine
Oxprenolol may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Fesoterodine
Oxprenolol may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Fesoterodine
Oxprenolol may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Fesoterodine
Oxprenolol may increase the atrioventricular blocking activities of Dihydroergotamine and Dihydroergotamine may decrease the metabolism of Fesoterodine
Oxprenolol may increase the hypotensive activities of Isradipine and Isradipine may decrease the metabolism of Fesoterodine
|
DB00228
|
DB01159
| 1,004 | 522 |
Enflurane
|
Halothane
|
Enflurane is a halogenated inhalational anesthetic initially approved by the FDA in 1972. Since this date, it has been withdrawn from the US market.[L13646,L13649] Unlike its other inhalational anesthetic counterparts including [isoflurane] and [halothane], enflurane is known to induce seizure activity. In addition, it is known to cause increased cardio depressant effects when compared to other inhaled anesthetics.
|
A nonflammable, halogenated, hydrocarbon anesthetic that provides relatively rapid induction with little or no excitement. Analgesia may not be adequate. nitrous oxide is often given concomitantly. Because halothane may not produce sufficient muscle relaxation, supplemental neuromuscular blocking agents may be required. (From AMA Drug Evaluations Annual, 1994, p178)
|
The risk or severity of adverse effects can be increased when Enflurane is combined with Halothane.
| 48 |
[
[
[
1004,
71,
522
]
],
[
[
1004,
6,
11322
],
[
11322,
160,
522
]
],
[
[
1004,
225,
164
],
[
164,
26,
522
]
],
[
[
1004,
71,
161
],
[
161,
26,
522
]
],
[
[
1004,
184,
674
],
[
674,
30,
522
]
],
[
[
1004,
38,
702
],
[
702,
192,
522
]
],
[
[
1004,
192,
491
],
[
491,
38,
522
]
],
[
[
1004,
197,
25
],
[
25,
43,
522
]
],
[
[
1004,
71,
968
],
[
968,
206,
522
]
],
[
[
1004,
54,
1046
],
[
1046,
208,
522
]
]
] |
[
[
[
"Enflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} (Compound) binds {v} (Gene)",
"KCNK18"
],
[
"KCNK18",
"{u} (Gene) is bound by {v} (Compound)",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the neuromuscular blocking activities of {v}",
"Atracurium besylate"
],
[
"Atracurium besylate",
"{u} may increase the neuromuscular blocking activities of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levodopa"
],
[
"Levodopa",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Halothane"
]
],
[
[
"Enflurane",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Halothane"
]
]
] |
Enflurane (Compound) binds KCNK18 (Gene) and KCNK18 (Gene) is bound by Halothane (Compound)
Enflurane may increase the severity of adverse effects when combined with Phenobarbital and Phenobarbital can increase the metabolism of Halothane
Enflurane may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Halothane
Enflurane can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Halothane
Enflurane may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Halothane
Enflurane may increase the central nervous system depressant activities of Buprenorphine and Buprenorphine may increase the central nervous system depressant activities of Halothane
Enflurane may increase the neuromuscular blocking activities of Atracurium besylate and Atracurium besylate may increase the neuromuscular blocking activities of Halothane
Enflurane may increase the severity of adverse effects when combined with Levodopa and Levodopa may increase the orthostatic hypotensive activities of Halothane
Enflurane may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Halothane
|
DB01234
|
DB04575
| 119 | 1,129 |
Dexamethasone
|
Quinestrol
|
Dexamethasone, or MK-125, is a corticosteroid fluorinated at position 9 used to treat endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, gastrointestinal, respiratory, hematologic, neoplastic, edematous, and other conditions. Developed in 1957, it is structurally similar to other corticosteroids like [hydrocortisone] and [prednisolone]. Dexamethasone was granted FDA approval on 30 October 1958. In a press release for the Randomized Evaluation of COVID-19 Therapy (RECOVERY) trial on 16 June 2020, dexamethasone was recommended for use in COVID-19 patients with severe respiratory symptoms. Dexamethasone reduced deaths by approximately one third in patients requiring ventilation and by one fifth in those requiring oxygen.
|
The 3-cyclopentyl ether of ethinyl estradiol.
|
The serum concentration of Quinestrol can be increased when it is combined with Dexamethasone.
| 72 |
[
[
[
119,
95,
1129
]
],
[
[
119,
95,
1127
],
[
1127,
155,
1129
]
],
[
[
119,
95,
622
],
[
622,
1,
1129
]
],
[
[
119,
96,
824
],
[
824,
155,
1129
]
],
[
[
119,
99,
677
],
[
677,
34,
1129
]
],
[
[
119,
182,
219
],
[
219,
34,
1129
]
],
[
[
119,
249,
744
],
[
744,
34,
1129
]
],
[
[
119,
155,
107
],
[
107,
95,
1129
]
],
[
[
119,
1,
96
],
[
96,
95,
1129
]
],
[
[
119,
225,
349
],
[
349,
257,
1129
]
]
] |
[
[
[
"Dexamethasone",
"{u} may increase the serum concentration of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the serum concentration of {v}",
"Estriol"
],
[
"Estriol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the serum concentration of {v}",
"Mestranol"
],
[
"Mestranol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the fluid retaining activities of {v}",
"Danazol"
],
[
"Danazol",
"{u} (Compound) resembles {v} (Compound)",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may decrease the anticoagulant activities of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may decrease the anticoagulant activities of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the serum concentration of {v}",
"Edoxaban"
],
[
"Edoxaban",
"{u} may decrease the anticoagulant activities of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Fludrocortisone"
],
[
"Fludrocortisone",
"{u} may increase the serum concentration of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} (Compound) resembles {v} (Compound)",
"Methylprednisolone"
],
[
"Methylprednisolone",
"{u} may increase the serum concentration of {v}",
"Quinestrol"
]
],
[
[
"Dexamethasone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lumiracoxib"
],
[
"Lumiracoxib",
"{u} may increase the thrombogenic activities of {v}",
"Quinestrol"
]
]
] |
Dexamethasone may increase the serum concentration of Estriol and Estriol (Compound) resembles Quinestrol (Compound)
Dexamethasone may increase the serum concentration of Mestranol and Mestranol (Compound) resembles Quinestrol (Compound)
Dexamethasone may increase the fluid retaining activities of Danazol and Danazol (Compound) resembles Quinestrol (Compound)
Dexamethasone may increase the serum concentration of the active metabolites of Dabigatran etexilate and Dabigatran etexilate may decrease the anticoagulant activities of Quinestrol
Dexamethasone may increase the anticoagulant activities of Warfarin and Warfarin may decrease the anticoagulant activities of Quinestrol
Dexamethasone may increase the serum concentration of Edoxaban and Edoxaban may decrease the anticoagulant activities of Quinestrol
Dexamethasone (Compound) resembles Fludrocortisone (Compound) and Fludrocortisone may increase the serum concentration of Quinestrol
Dexamethasone (Compound) resembles Methylprednisolone (Compound) and Methylprednisolone may increase the serum concentration of Quinestrol
Dexamethasone may increase the severity of adverse effects when combined with Lumiracoxib and Lumiracoxib may increase the thrombogenic activities of Quinestrol
|
DB01229
|
DB06769
| 292 | 1,225 |
Paclitaxel
|
Bendamustine
|
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
|
Bendamustine is a nitrogen mustard drug indicated for use in the treatment of chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin lymphoma (NHL) that has progressed during or within six months of treatment with rituximab or a rituximab-containing regimen. Bendamustine is a bifunctional mechlorethamine derivative capable of forming electrophilic alkyl groups that covalently bond to other molecules. Through this function as an alkylating agent, bendamustine causes intra- and inter-strand crosslinks between DNA bases resulting in cell death. It is active against both active and quiescent cells, although the exact mechanism of action is unknown.
|
The risk or severity of adverse effects can be increased when Paclitaxel is combined with Bendamustine.
| 48 |
[
[
[
292,
71,
1225
]
],
[
[
292,
191,
243
],
[
243,
37,
1225
]
],
[
[
292,
69,
1122
],
[
1122,
223,
1225
]
],
[
[
292,
95,
631
],
[
631,
223,
1225
]
],
[
[
292,
180,
173
],
[
173,
223,
1225
]
],
[
[
292,
71,
227
],
[
227,
223,
1225
]
],
[
[
292,
71,
681
],
[
681,
225,
1225
]
],
[
[
292,
71,
152
],
[
152,
71,
1225
]
],
[
[
292,
80,
1348
],
[
1348,
234,
1225
]
],
[
[
292,
95,
495
],
[
495,
249,
1225
]
]
] |
[
[
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may decrease the metabolism of {v}",
"Lobeglitazone"
],
[
"Lobeglitazone",
"{u} may decrease the metabolism of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the serum concentration of {v}",
"Simeprevir"
],
[
"Simeprevir",
"{u} may decrease the metabolism of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} may decrease the metabolism of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bortezomib"
],
[
"Bortezomib",
"{u} may decrease the metabolism of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cabazitaxel"
],
[
"Cabazitaxel",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
],
[
"Ouabain",
"{u} may decrease the cardiotoxic activities of {v}",
"Bendamustine"
]
],
[
[
"Paclitaxel",
"{u} may increase the serum concentration of {v}",
"Vemurafenib"
],
[
"Vemurafenib",
"{u} may increase the serum concentration of {v}",
"Bendamustine"
]
]
] |
Paclitaxel may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may increase the cardiotoxic activities of Bendamustine
Paclitaxel may decrease the metabolism of Lobeglitazone and Lobeglitazone may decrease the metabolism of Bendamustine
Paclitaxel may increase the serum concentration of Simeprevir and Simeprevir may decrease the metabolism of Bendamustine
Paclitaxel can increase the metabolism of Nevirapine and Nevirapine may decrease the metabolism of Bendamustine
Paclitaxel may increase the severity of adverse effects when combined with Bortezomib and Bortezomib may decrease the metabolism of Bendamustine
Paclitaxel may increase the severity of adverse effects when combined with Clozapine and Clozapine may increase the severity of adverse effects when combined with Bendamustine
Paclitaxel may increase the severity of adverse effects when combined with Cabazitaxel and Cabazitaxel may increase the severity of adverse effects when combined with Bendamustine
Paclitaxel may decrease the cardiotoxic activities of Ouabain and Ouabain may decrease the cardiotoxic activities of Bendamustine
Paclitaxel may increase the serum concentration of Vemurafenib and Vemurafenib may increase the serum concentration of Bendamustine
|
DB01018
|
DB09074
| 643 | 1,085 |
Guanfacine
|
Olaparib
|
Guanfacine, or BS 100-141,[A189838,A189841] is a selective alpha-A2 adrenergic receptor agonist initially indicated for the treatment of hypertension but is now indicated as an extended release tablet for the treatment of ADHD. Guanfacine was first described in the literature in 1974. Guanfacine was granted FDA approval on 27 October 1986.
|
Olaparib is a selective and potent inhibitor of poly (ADP-ribose) polymerase (PARP) enzymes, PARP1 and PARP2.[L41100, L40908, L43792] PARP inhibitors represent a novel class of anti-cancer therapy and they work by taking advantage of a defect in DNA repair in cancer cells with BRCA mutations and inducing cell death. Olaparib is used to treat a number of BRCA-associated tumours, including ovarian cancer, breast cancer, pancreatic cancer, and prostate cancer.[L41100, L40908, L43792] It was first approved by the FDA and EU in December 2014, and by Health Canada in April 2016.
|
The metabolism of Olaparib can be decreased when combined with Guanfacine.
| 46 |
[
[
[
643,
69,
1085
]
],
[
[
643,
225,
247
],
[
247,
69,
1085
]
],
[
[
643,
236,
278
],
[
278,
69,
1085
]
],
[
[
643,
69,
571
],
[
571,
69,
1085
]
],
[
[
643,
82,
1068
],
[
1068,
69,
1085
]
],
[
[
643,
59,
543
],
[
543,
69,
1085
]
],
[
[
643,
71,
516
],
[
516,
69,
1085
]
],
[
[
643,
192,
287
],
[
287,
69,
1085
]
],
[
[
643,
261,
193
],
[
193,
69,
1085
]
],
[
[
643,
246,
16
],
[
16,
69,
1085
]
]
] |
[
[
[
"Guanfacine",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Bromocriptine"
],
[
"Bromocriptine",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the hypotensive activities of {v}",
"Alfuzosin"
],
[
"Alfuzosin",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may decrease the metabolism of {v}",
"Esomeprazole"
],
[
"Esomeprazole",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the hypotensive activities of {v}",
"Macitentan"
],
[
"Macitentan",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may decrease the antihypertensive activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Felodipine"
],
[
"Felodipine",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may increase the tachycardic activities of {v}",
"Levomilnacipran"
],
[
"Levomilnacipran",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
],
[
[
"Guanfacine",
"{u} may decrease the therapeutic efficacy of {v}",
"Mianserin"
],
[
"Mianserin",
"{u} may decrease the metabolism of {v}",
"Olaparib"
]
]
] |
Guanfacine may increase the severity of adverse effects when combined with Bromocriptine and Bromocriptine may decrease the metabolism of Olaparib
Guanfacine may increase the hypotensive activities of Alfuzosin and Alfuzosin may decrease the metabolism of Olaparib
Guanfacine may decrease the metabolism of Esomeprazole and Esomeprazole may decrease the metabolism of Olaparib
Guanfacine may increase the hypotensive activities of Macitentan and Macitentan may decrease the metabolism of Olaparib
Guanfacine may decrease the antihypertensive activities of Mirtazapine and Mirtazapine may decrease the metabolism of Olaparib
Guanfacine may increase the severity of adverse effects when combined with Felodipine and Felodipine may decrease the metabolism of Olaparib
Guanfacine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may decrease the metabolism of Olaparib
Guanfacine may increase the tachycardic activities of Levomilnacipran and Levomilnacipran may decrease the metabolism of Olaparib
Guanfacine may decrease the therapeutic efficacy of Mianserin and Mianserin may decrease the metabolism of Olaparib
|
DB00584
|
DB01628
| 315 | 364 |
Enalapril
|
Etoricoxib
|
Enalapril is a prodrug belonging to the angiotensin-converting enzyme (ACE) inhibitor drug class that works on the renin-angiotensin-aldosterone system, which is responsible for the regulation of blood pressure and fluid and electrolyte homeostasis. Enalapril is an orally-active and long-acting nonsulphydryl antihypertensive agent that suppresses the renin-angiotensin-aldosterone system to lower blood pressure. It was developed from a targeted research programmed using molecular modelling. Being a prodrug, enalapril is rapidly biotransformed into its active metabolite, [enalaprilat], which is responsible for the pharmacological actions of enalapril. The active metabolite of enalapril competitively inhibits the ACE to hinder the production of angiotensin II, a key component of the renin-angiotensin-aldosterone system that promotes v
|
Etoricoxib is a new COX-2 selective inhibitor. Current therapeutic indications are: treatment of rheumatoid arthritis, osteoarthritis, ankylosing spondylitis, chronic low back pain, acute pain and gout. Like any other COX-2 selective inhibitor, Etoricoxib selectively inhibits isoform 2 of cyclo-oxigenase enzyme (COX-2) to reduce the generation of prostaglandins (PGs) from arachidonic acid. It is approved in more than 60 countries worldwide but not in the US.
|
The risk or severity of adverse effects can be increased when Enalapril is combined with Etoricoxib.
| 48 |
[
[
[
315,
71,
364
]
],
[
[
315,
6,
4590
],
[
4590,
160,
364
]
],
[
[
315,
21,
28556
],
[
28556,
175,
364
]
],
[
[
315,
180,
142
],
[
142,
26,
364
]
],
[
[
315,
99,
677
],
[
677,
28,
364
]
],
[
[
315,
71,
687
],
[
687,
28,
364
]
],
[
[
315,
225,
557
],
[
557,
205,
364
]
],
[
[
315,
71,
893
],
[
893,
205,
364
]
],
[
[
315,
71,
731
],
[
731,
59,
364
]
],
[
[
315,
90,
306
],
[
306,
59,
364
]
]
] |
[
[
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Dabigatran etexilate"
],
[
"Dabigatran etexilate",
"{u} may increase the anticoagulant activities of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the anticoagulant activities of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Torasemide"
],
[
"Torasemide",
"{u} may decrease the diuretic activities of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nebivolol"
],
[
"Nebivolol",
"{u} may decrease the antihypertensive activities of {v}",
"Etoricoxib"
]
],
[
[
"Enalapril",
"{u} may increase the hyperkalemic activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may decrease the antihypertensive activities of {v}",
"Etoricoxib"
]
]
] |
Enalapril (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Etoricoxib (Compound)
Enalapril (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Etoricoxib (Compound)
Enalapril can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Etoricoxib
Enalapril may increase the serum concentration of the active metabolites of Dabigatran etexilate and Dabigatran etexilate may increase the anticoagulant activities of Etoricoxib
Enalapril may increase the severity of adverse effects when combined with Nafamostat and Nafamostat may increase the anticoagulant activities of Etoricoxib
Enalapril may increase the severity of adverse effects when combined with Torasemide and Torasemide may decrease the diuretic activities of Etoricoxib
Enalapril may increase the severity of adverse effects when combined with Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Etoricoxib
Enalapril may increase the severity of adverse effects when combined with Nebivolol and Nebivolol may decrease the antihypertensive activities of Etoricoxib
Enalapril may increase the hyperkalemic activities of Aliskiren and Aliskiren may decrease the antihypertensive activities of Etoricoxib
|
DB00946
|
DB04951
| 384 | 746 |
Phenprocoumon
|
Pirfenidone
|
Coumarin derivative that acts as a long-acting oral anticoagulant.
|
Pirfenidone is a synthetic pyridone drug. It is an antifibrotic agent with anti-inflammatory and antioxidant properties that is used to treat idiopathic pulmonary fibrosis (IPF), which is a chronic, progressive form of interstitial pneumonia. While its mechanism of action is not yet fully understood, pirfenidone is proposed to primarily regulate tumor necrosis factor (TNF) pathways and modulate cellular oxidation. The FDA first approved pirfenidone alongside [nintedanib] as one of the first drugs to treat IPF.
|
Phenprocoumon may increase the anticoagulant activities of Pirfenidone.
| 5 |
[
[
[
384,
28,
746
]
],
[
[
384,
28,
665
],
[
665,
28,
746
]
],
[
[
384,
285,
342
],
[
342,
28,
746
]
],
[
[
384,
131,
498
],
[
498,
28,
746
]
],
[
[
384,
182,
560
],
[
560,
28,
746
]
],
[
[
384,
28,
877
],
[
877,
203,
746
]
],
[
[
384,
95,
893
],
[
893,
205,
746
]
],
[
[
384,
88,
1188
],
[
1188,
225,
746
]
],
[
[
384,
28,
833
],
[
833,
71,
746
]
],
[
[
384,
28,
743
],
[
743,
225,
746
]
]
] |
[
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Bivalirudin"
],
[
"Bivalirudin",
"{u} may increase the anticoagulant activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Rivaroxaban"
],
[
"Rivaroxaban",
"{u} may increase the anticoagulant activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Fleroxacin"
],
[
"Fleroxacin",
"{u} may increase the neuroexcitatory activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the serum concentration of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may decrease the diuretic activities of {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase bleeding risks when combined with {v}",
"Omacetaxine mepesuccinate"
],
[
"Omacetaxine mepesuccinate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Tolmetin"
],
[
"Tolmetin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pirfenidone"
]
],
[
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Apremilast"
],
[
"Apremilast",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pirfenidone"
]
]
] |
Phenprocoumon may increase the anticoagulant activities of Bivalirudin and Bivalirudin may increase the anticoagulant activities of Pirfenidone
Phenprocoumon (Compound) resembles Acenocoumarol (Compound) and Phenprocoumon may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Pirfenidone
Phenprocoumon (Compound) resembles Dicoumarol (Compound) and Phenprocoumon may increase the anticoagulant activities of Dicoumarol and Dicoumarol may increase the anticoagulant activities of Pirfenidone
Phenprocoumon may increase the anticoagulant activities of Rivaroxaban and Rivaroxaban may increase the anticoagulant activities of Pirfenidone
Phenprocoumon may increase the anticoagulant activities of Fleroxacin and Fleroxacin may increase the neuroexcitatory activities of Pirfenidone
Phenprocoumon may increase the serum concentration of Etacrynic acid and Etacrynic acid may decrease the diuretic activities of Pirfenidone
Phenprocoumon may increase bleeding risks when combined with Omacetaxine mepesuccinate and Omacetaxine mepesuccinate may increase the severity of adverse effects when combined with Pirfenidone
Phenprocoumon may increase the anticoagulant activities of Tolmetin and Tolmetin may increase the severity of adverse effects when combined with Pirfenidone
Phenprocoumon may increase the anticoagulant activities of Apremilast and Apremilast may increase the severity of adverse effects when combined with Pirfenidone
|
DB01273
|
DB00863
| 1,447 | 599 |
Varenicline
|
Ranitidine
|
Varenicline is a prescription medication used to treat smoking addiction. This medication is the first approved nicotinic receptor partial agonist. Specifically, varenicline is a partial agonist of the alpha4/beta2 subtype of the nicotinic acetylcholine receptor. In addition it acts on alpha3/beta4 and weakly on alpha3beta2 and alpha6-containing receptors. A full agonism was displayed on alpha7-receptors. On March 9, 2015, the U.S. Food and Drug Administration warned that Varenicline, in the form of Pfizer Inc's quit-smoking drug, Chantix, has been associated with seizures and that some patients who drink while taking the drug may become aggressive or black out. Pfizer is conducting an additional safety study of the drug, results of which are expected in late 2015. The FDA said it is keeping the black box in place at least until the results of the trial are announced
|
Ranitidine is a commonly used drug, classified as a histamine H2-receptor antagonist, and belongs to the same drug class as [cimetidine] and [famotidine]. This drug helps to prevent and treat gastric-acid associated conditions, including ulcers, because of its ability to decrease gastric acid secretion.[A176759,L10818] Ranitidine is often referred to as Zantac, and is available in various forms, including tablet, injection, and effervescent tablet preparations.[L10818,F4253] The prevalence of GERD is thought to be 10-20% in western countries. Ranitidine has proven to be an effective treatment for relieving uncomfortable symptoms of gastric acid associated conditions and is therefore widely used in GERD and other gastric-acid related conditions.[A176849,L10818]
|
The serum concentration of Ranitidine can be increased when it is combined with Varenicline.
| 72 |
[
[
[
1447,
95,
599
]
],
[
[
1447,
95,
1301
],
[
1301,
1,
599
]
],
[
[
1447,
7,
5499
],
[
5499,
161,
599
]
],
[
[
1447,
18,
5650
],
[
5650,
172,
599
]
],
[
[
1447,
21,
28784
],
[
28784,
175,
599
]
],
[
[
1447,
225,
1037
],
[
1037,
223,
599
]
],
[
[
1447,
95,
886
],
[
886,
223,
599
]
],
[
[
1447,
225,
576
],
[
576,
95,
599
]
],
[
[
1447,
95,
1301
],
[
1301,
6,
15483
],
[
15483,
160,
599
]
],
[
[
1447,
7,
5499
],
[
5499,
17,
8105
],
[
8105,
172,
599
]
]
] |
[
[
[
"Varenicline",
"{u} may increase the serum concentration of {v}",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} may increase the serum concentration of {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} (Compound) resembles {v} (Compound)",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} (Compound) downregulates {v} (Gene)",
"SDC1"
],
[
"SDC1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} (Compound) causes {v} (Side Effect)",
"Angina pectoris"
],
[
"Angina pectoris",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Betaxolol"
],
[
"Betaxolol",
"{u} may decrease the metabolism of {v}",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} may increase the serum concentration of {v}",
"Cimetidine"
],
[
"Cimetidine",
"{u} may decrease the metabolism of {v}",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Metoprolol"
],
[
"Metoprolol",
"{u} may increase the serum concentration of {v}",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} may increase the serum concentration of {v}",
"Nizatidine"
],
[
"Nizatidine",
"{u} (Compound) binds {v} (Gene)",
"HRH2"
],
[
"HRH2",
"{u} (Gene) is bound by {v} (Compound)",
"Ranitidine"
]
],
[
[
"Varenicline",
"{u} (Compound) upregulates {v} (Gene)",
"GPATCH8"
],
[
"GPATCH8",
"{u} (Gene) regulates {v} (Gene)",
"ACAT2"
],
[
"ACAT2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ranitidine"
]
]
] |
Varenicline may increase the serum concentration of Nizatidine and Nizatidine (Compound) resembles Ranitidine (Compound)
Varenicline (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) is upregulated by Ranitidine (Compound)
Varenicline (Compound) downregulates SDC1 (Gene) and SDC1 (Gene) is downregulated by Ranitidine (Compound)
Varenicline (Compound) causes Angina pectoris (Side Effect) and Angina pectoris (Side Effect) is caused by Ranitidine (Compound)
Varenicline may increase the severity of adverse effects when combined with Betaxolol and Betaxolol may decrease the metabolism of Ranitidine
Varenicline may increase the serum concentration of Cimetidine and Cimetidine may decrease the metabolism of Ranitidine
Varenicline may increase the severity of adverse effects when combined with Metoprolol and Metoprolol may increase the serum concentration of Ranitidine
Varenicline may increase the serum concentration of Nizatidine and Nizatidine (Compound) binds HRH2 (Gene) and HRH2 (Gene) is bound by Ranitidine (Compound)
Varenicline (Compound) upregulates GPATCH8 (Gene) and GPATCH8 (Gene) regulates ACAT2 (Gene) and ACAT2 (Gene) is downregulated by Ranitidine (Compound)
|
DB00455
|
DB00503
| 401 | 244 |
Loratadine
|
Ritonavir
|
Loratadine is a second generation antihistamine used to manage symptoms of allergic rhinitis. A lack of sedative and CNS adverse effects make loratadine, along with other second generation antihistamines, preferable over their 1st generation counterparts in many clinical situations.
|
Ritonavir is an HIV protease inhibitor that interferes with the reproductive cycle of HIV. Although it was initially developed as an independent antiviral agent, it has been shown to possess advantageous properties in combination regimens with low-dose ritonavir and other protease inhibitors. It is now more commonly used as a booster of other protease inhibitors and is available in both liquid formulations and as capsules. While ritonavir is not an active antiviral agent against hepatitis C virus (HCV) infection, it is added in combination therapies indicated for the treatment of HCV infections as a booster. Ritonavir is a potent CYP3A inhibitor that increases peak and trough plasma drug concentrations of other protease inhibitors such as and overall drug exposure. American Association for the Study of Liver Diseases (AASLD) and the Infectious Diseases Society of America (IDSA) guidelines recommend ritonavir-boosted combination therapies as first-line therapy for HCV Genotype 1a/b and
|
The metabolism of Ritonavir can be decreased when combined with Loratadine.
| 46 |
[
[
[
401,
69,
244
]
],
[
[
401,
69,
429
],
[
429,
223,
244
]
],
[
[
401,
6,
10999
],
[
10999,
160,
244
]
],
[
[
401,
21,
28646
],
[
28646,
175,
244
]
],
[
[
401,
180,
171
],
[
171,
26,
244
]
],
[
[
401,
192,
1083
],
[
1083,
187,
244
]
],
[
[
401,
69,
288
],
[
288,
42,
244
]
],
[
[
401,
225,
1007
],
[
1007,
42,
244
]
],
[
[
401,
71,
165
],
[
165,
69,
244
]
],
[
[
401,
225,
990
],
[
990,
69,
244
]
]
] |
[
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} (Compound) causes {v} (Side Effect)",
"Abdominal pain"
],
[
"Abdominal pain",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} can increase the metabolism of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may reduce the serum concentration of the active metabolites of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may decrease the metabolism of {v}",
"Promazine"
],
[
"Promazine",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
],
[
[
"Loratadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mesoridazine"
],
[
"Mesoridazine",
"{u} may decrease the metabolism of {v}",
"Ritonavir"
]
]
] |
Loratadine may decrease the metabolism of Lopinavir and Lopinavir may decrease the metabolism of Ritonavir
Loratadine (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ritonavir (Compound)
Loratadine (Compound) causes Abdominal pain (Side Effect) and Abdominal pain (Side Effect) is caused by Ritonavir (Compound)
Loratadine can increase the metabolism of Pentobarbital and Pentobarbital can increase the metabolism of Ritonavir
Loratadine may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may reduce the serum concentration of the active metabolites of Ritonavir
Loratadine may decrease the metabolism of Promazine and Promazine may increase the QTc prolonging activities of Ritonavir
Loratadine may increase the severity of adverse effects when combined with Paliperidone and Paliperidone may increase the QTc prolonging activities of Ritonavir
Loratadine may increase the severity of adverse effects when combined with Brompheniramine and Brompheniramine may decrease the metabolism of Ritonavir
Loratadine may increase the severity of adverse effects when combined with Mesoridazine and Mesoridazine may decrease the metabolism of Ritonavir
|
DB00232
|
DB00703
| 1,326 | 1,367 |
Methyclothiazide
|
Methazolamide
|
A thiazide diuretic with properties similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p825)
|
A carbonic anhydrase inhibitor that is used as a diuretic and in the treatment of glaucoma.
|
The risk or severity of adverse effects can be increased when Methyclothiazide is combined with Methazolamide.
| 48 |
[
[
[
1326,
71,
1367
]
],
[
[
1326,
6,
6793
],
[
6793,
160,
1367
]
],
[
[
1326,
21,
28556
],
[
28556,
175,
1367
]
],
[
[
1326,
52,
828
],
[
828,
206,
1367
]
],
[
[
1326,
225,
1083
],
[
1083,
71,
1367
]
],
[
[
1326,
71,
1354
],
[
1354,
225,
1367
]
],
[
[
1326,
246,
798
],
[
798,
71,
1367
]
],
[
[
1326,
71,
1054
],
[
1054,
71,
1367
]
],
[
[
1326,
1,
1048
],
[
1048,
225,
1367
]
],
[
[
1326,
206,
161
],
[
161,
225,
1367
]
]
] |
[
[
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} (Compound) binds {v} (Gene)",
"CA2"
],
[
"CA2",
"{u} (Gene) is bound by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} (Compound) causes {v} (Side Effect)",
"Anaphylactic shock"
],
[
"Anaphylactic shock",
"{u} (Side Effect) is caused by {v} (Compound)",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nitroglycerin"
],
[
"Nitroglycerin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may decrease the therapeutic efficacy of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olmesartan"
],
[
"Olmesartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} (Compound) resembles {v} (Compound)",
"Chlorothiazide"
],
[
"Chlorothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
],
[
[
"Methyclothiazide",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Primidone"
],
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methazolamide"
]
]
] |
Methyclothiazide (Compound) binds CA2 (Gene) and CA2 (Gene) is bound by Methazolamide (Compound)
Methyclothiazide (Compound) causes Anaphylactic shock (Side Effect) and Anaphylactic shock (Side Effect) is caused by Methazolamide (Compound)
Methyclothiazide may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Methazolamide
Methyclothiazide may increase the severity of adverse effects when combined with Hydrocodone and Hydrocodone may increase the severity of adverse effects when combined with Methazolamide
Methyclothiazide may increase the severity of adverse effects when combined with Nitroglycerin and Nitroglycerin may increase the severity of adverse effects when combined with Methazolamide
Methyclothiazide may decrease the therapeutic efficacy of Balsalazide and Balsalazide may increase the severity of adverse effects when combined with Methazolamide
Methyclothiazide may increase the severity of adverse effects when combined with Olmesartan and Olmesartan may increase the severity of adverse effects when combined with Methazolamide
Methyclothiazide (Compound) resembles Chlorothiazide (Compound) and Chlorothiazide may increase the severity of adverse effects when combined with Methazolamide
Methyclothiazide may increase the orthostatic hypotensive activities of Primidone and Primidone may increase the severity of adverse effects when combined with Methazolamide
|
DB12161
|
DB00224
| 399 | 266 |
Deutetrabenazine
|
Indinavir
|
Deutetrabenazine is a novel, highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor indicated for the management of chorea associated with Huntington’s disease. It is a hexahydro-dimethoxybenzoquinolizine derivative and a deuterated. The presence of deuterium in deutetrabenazine increases the half-lives of the active metabolite and prolongs their pharmacological activity by attenuating CYP2D6 metabolism of the compound. This allows less frequent dosing and a lower daily dose with improvement in tolerability. Decreased plasma fluctuations of deutetrabenazine due to attenuated metabolism may explain a lower incidence of adverse reactions associated with deutetrabenazine. Deutetrabenazine is a racemic mixture containing RR-Deutetrabenazine and SS-Deutetrabenazine [FDA Label]. Huntington's disease (HD) is a hereditary, progressive neurodegenerative disorder characterized by motor dysfunction,
|
A potent and specific HIV protease inhibitor that appears to have good oral bioavailability. [PubChem]
|
The metabolism of Indinavir can be decreased when combined with Deutetrabenazine.
| 46 |
[
[
[
399,
69,
266
]
],
[
[
399,
69,
269
],
[
269,
223,
266
]
],
[
[
399,
180,
156
],
[
156,
26,
266
]
],
[
[
399,
69,
645
],
[
645,
69,
266
]
],
[
[
399,
69,
564
],
[
564,
71,
266
]
],
[
[
399,
95,
1324
],
[
1324,
95,
266
]
],
[
[
399,
95,
1019
],
[
1019,
249,
266
]
],
[
[
399,
69,
198
],
[
198,
95,
266
]
],
[
[
399,
69,
496
],
[
496,
249,
266
]
],
[
[
399,
249,
531
],
[
531,
95,
266
]
]
] |
[
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Nelfinavir"
],
[
"Nelfinavir",
"{u} may decrease the metabolism of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} can increase the metabolism of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Azithromycin"
],
[
"Azithromycin",
"{u} may decrease the metabolism of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Atazanavir"
],
[
"Atazanavir",
"{u} may increase the severity of adverse effects when combined with {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Ceritinib"
],
[
"Ceritinib",
"{u} may increase the serum concentration of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the serum concentration of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Cyclosporine"
],
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may decrease the metabolism of {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may increase the serum concentration of {v}",
"Indinavir"
]
],
[
[
"Deutetrabenazine",
"{u} may increase the serum concentration of {v}",
"Conivaptan"
],
[
"Conivaptan",
"{u} may increase the serum concentration of {v}",
"Indinavir"
]
]
] |
Deutetrabenazine may decrease the metabolism of Nelfinavir and Nelfinavir may decrease the metabolism of Indinavir
Deutetrabenazine can increase the metabolism of Carbamazepine and Carbamazepine can increase the metabolism of Indinavir
Deutetrabenazine may decrease the metabolism of Azithromycin and Azithromycin may decrease the metabolism of Indinavir
Deutetrabenazine may decrease the metabolism of Atazanavir and Atazanavir may increase the severity of adverse effects when combined with Indinavir
Deutetrabenazine may increase the serum concentration of Ceritinib and Ceritinib may increase the serum concentration of Indinavir
Deutetrabenazine may increase the serum concentration of Mifepristone and Mifepristone may increase the serum concentration of Indinavir
Deutetrabenazine may decrease the metabolism of Cyclosporine and Cyclosporine may increase the serum concentration of Indinavir
Deutetrabenazine may decrease the metabolism of Ketoconazole and Ketoconazole may increase the serum concentration of Indinavir
Deutetrabenazine may increase the serum concentration of Conivaptan and Conivaptan may increase the serum concentration of Indinavir
|
DB01356
|
DB09216
| 997 | 449 |
Lithium cation
|
Tolfenamic acid
|
Lithium was used during the 19th century to treat gout. Lithium salts such as lithium carbonate (Li2CO3), lithium citrate, and lithium orotate are mood stabilizers. They are used in the treatment of bipolar disorder, since unlike most other mood altering drugs, they counteract both mania and depression. Lithium can also be used to augment other antidepressant drugs. It is also sometimes prescribed as a preventive treatment for migraine disease and cluster headaches. The active principle in these salts is the lithium ion Li+, which having a smaller diameter, can easily displace K+ and Na+ and even Ca+2, in spite of its greater charge, occupying their sites in several critical neuronal enzymes and neurotransmitter receptors.
|
Tolfenamic acid, with the formula N-(2-methyl-3-chlorphenyl)-anthranilic acid, is a nonsteroidal anti-inflammatory agent. It was discovered by scientists at Medica Pharmaceutical Company in Finland. It is used in the UK as a treatment for migraine under the name of Clotam. In the US, it presents a Status class I by the FDA. By the European Medicine Agency, it was granted in 2016 with the status of orphan for the treatment of supranuclear palsy.
|
The serum concentration of Tolfenamic acid can be increased when it is combined with Lithium cation.
| 72 |
[
[
[
997,
95,
449
]
],
[
[
997,
225,
171
],
[
171,
26,
449
]
],
[
[
997,
71,
161
],
[
161,
26,
449
]
],
[
[
997,
251,
894
],
[
894,
205,
449
]
],
[
[
997,
95,
462
],
[
462,
59,
449
]
],
[
[
997,
196,
1027
],
[
1027,
59,
449
]
],
[
[
997,
196,
143
],
[
143,
223,
449
]
],
[
[
997,
95,
1071
],
[
1071,
71,
449
]
],
[
[
997,
57,
245
],
[
245,
225,
449
]
],
[
[
997,
38,
405
],
[
405,
225,
449
]
]
] |
[
[
[
"Lithium cation",
"{u} may increase the serum concentration of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may decrease the serum concentration of {v}",
"Furosemide"
],
[
"Furosemide",
"{u} may decrease the diuretic activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the serum concentration of {v}",
"Eplerenone"
],
[
"Eplerenone",
"{u} may decrease the antihypertensive activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the QTc prolonging activities of {v}",
"Sotalol"
],
[
"Sotalol",
"{u} may decrease the antihypertensive activities of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may decrease the metabolism of {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the serum concentration of {v}",
"Telmisartan"
],
[
"Telmisartan",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
],
[
[
"Lithium cation",
"{u} may increase the central nervous system depressant activities of {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolfenamic acid"
]
]
] |
Lithium cation may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Tolfenamic acid
Lithium cation may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Tolfenamic acid
Lithium cation may decrease the serum concentration of Furosemide and Furosemide may decrease the diuretic activities of Tolfenamic acid
Lithium cation may increase the serum concentration of Eplerenone and Eplerenone may decrease the antihypertensive activities of Tolfenamic acid
Lithium cation may increase the QTc prolonging activities of Sotalol and Sotalol may decrease the antihypertensive activities of Tolfenamic acid
Lithium cation may increase the QTc prolonging activities of Erythromycin and Erythromycin may decrease the metabolism of Tolfenamic acid
Lithium cation may increase the serum concentration of Telmisartan and Telmisartan may increase the severity of adverse effects when combined with Tolfenamic acid
Lithium cation may increase the neurotoxic activities of Haloperidol and Haloperidol may increase the severity of adverse effects when combined with Tolfenamic acid
Lithium cation may increase the central nervous system depressant activities of Magnesium sulfate and Magnesium sulfate may increase the severity of adverse effects when combined with Tolfenamic acid
|
DB01409
|
DB00243
| 26 | 379 |
Tiotropium
|
Ranolazine
|
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004.
|
Chronic angina is a common cardiovascular condition affecting millions worldwide and causes significant disability while interfering with daily activities. Ranolazine is a well-tolerated piperazine derivative used for the management of this condition, offering relief from uncomfortable and debilitating symptoms. With a mechanism of action different from drugs used to treat the same condition, ranolazine is a promising anti-anginal therapy. It was originally approved by the FDA in 2006.
|
The metabolism of Ranolazine can be decreased when combined with Tiotropium.
| 46 |
[
[
[
26,
69,
379
]
],
[
[
26,
6,
4590
],
[
4590,
160,
379
]
],
[
[
26,
21,
28770
],
[
28770,
175,
379
]
],
[
[
26,
180,
150
],
[
150,
26,
379
]
],
[
[
26,
69,
539
],
[
539,
42,
379
]
],
[
[
26,
24,
46
],
[
46,
69,
379
]
],
[
[
26,
71,
289
],
[
289,
69,
379
]
],
[
[
26,
246,
1293
],
[
1293,
69,
379
]
],
[
[
26,
69,
414
],
[
414,
69,
379
]
],
[
[
26,
69,
396
],
[
396,
249,
379
]
]
] |
[
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} (Compound) causes {v} (Side Effect)",
"Paraesthesia"
],
[
"Paraesthesia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} can increase the metabolism of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the QTc prolonging activities of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may decrease the therapeutic efficacy of {v}",
"Metoclopramide"
],
[
"Metoclopramide",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Terbinafine"
],
[
"Terbinafine",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
]
]
] |
Tiotropium (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Ranolazine (Compound)
Tiotropium (Compound) causes Paraesthesia (Side Effect) and Paraesthesia (Side Effect) is caused by Ranolazine (Compound)
Tiotropium can increase the metabolism of Fosphenytoin and Fosphenytoin can increase the metabolism of Ranolazine
Tiotropium may decrease the metabolism of Artemether and Artemether may increase the QTc prolonging activities of Ranolazine
Tiotropium may increase the anticholinergic activities of Solifenacin and Solifenacin may decrease the metabolism of Ranolazine
Tiotropium may increase the severity of adverse effects when combined with Levacetylmethadol and Levacetylmethadol may decrease the metabolism of Ranolazine
Tiotropium may decrease the therapeutic efficacy of Metoclopramide and Metoclopramide may decrease the metabolism of Ranolazine
Tiotropium may decrease the metabolism of Cholecalciferol and Cholecalciferol may decrease the metabolism of Ranolazine
Tiotropium may decrease the metabolism of Terbinafine and Terbinafine may increase the serum concentration of Ranolazine
|
DB00432
|
DB01092
| 1,178 | 1,348 |
Trifluridine
|
Ouabain
|
Trifluridine is a fluorinated pyrimidine nucleoside that is structurally related to [idoxuridine]. It is an active antiviral agent in ophthalmic solutions used mainly in the treatment of primary keratoconjunctivitis and recurrent epithelial keratitis due to herpes simplex virus. It displays effective antiviral activity against Herpes simplex virus type 1 and 2. The combination product of trifluridine with tipiracil marketed as Lonsurf has been approved in Japan, the United States, and the European Union for the treatment of adult patients with metastatic colorectal cancer who have been previously treated with fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF biological therapy, and if RAS wild-type, an anti-EGFR therapy. In the anticancer therapy, trifluridine acts as a thymidine-based nucleoside metabolic inhibitor that gets
|
A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
|
Trifluridine may decrease the cardiotoxic activities of Ouabain.
| 57 |
[
[
[
1178,
80,
1348
]
],
[
[
1178,
80,
232
],
[
232,
155,
1348
]
],
[
[
1178,
80,
1347
],
[
1347,
1,
1348
]
],
[
[
1178,
7,
9144
],
[
9144,
161,
1348
]
],
[
[
1178,
6,
11160
],
[
11160,
172,
1348
]
],
[
[
1178,
7,
5388
],
[
5388,
172,
1348
]
],
[
[
1178,
18,
8994
],
[
8994,
172,
1348
]
],
[
[
1178,
225,
357
],
[
357,
80,
1348
]
],
[
[
1178,
191,
243
],
[
243,
80,
1348
]
],
[
[
1178,
155,
1214
],
[
1214,
80,
1348
]
]
] |
[
[
[
"Trifluridine",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} may decrease the cardiotoxic activities of {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
],
[
"Acetyldigitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} (Compound) upregulates {v} (Gene)",
"ATP1B1"
],
[
"ATP1B1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} (Compound) binds {v} (Gene)",
"TYMS"
],
[
"TYMS",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} (Compound) upregulates {v} (Gene)",
"LOXL1"
],
[
"LOXL1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} (Compound) downregulates {v} (Gene)",
"KIF20A"
],
[
"KIF20A",
"{u} (Gene) is downregulated by {v} (Compound)",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Docetaxel"
],
[
"Docetaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Trifluridine",
"{u} (Compound) resembles {v} (Compound)",
"Pentostatin"
],
[
"Pentostatin",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
]
] |
Trifluridine may decrease the cardiotoxic activities of Digitoxin and Digitoxin (Compound) resembles Ouabain (Compound)
Trifluridine may decrease the cardiotoxic activities of Acetyldigitoxin and Acetyldigitoxin (Compound) resembles Ouabain (Compound)
Trifluridine (Compound) upregulates ATP1B1 (Gene) and ATP1B1 (Gene) is upregulated by Ouabain (Compound)
Trifluridine (Compound) binds TYMS (Gene) and TYMS (Gene) is downregulated by Ouabain (Compound)
Trifluridine (Compound) upregulates LOXL1 (Gene) and LOXL1 (Gene) is downregulated by Ouabain (Compound)
Trifluridine (Compound) downregulates KIF20A (Gene) and KIF20A (Gene) is downregulated by Ouabain (Compound)
Trifluridine may increase the severity of adverse effects when combined with Docetaxel and Docetaxel may decrease the cardiotoxic activities of Ouabain
Trifluridine may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the cardiotoxic activities of Ouabain
Trifluridine (Compound) resembles Pentostatin (Compound) and Pentostatin may decrease the cardiotoxic activities of Ouabain
|
DB01409
|
DB00188
| 26 | 227 |
Tiotropium
|
Bortezomib
|
Tiotropium is a long-acting, antimuscarinic bronchodilator used in the management of chronic obstructive pulmonary disease (COPD) and asthma.[A180163,L7084,L7087,L7090,L7093] Tiotropium acts mainly on M3 muscarinic receptors located in the airways to produce smooth muscle relaxation and bronchodilation.[A180163,L7084,L7087,L7090,L7093] Tiotropium is more specific for the subset of muscarinic receptors commonly found in the lungs than [ipratropium]. Tiotropium was granted FDA approval on 30 January 2004.
|
Bortezomib is a dipeptide boronic acid derivative and proteasome inhibitor used to treat multiple myeloma and mantle cell lymphoma. The 26S proteasome is a protein complex that degrades ubiquitinated proteins in the ubiquitin-proteasome pathway: reversible inhibition of the 26S proteasome, leading to cell cycle arrest and apoptosis of cancer cells, is thought to be the main mechanism of action of bortezomib. However, multiple mechanisms may be involved in the anticancer activity of bortezomib. Bortezomib was first synthesized in 1995. In May 2003, bortezomib became the first anticancer proteasome inhibitor that was approved by the FDA under the trade name VELCADE. Phase I, II, III, and IV clinical trials are undergoing to investigate the therapeutic efficacy of bortezomib in leukemia, myasthenia gravis, systemic
|
The metabolism of Bortezomib can be decreased when combined with Tiotropium.
| 46 |
[
[
[
26,
69,
227
]
],
[
[
26,
6,
18777
],
[
18777,
160,
227
]
],
[
[
26,
21,
28803
],
[
28803,
175,
227
]
],
[
[
26,
69,
394
],
[
394,
42,
227
]
],
[
[
26,
69,
828
],
[
828,
206,
227
]
],
[
[
26,
69,
414
],
[
414,
69,
227
]
],
[
[
26,
71,
419
],
[
419,
69,
227
]
],
[
[
26,
24,
46
],
[
46,
69,
227
]
],
[
[
26,
69,
1086
],
[
1086,
223,
227
]
],
[
[
26,
246,
285
],
[
285,
69,
227
]
]
] |
[
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} (Compound) binds {v} (Gene)",
"CYP2D6"
],
[
"CYP2D6",
"{u} (Gene) is bound by {v} (Compound)",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} (Compound) causes {v} (Side Effect)",
"Arrhythmia"
],
[
"Arrhythmia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Cholecalciferol"
],
[
"Cholecalciferol",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alfentanil"
],
[
"Alfentanil",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may increase the anticholinergic activities of {v}",
"Solifenacin"
],
[
"Solifenacin",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may decrease the metabolism of {v}",
"Clotrimazole"
],
[
"Clotrimazole",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
],
[
[
"Tiotropium",
"{u} may decrease the therapeutic efficacy of {v}",
"Mefloquine"
],
[
"Mefloquine",
"{u} may decrease the metabolism of {v}",
"Bortezomib"
]
]
] |
Tiotropium (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Bortezomib (Compound)
Tiotropium (Compound) causes Arrhythmia (Side Effect) and Arrhythmia (Side Effect) is caused by Bortezomib (Compound)
Tiotropium may decrease the metabolism of Fluoxetine and Fluoxetine may increase the QTc prolonging activities of Bortezomib
Tiotropium may decrease the metabolism of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Bortezomib
Tiotropium may decrease the metabolism of Cholecalciferol and Cholecalciferol may decrease the metabolism of Bortezomib
Tiotropium may increase the severity of adverse effects when combined with Alfentanil and Alfentanil may decrease the metabolism of Bortezomib
Tiotropium may increase the anticholinergic activities of Solifenacin and Solifenacin may decrease the metabolism of Bortezomib
Tiotropium may decrease the metabolism of Clotrimazole and Clotrimazole may decrease the metabolism of Bortezomib
Tiotropium may decrease the therapeutic efficacy of Mefloquine and Mefloquine may decrease the metabolism of Bortezomib
|
DB01039
|
DB00227
| 432 | 267 |
Fenofibrate
|
Lovastatin
|
Fenofibrate is a fibric acid derivative like [clofibrate] and [gemfibrozil]. Fenofibrate is used to treat primary hypercholesterolemia, mixed dyslipidemia, severe hypertriglyceridemia.[L8588,L8591] Fenofibrate was granted FDA approval on 31 December 1993.
|
Lovastatin, also known as the brand name product Mevacor, is a lipid-lowering drug and fungal metabolite derived synthetically from a fermentation product of _Aspergillus terreus_. Originally named Mevinolin, lovastatin belongs to the statin class of medications, which are used to lower the risk of cardiovascular disease and manage abnormal lipid levels by inhibiting the endogenous production of cholesterol in the liver. More specifically, statin medications competitively inhibit the enzyme hydroxymethylglutaryl-coenzyme A (HMG-CoA) Reductase, which catalyzes the conversion of HMG-CoA to mevalonic acid and is the third step in a sequence of metabolic reactions involved in the production of several compounds involved in lipid metabolism and transport including cholesterol, low-density lipoprotein (LDL) (sometimes referred to as "bad cholesterol"), and very low-density lipoprotein (VLDL). Prescribing of statin medications is considered
|
The metabolism of Lovastatin can be decreased when combined with Fenofibrate.
| 46 |
[
[
[
432,
69,
267
]
],
[
[
432,
5,
17096
],
[
17096,
159,
267
]
],
[
[
432,
6,
4590
],
[
4590,
160,
267
]
],
[
[
432,
21,
29390
],
[
29390,
175,
267
]
],
[
[
432,
180,
161
],
[
161,
26,
267
]
],
[
[
432,
251,
225
],
[
225,
26,
267
]
],
[
[
432,
185,
326
],
[
326,
69,
267
]
],
[
[
432,
69,
615
],
[
615,
69,
267
]
],
[
[
432,
71,
307
],
[
307,
69,
267
]
],
[
[
432,
182,
498
],
[
498,
69,
267
]
]
] |
[
[
[
"Fenofibrate",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} (Compound) treats {v} (Disease)",
"coronary artery disease"
],
[
"coronary artery disease",
"{u} (Disease) is treated by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} (Compound) causes {v} (Side Effect)",
"Creatine phosphokinase increased"
],
[
"Creatine phosphokinase increased",
"{u} (Side Effect) is caused by {v} (Compound)",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} may decrease the serum concentration of {v}",
"Bosentan"
],
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} may increase the hypoglycemic activities of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluvastatin"
],
[
"Fluvastatin",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
],
[
[
"Fenofibrate",
"{u} may increase the anticoagulant activities of {v}",
"Dicoumarol"
],
[
"Dicoumarol",
"{u} may decrease the metabolism of {v}",
"Lovastatin"
]
]
] |
Fenofibrate (Compound) treats coronary artery disease (Disease) and coronary artery disease (Disease) is treated by Lovastatin (Compound)
Fenofibrate (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Lovastatin (Compound)
Fenofibrate (Compound) causes Creatine phosphokinase increased (Side Effect) and Creatine phosphokinase increased (Side Effect) is caused by Lovastatin (Compound)
Fenofibrate can increase the metabolism of Primidone and Primidone can increase the metabolism of Lovastatin
Fenofibrate may decrease the serum concentration of Bosentan and Bosentan can increase the metabolism of Lovastatin
Fenofibrate may increase the hypoglycemic activities of Glipizide and Glipizide may decrease the metabolism of Lovastatin
Fenofibrate may decrease the metabolism of Sildenafil and Sildenafil may decrease the metabolism of Lovastatin
Fenofibrate may increase the severity of adverse effects when combined with Fluvastatin and Fluvastatin may decrease the metabolism of Lovastatin
Fenofibrate may increase the anticoagulant activities of Dicoumarol and Dicoumarol may decrease the metabolism of Lovastatin
|
DB00680
|
DB00254
| 1,450 | 755 |
Moricizine
|
Doxycycline
|
An antiarrhythmia agent used primarily for ventricular rhythm disturbances.
|
Doxycycline is a broad-spectrum antibiotic synthetically derived from [oxytetracycline]. It is a second-generation tetracycline that was first discovered in 1967. Second-generation tetracyclines exhibit lesser toxicity than first-generation tetracyclines. Doxycycline is used to treat a wide variety of gram-positive and gram-negative bacterial infections. It is also used to treat acne and malaria.
|
The serum concentration of Doxycycline can be increased when it is combined with Moricizine.
| 72 |
[
[
[
1450,
95,
755
]
],
[
[
1450,
95,
417
],
[
417,
69,
755
]
],
[
[
1450,
71,
648
],
[
648,
69,
755
]
],
[
[
1450,
82,
491
],
[
491,
69,
755
]
],
[
[
1450,
89,
89
],
[
89,
243,
755
]
],
[
[
1450,
1,
653
],
[
653,
95,
755
]
],
[
[
1450,
82,
1083
],
[
1083,
95,
755
]
],
[
[
1450,
95,
272
],
[
272,
95,
755
]
],
[
[
1450,
89,
78
],
[
78,
97,
755
]
],
[
[
1450,
95,
417
],
[
417,
6,
4590
],
[
4590,
160,
755
]
]
] |
[
[
[
"Moricizine",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the serum concentration of {v}",
"Primaquine"
],
[
"Primaquine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nefazodone"
],
[
"Nefazodone",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Buprenorphine"
],
[
"Buprenorphine",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may decrease the absorption and serum concentration of {v}",
"Almasilate"
],
[
"Almasilate",
"{u} may decrease the absorption and serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the hypotensive activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the serum concentration of {v}",
"Halofantrine"
],
[
"Halofantrine",
"{u} may increase the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may decrease the absorption and serum concentration of {v}",
"Bismuth subcitrate potassium"
],
[
"Bismuth subcitrate potassium",
"{u} may decrease the serum concentration of {v}",
"Doxycycline"
]
],
[
[
"Moricizine",
"{u} may increase the serum concentration of {v}",
"Primaquine"
],
[
"Primaquine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Doxycycline"
]
]
] |
Moricizine may increase the serum concentration of Primaquine and Primaquine may decrease the metabolism of Doxycycline
Moricizine may increase the severity of adverse effects when combined with Nefazodone and Nefazodone may decrease the metabolism of Doxycycline
Moricizine may increase the hypotensive activities of Buprenorphine and Buprenorphine may decrease the metabolism of Doxycycline
Moricizine may decrease the absorption and serum concentration of Almasilate and Almasilate may decrease the absorption and serum concentration of Doxycycline
Moricizine (Compound) resembles Thioridazine (Compound) and Thioridazine may increase the serum concentration of Doxycycline
Moricizine may increase the hypotensive activities of Hydrocodone and Hydrocodone may increase the serum concentration of Doxycycline
Moricizine may increase the serum concentration of Halofantrine and Halofantrine may increase the serum concentration of Doxycycline
Moricizine may decrease the absorption and serum concentration of Bismuth subcitrate potassium and Bismuth subcitrate potassium may decrease the serum concentration of Doxycycline
Moricizine may increase the serum concentration of Primaquine and Primaquine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Doxycycline (Compound)
|
DB00681
|
DB01092
| 1,151 | 1,348 |
Amphotericin B
|
Ouabain
|
Amphotericin B shows a high order of in vitro activity against many species of fungi. Histoplasma capsulatum, Coccidioides immitis, Candida species, Blastomyces dermatitidis, Rhodotorula, Cryptococcus neoformans, Sporothrix schenckii, Mucor mucedo, and Aspergillus fumigatus are all inhibited by concentrations of amphotericin B ranging from 0.03 to 1.0 mcg/mL in vitro. While Candida albicans is generally quite susceptible to amphotericin B, non-albicans species may be less susceptible. Pseudallescheria boydii and Fusarium sp. are often resistant to amphotericin B. The antibiotic is without effect on bacteria, rickettsiae, and viruses.
|
A cardioactive glycoside consisting of rhamnose and ouabagenin, obtained from the seeds of Strophanthus gratus and other plants of the Apocynaceae; used like digitalis. It is commonly used in cell biological studies as an inhibitor of the NA(+)-K(+)-exchanging ATPase.
|
The risk or severity of adverse effects can be increased when Amphotericin B is combined with Ouabain.
| 48 |
[
[
[
1151,
71,
1348
]
],
[
[
1151,
71,
232
],
[
232,
155,
1348
]
],
[
[
1151,
71,
1347
],
[
1347,
1,
1348
]
],
[
[
1151,
71,
461
],
[
461,
47,
1348
]
],
[
[
1151,
71,
183
],
[
183,
71,
1348
]
],
[
[
1151,
71,
248
],
[
248,
76,
1348
]
],
[
[
1151,
233,
899
],
[
899,
80,
1348
]
],
[
[
1151,
246,
404
],
[
404,
80,
1348
]
],
[
[
1151,
71,
292
],
[
292,
80,
1348
]
],
[
[
1151,
259,
80
],
[
80,
80,
1348
]
]
] |
[
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Digitoxin"
],
[
"Digitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetyldigitoxin"
],
[
"Acetyldigitoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the atrioventricular blocking activities of {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carvedilol"
],
[
"Carvedilol",
"{u} may increase the bradycardic activities of {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the nephrotoxic activities of {v}",
"Plicamycin"
],
[
"Plicamycin",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may decrease the therapeutic efficacy of {v}",
"Sirolimus"
],
[
"Sirolimus",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the severity of adverse effects when combined with {v}",
"Paclitaxel"
],
[
"Paclitaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
],
[
[
"Amphotericin B",
"{u} may increase the hypokalemic activities of {v}",
"Prednisone"
],
[
"Prednisone",
"{u} may decrease the cardiotoxic activities of {v}",
"Ouabain"
]
]
] |
Amphotericin B may increase the severity of adverse effects when combined with Digitoxin and Digitoxin (Compound) resembles Ouabain (Compound)
Amphotericin B may increase the severity of adverse effects when combined with Acetyldigitoxin and Acetyldigitoxin (Compound) resembles Ouabain (Compound)
Amphotericin B may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may increase the atrioventricular blocking activities of Ouabain
Amphotericin B may increase the severity of adverse effects when combined with Indapamide and Indapamide may increase the severity of adverse effects when combined with Ouabain
Amphotericin B may increase the severity of adverse effects when combined with Carvedilol and Carvedilol may increase the bradycardic activities of Ouabain
Amphotericin B may increase the nephrotoxic activities of Plicamycin and Plicamycin may decrease the cardiotoxic activities of Ouabain
Amphotericin B may decrease the therapeutic efficacy of Sirolimus and Sirolimus may decrease the cardiotoxic activities of Ouabain
Amphotericin B may increase the severity of adverse effects when combined with Paclitaxel and Paclitaxel may decrease the cardiotoxic activities of Ouabain
Amphotericin B may increase the hypokalemic activities of Prednisone and Prednisone may decrease the cardiotoxic activities of Ouabain
|
DB06802
|
DB00827
| 780 | 830 |
Nepafenac
|
Cinoxacin
|
Nepafenac is a non-steroidal anti-inflammatory prodrug (NSAID) usually sold as a prescription eye drop. It is used to treat pain and inflammation associated with cataract surgery.
|
Synthetic antimicrobial related to oxolinic acid and nalidixic acid and used in urinary tract infections.
|
Nepafenac may increase the neuroexcitatory activities of Cinoxacin.
| 26 |
[
[
[
780,
49,
830
]
],
[
[
780,
21,
28512
],
[
28512,
175,
830
]
],
[
[
780,
182,
342
],
[
342,
28,
830
]
],
[
[
780,
71,
211
],
[
211,
49,
830
]
],
[
[
780,
233,
798
],
[
798,
49,
830
]
],
[
[
780,
155,
375
],
[
375,
49,
830
]
],
[
[
780,
182,
687
],
[
687,
49,
830
]
],
[
[
780,
71,
125
],
[
125,
71,
830
]
],
[
[
780,
95,
1401
],
[
1401,
249,
830
]
],
[
[
780,
155,
808
],
[
808,
97,
830
]
]
] |
[
[
[
"Nepafenac",
"{u} may increase the neuroexcitatory activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the anticoagulant activities of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} may increase the anticoagulant activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoprofen"
],
[
"Ketoprofen",
"{u} may increase the neuroexcitatory activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the nephrotoxic activities of {v}",
"Balsalazide"
],
[
"Balsalazide",
"{u} may increase the neuroexcitatory activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} (Compound) resembles {v} (Compound)",
"Mefenamic acid"
],
[
"Mefenamic acid",
"{u} may increase the neuroexcitatory activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the anticoagulant activities of {v}",
"Nafamostat"
],
[
"Nafamostat",
"{u} may increase the neuroexcitatory activities of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunisolide"
],
[
"Flunisolide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} may increase the serum concentration of {v}",
"Probenecid"
],
[
"Probenecid",
"{u} may increase the serum concentration of {v}",
"Cinoxacin"
]
],
[
[
"Nepafenac",
"{u} (Compound) resembles {v} (Compound)",
"Magnesium salicylate"
],
[
"Magnesium salicylate",
"{u} may decrease the serum concentration of {v}",
"Cinoxacin"
]
]
] |
Nepafenac (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Cinoxacin (Compound)
Nepafenac may increase the anticoagulant activities of Acenocoumarol and Acenocoumarol may increase the anticoagulant activities of Cinoxacin
Nepafenac may increase the severity of adverse effects when combined with Ketoprofen and Ketoprofen may increase the neuroexcitatory activities of Cinoxacin
Nepafenac may increase the nephrotoxic activities of Balsalazide and Balsalazide may increase the neuroexcitatory activities of Cinoxacin
Nepafenac (Compound) resembles Mefenamic acid (Compound) and Mefenamic acid may increase the neuroexcitatory activities of Cinoxacin
Nepafenac may increase the anticoagulant activities of Nafamostat and Nafamostat may increase the neuroexcitatory activities of Cinoxacin
Nepafenac may increase the severity of adverse effects when combined with Flunisolide and Flunisolide may increase the severity of adverse effects when combined with Cinoxacin
Nepafenac may increase the serum concentration of Probenecid and Probenecid may increase the serum concentration of Cinoxacin
Nepafenac (Compound) resembles Magnesium salicylate (Compound) and Magnesium salicylate may decrease the serum concentration of Cinoxacin
|
DB00528
|
DB01002
| 444 | 214 |
Lercanidipine
|
Levobupivacaine
|
Lercanidipine is a calcium channel blocker of the dihydropyridine class. It is sold under various commercial names including Zanidip.
|
Levobupivacaine is an amino-amide local anaesthetic drug belonging to the family of n-alkylsubstituted pipecoloxylidide. It is the S-enantiomer of bupivacaine. Levobupivacaine hydrochloride is commonly marketed by AstraZeneca under the trade name Chirocaine. In particular, the specific levobupivacaine enantiomer is a worthwhile pursuit because it demonstrates less vasodilation and possesses a greater length of action in comparison to bupivacaine. It is approximately 13 per cent less potent (by molarity) than racemic bupivacaine.Levobupivacaine is indicated for local anaesthesia including infiltration, nerve block, ophthalmic, epidural and intrathecal anaesthesia in adults; and infiltration analgesia in children. When administered appropriately, the occurrence of adverse effects is not anticipated much if at all. In
|
The risk or severity of adverse effects can be increased when Lercanidipine is combined with Levobupivacaine.
| 48 |
[
[
[
444,
71,
214
]
],
[
[
444,
69,
379
],
[
379,
223,
214
]
],
[
[
444,
71,
541
],
[
541,
71,
214
]
],
[
[
444,
6,
4590
],
[
4590,
160,
214
]
],
[
[
444,
21,
28396
],
[
28396,
175,
214
]
],
[
[
444,
180,
161
],
[
161,
26,
214
]
],
[
[
444,
249,
150
],
[
150,
26,
214
]
],
[
[
444,
71,
405
],
[
405,
192,
214
]
],
[
[
444,
71,
679
],
[
679,
38,
214
]
],
[
[
444,
186,
702
],
[
702,
192,
214
]
]
] |
[
[
[
"Lercanidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may decrease the metabolism of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} may decrease the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ropivacaine"
],
[
"Ropivacaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} (Compound) causes {v} (Side Effect)",
"Hyperhidrosis"
],
[
"Hyperhidrosis",
"{u} (Side Effect) is caused by {v} (Compound)",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Magnesium sulfate"
],
[
"Magnesium sulfate",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
],
[
[
"Lercanidipine",
"{u} may increase the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Levobupivacaine"
]
]
] |
Lercanidipine may decrease the metabolism of Ranolazine and Ranolazine may decrease the metabolism of Levobupivacaine
Lercanidipine may increase the severity of adverse effects when combined with Ropivacaine and Ropivacaine may increase the severity of adverse effects when combined with Levobupivacaine
Lercanidipine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Levobupivacaine (Compound)
Lercanidipine (Compound) causes Hyperhidrosis (Side Effect) and Hyperhidrosis (Side Effect) is caused by Levobupivacaine (Compound)
Lercanidipine can increase the metabolism of Primidone and Primidone can increase the metabolism of Levobupivacaine
Lercanidipine may increase the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Levobupivacaine
Lercanidipine may increase the severity of adverse effects when combined with Magnesium sulfate and Magnesium sulfate may increase the central nervous system depressant activities of Levobupivacaine
Lercanidipine may increase the severity of adverse effects when combined with Thalidomide and Thalidomide may increase the central nervous system depressant activities of Levobupivacaine
Lercanidipine may increase the antihypertensive activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Levobupivacaine
|
DB00559
|
DB00682
| 225 | 219 |
Bosentan
|
Warfarin
|
Bosentan is a dual endothelin receptor antagonist marketed under the trade name Tracleer by Actelion Pharmaceuticals. Bosentan is used to treat pulmonary hypertension by blocking the action of endothelin molecules that would otherwise promote narrowing of the blood vessels and lead to high blood pressure.
|
Warfarin is an anticoagulant drug normally used to prevent blood clot formation as well as migration. Although originally marketed as a pesticide (d-Con, Rodex, among others), Warfarin has since become the most frequently prescribed oral anticoagulant in North America. Warfarin has several properties that should be noted when used medicinally, including its ability to cross the placental barrier during pregnancy which can result in fetal bleeding, spontaneous abortion, preterm birth, stillbirth, and neonatal death. Additional adverse effects such as necrosis, purple toe syndrome, osteoporosis, valve and artery calcification, and drug interactions have also been documented with warfarin use. Warfarin does not actually affect blood viscosity, rather, it inhibits vitamin-k dependent synthesis of biologically active forms of various clotting factors in addition to several regulatory factors.
|
The metabolism of Warfarin can be increased when combined with Bosentan.
| 3 |
[
[
[
225,
26,
219
]
],
[
[
225,
26,
384
],
[
384,
28,
219
]
],
[
[
225,
95,
610
],
[
610,
155,
219
]
],
[
[
225,
26,
342
],
[
342,
155,
219
]
],
[
[
225,
97,
72
],
[
72,
155,
219
]
],
[
[
225,
6,
4590
],
[
4590,
160,
219
]
],
[
[
225,
180,
177
],
[
177,
26,
219
]
],
[
[
225,
95,
173
],
[
173,
26,
219
]
],
[
[
225,
97,
298
],
[
298,
26,
219
]
],
[
[
225,
251,
147
],
[
147,
26,
219
]
]
] |
[
[
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Phenprocoumon"
],
[
"Phenprocoumon",
"{u} may increase the anticoagulant activities of {v}",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Acenocoumarol"
],
[
"Acenocoumarol",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} may decrease the serum concentration of {v}",
"Orphenadrine"
],
[
"Orphenadrine",
"{u} (Compound) resembles {v} (Compound)",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} can increase the metabolism of {v}",
"Rifapentine"
],
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} may increase the serum concentration of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} may decrease the serum concentration of {v}",
"Hexobarbital"
],
[
"Hexobarbital",
"{u} can increase the metabolism of {v}",
"Warfarin"
]
],
[
[
"Bosentan",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Warfarin"
]
]
] |
Bosentan can increase the metabolism of Phenprocoumon and Phenprocoumon may increase the anticoagulant activities of Warfarin
Bosentan may increase the serum concentration of Atomoxetine and Atomoxetine (Compound) resembles Warfarin (Compound)
Bosentan can increase the metabolism of Acenocoumarol and Acenocoumarol (Compound) resembles Warfarin (Compound)
Bosentan may decrease the serum concentration of Orphenadrine and Orphenadrine (Compound) resembles Warfarin (Compound)
Bosentan (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Warfarin (Compound)
Bosentan can increase the metabolism of Rifapentine and Rifapentine can increase the metabolism of Warfarin
Bosentan may increase the serum concentration of Nevirapine and Nevirapine can increase the metabolism of Warfarin
Bosentan may decrease the serum concentration of Hexobarbital and Hexobarbital can increase the metabolism of Warfarin
Bosentan may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Warfarin
|
DB01174
|
DB00980
| 164 | 250 |
Phenobarbital
|
Ramelteon
|
A barbituric acid derivative that acts as a nonselective central nervous system depressant. It promotes binding to inhibitory gamma-aminobutyric acid subtype receptors, and modulates chloride currents through receptor channels. It also inhibits glutamate induced depolarizations.
|
Ramelteon is the first in a new class of sleep agents that selectively binds to the melatonin receptors in the suprachiasmatic nucleus (SCN). It is used for insomnia, particularly delayed sleep onset. Ramelteon has not been shown to produce dependence and has shown no potential for abuse.
|
The metabolism of Ramelteon can be increased when combined with Phenobarbital.
| 3 |
[
[
[
164,
26,
250
]
],
[
[
164,
6,
10999
],
[
10999,
160,
250
]
],
[
[
164,
21,
28512
],
[
28512,
175,
250
]
],
[
[
164,
180,
218
],
[
218,
26,
250
]
],
[
[
164,
38,
142
],
[
142,
26,
250
]
],
[
[
164,
270,
171
],
[
171,
26,
250
]
],
[
[
164,
26,
173
],
[
173,
26,
250
]
],
[
[
164,
38,
1261
],
[
1261,
192,
250
]
],
[
[
164,
192,
1266
],
[
1266,
38,
250
]
],
[
[
164,
54,
1365
],
[
1365,
208,
250
]
]
] |
[
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} (Compound) binds {v} (Gene)",
"CYP2C19"
],
[
"CYP2C19",
"{u} (Gene) is bound by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Rifaximin"
],
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Dronabinol"
],
[
"Dronabinol",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Paraldehyde"
],
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Ramelteon"
]
],
[
[
"Phenobarbital",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Ramelteon"
]
]
] |
Phenobarbital (Compound) binds CYP2C19 (Gene) and CYP2C19 (Gene) is bound by Ramelteon (Compound)
Phenobarbital (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Ramelteon (Compound)
Phenobarbital can increase the metabolism of Rifaximin and Rifaximin can increase the metabolism of Ramelteon
Phenobarbital may increase the central nervous system depressant activities of Phenytoin and Phenytoin can increase the metabolism of Ramelteon
Phenobarbital (Compound) resembles Pentobarbital (Compound) and Phenobarbital may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Ramelteon
Phenobarbital can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Ramelteon
Phenobarbital may increase the central nervous system depressant activities of Dronabinol and Dronabinol may increase the central nervous system depressant activities of Ramelteon
Phenobarbital may increase the central nervous system depressant activities of Paraldehyde and Paraldehyde may increase the central nervous system depressant activities of Ramelteon
Phenobarbital may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Ramelteon
|
DB00531
|
DB01208
| 243 | 757 |
Cyclophosphamide
|
Sparfloxacin
|
Precursor of an alkylating nitrogen mustard antineoplastic and immunosuppressive agent that must be activated in the liver to form the active aldophosphamide. It has been used in the treatment of lymphoma and leukemia. Its side effect, alopecia, has been used for defleecing sheep. Cyclophosphamide may also cause sterility, birth defects, mutations, and cancer.
|
Sparfloxacin is a fluoroquinolone antibiotic indicated for bacterial infections. Sparfloxacin exerts its antibacterial activity by inhibiting DNA gyrase, a bacterial topoisomerase. DNA gyrase is an essential enzyme which controls DNA topology and assists in DNA replication, repair, deactivation, and transcription.
|
Cyclophosphamide may increase the cardiotoxic activities of Sparfloxacin.
| 14 |
[
[
[
243,
37,
757
]
],
[
[
243,
37,
1237
],
[
1237,
1,
757
]
],
[
[
243,
6,
8339
],
[
8339,
160,
757
]
],
[
[
243,
21,
28498
],
[
28498,
175,
757
]
],
[
[
243,
225,
555
],
[
555,
31,
757
]
],
[
[
243,
69,
514
],
[
514,
31,
757
]
],
[
[
243,
95,
1019
],
[
1019,
31,
757
]
],
[
[
243,
37,
1018
],
[
1018,
31,
757
]
],
[
[
243,
37,
772
],
[
772,
49,
757
]
],
[
[
243,
71,
582
],
[
582,
49,
757
]
]
] |
[
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Lomefloxacin"
],
[
"Lomefloxacin",
"{u} (Compound) resembles {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} (Compound) causes {v} (Side Effect)",
"Haemorrhage"
],
[
"Haemorrhage",
"{u} (Side Effect) is caused by {v} (Compound)",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may decrease the metabolism of {v}",
"Rosiglitazone"
],
[
"Rosiglitazone",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the serum concentration of {v}",
"Mifepristone"
],
[
"Mifepristone",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the cardiotoxic activities of {v}",
"Resveratrol"
],
[
"Resveratrol",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
],
[
[
"Cyclophosphamide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the neuroexcitatory activities of {v}",
"Sparfloxacin"
]
]
] |
Cyclophosphamide may increase the cardiotoxic activities of Lomefloxacin and Lomefloxacin (Compound) resembles Sparfloxacin (Compound)
Cyclophosphamide (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Sparfloxacin (Compound)
Cyclophosphamide (Compound) causes Haemorrhage (Side Effect) and Haemorrhage (Side Effect) is caused by Sparfloxacin (Compound)
Cyclophosphamide may increase the severity of adverse effects when combined with Alogliptin and Alogliptin may increase the hypoglycemic activities of Sparfloxacin
Cyclophosphamide may decrease the metabolism of Rosiglitazone and Rosiglitazone may increase the hypoglycemic activities of Sparfloxacin
Cyclophosphamide may increase the serum concentration of Mifepristone and Mifepristone may increase the hypoglycemic activities of Sparfloxacin
Cyclophosphamide may increase the cardiotoxic activities of Sunitinib and Sunitinib may increase the hypoglycemic activities of Sparfloxacin
Cyclophosphamide may increase the cardiotoxic activities of Resveratrol and Resveratrol may increase the neuroexcitatory activities of Sparfloxacin
Cyclophosphamide may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may increase the neuroexcitatory activities of Sparfloxacin
|
DB00241
|
DB00413
| 977 | 1,365 |
Butalbital
|
Pramipexole
|
Butalbital, or 5-allyl-5-isobutylbarbituric acid, is a derivative of barbituric acid which the hydrogens at position 5 are substituted by an allyl group and an isobutyl group. It is a short-to-intermediate acting member of barbiturates that exhibit muscle-relaxing and anti-anxiety properties that produce central nervous system (CNS) depression that ranges from mild sedation to general anesthesia. Butalbital has a low degree of selectivity and a narrow therapeutic index. Typically indicated to manage tension (or muscle contraction) headaches, butalbital is often combined with one or more therapeutic agents, such as acetylsalicylic acid, acetaminophen, aspirin, and caffeine. There have not been clinical trials that evaluate the clinical efficacy of butalbital in migraines thus it is not indicated for such condition. As with other barbiturates
|
Pramipexole is a drug used to treat the symptoms of Parkinson's Disease (PD). It is a _non-ergot dopamine agonist_ drug that is efficacious in treating various Parkinson's symptoms such as tremor, rigidity, and bradykinesia (slow movement). It was first approved by the FDA in 1997. Parkinson's Disease is one of the most common neurodegenerative disorders and causes a high level of disability in patients, leading to increased difficulty in performing activities of daily living due to symptoms that progress over time. The prevalence of Parkinson's Disease worldwide has increased from approximately 2.5 million in 1990 to about 6.1 million in 2016. This increase may be attributed to an aging population along with other contributing factors. In addition to the above FDA approval for Parkinson's Disease, pramipexole was also approved by the FDA in 2006 for the treatment of Restless Legs Syndrome (
|
Butalbital may increase the sedative activities of Pramipexole.
| 31 |
[
[
[
977,
54,
1365
]
],
[
[
977,
71,
828
],
[
828,
206,
1365
]
],
[
[
977,
225,
962
],
[
962,
54,
1365
]
],
[
[
977,
71,
959
],
[
959,
54,
1365
]
],
[
[
977,
38,
1262
],
[
1262,
54,
1365
]
],
[
[
977,
192,
1083
],
[
1083,
54,
1365
]
],
[
[
977,
155,
145
],
[
145,
54,
1365
]
],
[
[
977,
270,
197
],
[
197,
54,
1365
]
],
[
[
977,
225,
18
],
[
18,
246,
1365
]
],
[
[
977,
71,
828
],
[
828,
6,
5586
],
[
5586,
160,
1365
]
]
] |
[
[
[
"Butalbital",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mepivacaine"
],
[
"Mepivacaine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound)",
"Thiamylal"
],
[
"Thiamylal",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} (Compound) resembles {v} (Compound) and {u} may increase the severity of adverse effects when combined with {v}",
"Amobarbital"
],
[
"Amobarbital",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may decrease the therapeutic efficacy of {v}",
"Pramipexole"
]
],
[
[
"Butalbital",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} (Compound) binds {v} (Gene)",
"HTR2A"
],
[
"HTR2A",
"{u} (Gene) is bound by {v} (Compound)",
"Pramipexole"
]
]
] |
Butalbital may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Pramipexole
Butalbital may increase the severity of adverse effects when combined with Mepivacaine and Mepivacaine may increase the sedative activities of Pramipexole
Butalbital may increase the severity of adverse effects when combined with Fexofenadine and Fexofenadine may increase the sedative activities of Pramipexole
Butalbital may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the sedative activities of Pramipexole
Butalbital may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the sedative activities of Pramipexole
Butalbital (Compound) resembles Thiamylal (Compound) and Thiamylal may increase the sedative activities of Pramipexole
Butalbital (Compound) resembles Amobarbital (Compound) and Butalbital may increase the severity of adverse effects when combined with Amobarbital and Amobarbital may increase the sedative activities of Pramipexole
Butalbital may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may decrease the therapeutic efficacy of Pramipexole
Butalbital may increase the severity of adverse effects when combined with Duloxetine and Duloxetine (Compound) binds HTR2A (Gene) and HTR2A (Gene) is bound by Pramipexole (Compound)
|
DB01380
|
DB09073
| 128 | 1,394 |
Cortisone acetate
|
Palbociclib
|
Cortisone acetate was first isolate in 1935 and became more widely researched in 1949. Since then, glucocorticoids such as cortisone acetate have been used to treat a number of inflammatory conditions such as endocrine, rheumatic, collagen, dermatologic, allergic, ophthalmic, respiratory, hematologic, neoplastic, edematous, and gastrointestinal diseases and disorders.[A226300,L13203] Cortisone acetate was granted FDA approval on 13 June 1950.
|
Palbociclib is a piperazine pyridopyrimidine that acts in the cell cycle machinery. It is a second generation cyclin-dependent kinase inhibitor selected from a group of pyridopyrimidine compounds due to its favorable physical and pharmaceutical properties. Palbociclib was developed by Pfizer Inc after the discovery that identified the cyclin-dependent kinases as key regulators of cell growth. It was originally FDA approved on March 2015 for the treatment of HR-positive, HER2-negative advanced or metastatic breast cancer and its indications were updated in April 2019 to include male patients based on findings from postmarketing reports and electronic health records demonstrating safety and clinical efficacy.
|
The serum concentration of Palbociclib can be increased when it is combined with Cortisone acetate.
| 72 |
[
[
[
128,
95,
1394
]
],
[
[
128,
210,
1388
],
[
1388,
56,
1394
]
],
[
[
128,
56,
340
],
[
340,
210,
1394
]
],
[
[
128,
69,
755
],
[
755,
223,
1394
]
],
[
[
128,
225,
1404
],
[
1404,
71,
1394
]
],
[
[
128,
71,
582
],
[
582,
225,
1394
]
],
[
[
128,
225,
563
],
[
563,
95,
1394
]
],
[
[
128,
69,
615
],
[
615,
95,
1394
]
],
[
[
128,
95,
1269
],
[
1269,
249,
1394
]
],
[
[
128,
155,
80
],
[
80,
95,
1394
]
]
] |
[
[
[
"Cortisone acetate",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the immunosuppressive activities of {v}",
"Roflumilast"
],
[
"Roflumilast",
"{u} may increase the immunosuppressive activities of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the immunosuppressive activities of {v}",
"Fingolimod"
],
[
"Fingolimod",
"{u} may increase the immunosuppressive activities of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may decrease the metabolism of {v}",
"Doxycycline"
],
[
"Doxycycline",
"{u} may decrease the metabolism of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Nicergoline"
],
[
"Nicergoline",
"{u} may increase the severity of adverse effects when combined with {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Leflunomide"
],
[
"Leflunomide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may decrease the metabolism of {v}",
"Sildenafil"
],
[
"Sildenafil",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} may increase the serum concentration of {v}",
"Stiripentol"
],
[
"Stiripentol",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
],
[
[
"Cortisone acetate",
"{u} (Compound) resembles {v} (Compound)",
"Prednisone"
],
[
"Prednisone",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
]
]
] |
Cortisone acetate may increase the immunosuppressive activities of Roflumilast and Roflumilast may increase the immunosuppressive activities of Palbociclib
Cortisone acetate may increase the immunosuppressive activities of Fingolimod and Fingolimod may increase the immunosuppressive activities of Palbociclib
Cortisone acetate may decrease the metabolism of Doxycycline and Doxycycline may decrease the metabolism of Palbociclib
Cortisone acetate may increase the severity of adverse effects when combined with Nicergoline and Nicergoline may increase the severity of adverse effects when combined with Palbociclib
Cortisone acetate may increase the severity of adverse effects when combined with Leflunomide and Leflunomide may increase the severity of adverse effects when combined with Palbociclib
Cortisone acetate may increase the severity of adverse effects when combined with Ergotamine and Ergotamine may increase the serum concentration of Palbociclib
Cortisone acetate may decrease the metabolism of Sildenafil and Sildenafil may increase the serum concentration of Palbociclib
Cortisone acetate may increase the serum concentration of Stiripentol and Stiripentol may increase the serum concentration of Palbociclib
Cortisone acetate (Compound) resembles Prednisone (Compound) and Prednisone may increase the serum concentration of Palbociclib
|
DB00735
|
DB00999
| 827 | 1,069 |
Naftifine
|
Hydrochlorothiazide
|
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
|
Hydrochlorothiazide is the most commonly prescribed thiazide diuretic. It is indicated to treat edema and hypertension.[A185138,L8447,L8450] Hydrochlorothiazide use is common but declining in favour of angiotensin converting enzyme inhibitors. Many combination products are available containing hydrochlorothiazide and angiotensin converting enzyme inhibitors[L8390,L8423] or angiotensin II receptor blockers.[L7426,L7459] Hydrochlorothiazide was granted FDA approval on 12 February 1959.
|
The therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Naftifine.
| 69 |
[
[
[
827,
92,
1069
]
],
[
[
827,
92,
1049
],
[
1049,
71,
1069
]
],
[
[
827,
92,
1066
],
[
1066,
236,
1069
]
],
[
[
827,
92,
1072
],
[
1072,
82,
1069
]
],
[
[
827,
92,
1325
],
[
1325,
1,
1069
]
],
[
[
827,
21,
28392
],
[
28392,
175,
1069
]
],
[
[
827,
249,
614
],
[
614,
42,
1069
]
],
[
[
827,
1,
828
],
[
828,
206,
1069
]
],
[
[
827,
213,
647
],
[
647,
71,
1069
]
],
[
[
827,
213,
306
],
[
306,
225,
1069
]
]
] |
[
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Hydroflumethiazide"
],
[
"Hydroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Quinethazone"
],
[
"Quinethazone",
"{u} (Compound) resembles {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} (Compound) causes {v} (Side Effect)",
"Headache"
],
[
"Headache",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may increase the serum concentration of {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the antihypertensive activities of {v}",
"Timolol"
],
[
"Timolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the antihypertensive activities of {v}",
"Aliskiren"
],
[
"Aliskiren",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydrochlorothiazide"
]
]
] |
Naftifine may decrease the therapeutic efficacy of Bendroflumethiazide and Bendroflumethiazide may increase the severity of adverse effects when combined with Hydrochlorothiazide
Naftifine may decrease the therapeutic efficacy of Polythiazide and Polythiazide may increase the hypotensive activities of Hydrochlorothiazide
Naftifine may decrease the therapeutic efficacy of Hydroflumethiazide and Hydroflumethiazide may increase the hypotensive activities of Hydrochlorothiazide
Naftifine may decrease the therapeutic efficacy of Quinethazone and Quinethazone (Compound) resembles Hydrochlorothiazide (Compound)
Naftifine (Compound) causes Headache (Side Effect) and Headache (Side Effect) is caused by Hydrochlorothiazide (Compound)
Naftifine may increase the serum concentration of Dofetilide and Dofetilide may increase the QTc prolonging activities of Hydrochlorothiazide
Naftifine (Compound) resembles Duloxetine (Compound) and Duloxetine may increase the orthostatic hypotensive activities of Hydrochlorothiazide
Naftifine may decrease the antihypertensive activities of Timolol and Timolol may increase the severity of adverse effects when combined with Hydrochlorothiazide
Naftifine may decrease the antihypertensive activities of Aliskiren and Aliskiren may increase the severity of adverse effects when combined with Hydrochlorothiazide
|
DB00921
|
DB00508
| 491 | 964 |
Buprenorphine
|
Triflupromazine
|
Buprenorphine is a weak partial mu-opioid receptor agonist and a weak kappa-opioid receptor antagonist used for the treatment of severe pain.[A186283,A186292] It is also commonly used as an alternative to [methadone] for the treatment of severe opioid addiction. Buprenorphine is commercially available as the brand name product Suboxone which is formulated in a 4:1 fixed-dose combination product along with [naloxone], a non-selective competitive opioid receptor antagonist. Combination with naloxone is intended to reduce the abuse potential of Suboxone, as naloxone is poorly absorbed by the oral route (and has no effect when taken orally), but would reverse the opioid agonist effects of buprenorphine if injected intravenously.[A186289,L46571] Buprenorphine has poor gastrointestinal absorption and is therefore formulated as a sublingual tablet. Buprenorphine has a
|
A phenothiazine used as an antipsychotic agent and as an antiemetic.
|
Buprenorphine may increase the central nervous system depressant (CNS depressant) activities of Triflupromazine.
| 15 |
[
[
[
491,
38,
964
]
],
[
[
491,
38,
973
],
[
973,
1,
964
]
],
[
[
491,
38,
499
],
[
499,
225,
964
]
],
[
[
491,
38,
270
],
[
270,
71,
964
]
],
[
[
491,
69,
461
],
[
461,
155,
964
]
],
[
[
491,
225,
69
],
[
69,
1,
964
]
],
[
[
491,
38,
438
],
[
438,
155,
964
]
],
[
[
491,
236,
1450
],
[
1450,
1,
964
]
],
[
[
491,
6,
8339
],
[
8339,
160,
964
]
],
[
[
491,
38,
674
],
[
674,
30,
964
]
]
] |
[
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clomipramine"
],
[
"Clomipramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Profenamine"
],
[
"Profenamine",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Imipramine"
],
[
"Imipramine",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the hypotensive activities of {v}",
"Moricizine"
],
[
"Moricizine",
"{u} (Compound) resembles {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Triflupromazine"
]
],
[
[
"Buprenorphine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Triflupromazine"
]
]
] |
Buprenorphine may increase the central nervous system depressant activities of Aceprometazine and Aceprometazine (Compound) resembles Triflupromazine (Compound)
Buprenorphine may increase the central nervous system depressant activities of Clomipramine and Clomipramine may increase the severity of adverse effects when combined with Triflupromazine
Buprenorphine may increase the central nervous system depressant activities of Prochlorperazine and Prochlorperazine may increase the severity of adverse effects when combined with Triflupromazine
Buprenorphine may decrease the metabolism of Diltiazem and Diltiazem (Compound) resembles Triflupromazine (Compound)
Buprenorphine may increase the severity of adverse effects when combined with Profenamine and Profenamine (Compound) resembles Triflupromazine (Compound)
Buprenorphine may increase the central nervous system depressant activities of Imipramine and Imipramine (Compound) resembles Triflupromazine (Compound)
Buprenorphine may increase the hypotensive activities of Moricizine and Moricizine (Compound) resembles Triflupromazine (Compound)
Buprenorphine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Triflupromazine (Compound)
Buprenorphine may increase the central nervous system depressant activities of Pregabalin and Pregabalin can increase the therapeutic efficacy of Triflupromazine
|
DB08912
|
DB08882
| 684 | 693 |
Dabrafenib
|
Linagliptin
|
Dabrafenib mesylate (Tafinlar) is a reversible ATP-competitive kinase inhibitor and targets the MAPK pathway. It was approved on May 29, 2013, for the treatment of melanoma with V600E or V6000K mutation. It was also used for metastatic non-small cell lung cancer with the same mutation. In May 2018, Tafinlar (dabrafenib), in combination with Mekinist (), was approved to treat anaplastic thyroid cancer caused by an abnormal BRAF V600E gene.
|
Linagliptin is a DPP-4 inhibitor developed by Boehringer Ingelheim for the treatment of type II diabetes. Linagliptin differs from other DPP-4 inhibitors in that it has a non-linear pharmacokinetic profile, is not primarily eliminated by the renal system, and obeys concentration dependant protein binding. Linagliptin was approved by the FDA on May 2, 2011.
|
The therapeutic efficacy of Linagliptin can be decreased when used in combination with Dabrafenib.
| 69 |
[
[
[
684,
92,
693
]
],
[
[
684,
97,
555
],
[
555,
1,
693
]
],
[
[
684,
6,
4590
],
[
4590,
160,
693
]
],
[
[
684,
21,
28509
],
[
28509,
175,
693
]
],
[
[
684,
97,
156
],
[
156,
26,
693
]
],
[
[
684,
97,
569
],
[
569,
31,
693
]
],
[
[
684,
97,
465
],
[
465,
225,
693
]
],
[
[
684,
97,
563
],
[
563,
71,
693
]
],
[
[
684,
97,
183
],
[
183,
92,
693
]
],
[
[
684,
196,
1007
],
[
1007,
92,
693
]
]
] |
[
[
[
"Dabrafenib",
"{u} may decrease the therapeutic efficacy of {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} (Compound) resembles {v} (Compound)",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Chlorpropamide"
],
[
"Chlorpropamide",
"{u} may increase the hypoglycemic activities of {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Meperidine"
],
[
"Meperidine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Ergotamine"
],
[
"Ergotamine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may decrease the serum concentration of {v}",
"Indapamide"
],
[
"Indapamide",
"{u} may decrease the therapeutic efficacy of {v}",
"Linagliptin"
]
],
[
[
"Dabrafenib",
"{u} may increase the QTc prolonging activities of {v}",
"Paliperidone"
],
[
"Paliperidone",
"{u} may decrease the therapeutic efficacy of {v}",
"Linagliptin"
]
]
] |
Dabrafenib may decrease the serum concentration of Alogliptin and Alogliptin (Compound) resembles Linagliptin (Compound)
Dabrafenib (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Linagliptin (Compound)
Dabrafenib (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Linagliptin (Compound)
Dabrafenib may decrease the serum concentration of Carbamazepine and Carbamazepine can increase the metabolism of Linagliptin
Dabrafenib may decrease the serum concentration of Chlorpropamide and Chlorpropamide may increase the hypoglycemic activities of Linagliptin
Dabrafenib may decrease the serum concentration of Meperidine and Meperidine may increase the severity of adverse effects when combined with Linagliptin
Dabrafenib may decrease the serum concentration of Ergotamine and Ergotamine may increase the severity of adverse effects when combined with Linagliptin
Dabrafenib may decrease the serum concentration of Indapamide and Indapamide may decrease the therapeutic efficacy of Linagliptin
Dabrafenib may increase the QTc prolonging activities of Paliperidone and Paliperidone may decrease the therapeutic efficacy of Linagliptin
|
DB01189
|
DB08910
| 914 | 208 |
Desflurane
|
Pomalidomide
|
Desflurane, or I-653, a a volatile anesthetic that is more rapidly cleared and less metabolized than previous inhaled anesthetics such as [methoxyflurane], [sevoflurane], [enflurane], or [isoflurane].[A226390,A39015,A226893]. It was developed in the late 1980s out of a need for a more rapidly acting and rapidly cleared inhaled anesthetic.[A226883,A226888] Desflurane was granted FDA approval on 18 September 1992.
|
Pomalidomide, an analogue of thalidomide, is an immunomodulatory antineoplastic agent. FDA approved on February 8, 2013.
|
The risk or severity of adverse effects can be increased when Desflurane is combined with Pomalidomide.
| 48 |
[
[
[
914,
71,
208
]
],
[
[
914,
192,
679
],
[
679,
38,
208
]
],
[
[
914,
21,
28509
],
[
28509,
175,
208
]
],
[
[
914,
225,
171
],
[
171,
26,
208
]
],
[
[
914,
71,
142
],
[
142,
26,
208
]
],
[
[
914,
184,
674
],
[
674,
30,
208
]
],
[
[
914,
38,
702
],
[
702,
192,
208
]
],
[
[
914,
54,
1046
],
[
1046,
208,
208
]
],
[
[
914,
196,
575
],
[
575,
223,
208
]
],
[
[
914,
71,
461
],
[
461,
223,
208
]
]
] |
[
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the sedative activities of {v}",
"Metyrosine"
],
[
"Metyrosine",
"{u} may increase the sedative activities of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the QTc prolonging activities of {v}",
"Sulfisoxazole"
],
[
"Sulfisoxazole",
"{u} may decrease the metabolism of {v}",
"Pomalidomide"
]
],
[
[
"Desflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may decrease the metabolism of {v}",
"Pomalidomide"
]
]
] |
Desflurane may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Pomalidomide
Desflurane (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Pomalidomide (Compound)
Desflurane may increase the severity of adverse effects when combined with Pentobarbital and Pentobarbital can increase the metabolism of Pomalidomide
Desflurane may increase the severity of adverse effects when combined with Phenytoin and Phenytoin can increase the metabolism of Pomalidomide
Desflurane can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Pomalidomide
Desflurane may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Pomalidomide
Desflurane may increase the sedative activities of Metyrosine and Metyrosine may increase the sedative activities of Pomalidomide
Desflurane may increase the QTc prolonging activities of Sulfisoxazole and Sulfisoxazole may decrease the metabolism of Pomalidomide
Desflurane may increase the severity of adverse effects when combined with Diltiazem and Diltiazem may decrease the metabolism of Pomalidomide
|
DB00794
|
DB00962
| 161 | 1,272 |
Primidone
|
Zaleplon
|
Primidone is an anticonvulsant used to treat essential tremor as well as grand mal, psychomotor, and focal epileptic seizures. Primidone was developed by J Yule Bogue and H C Carrington in 1949. Primidone was granted FDA Approval on 8 March 1954.
|
Zaleplon is a sedative/hypnotic, mainly used for insomnia. It is known as a nonbenzodiazepine hypnotic. Zaleplon interacts with the GABA receptor complex and shares some of the pharmacological properties of the benzodiazepines. Zaleplon is a schedule IV drug in the United States.
|
The serum concentration of Zaleplon can be decreased when it is combined with Primidone.
| 74 |
[
[
[
161,
97,
1272
]
],
[
[
161,
6,
7801
],
[
7801,
160,
1272
]
],
[
[
161,
21,
29170
],
[
29170,
175,
1272
]
],
[
[
161,
192,
287
],
[
287,
38,
1272
]
],
[
[
161,
38,
702
],
[
702,
192,
1272
]
],
[
[
161,
54,
471
],
[
471,
208,
1272
]
],
[
[
161,
97,
1095
],
[
1095,
223,
1272
]
],
[
[
161,
26,
429
],
[
429,
223,
1272
]
],
[
[
161,
225,
41
],
[
41,
223,
1272
]
],
[
[
161,
69,
1076
],
[
1076,
223,
1272
]
]
] |
[
[
[
"Primidone",
"{u} may decrease the serum concentration of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} (Compound) binds {v} (Gene)",
"GABRA1"
],
[
"GABRA1",
"{u} (Gene) is bound by {v} (Compound)",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} (Compound) causes {v} (Side Effect)",
"Nystagmus"
],
[
"Nystagmus",
"{u} (Side Effect) is caused by {v} (Compound)",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may increase the central nervous system depressant activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may decrease the serum concentration of {v}",
"Cobicistat"
],
[
"Cobicistat",
"{u} may decrease the metabolism of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Lopinavir"
],
[
"Lopinavir",
"{u} may decrease the metabolism of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clemastine"
],
[
"Clemastine",
"{u} may decrease the metabolism of {v}",
"Zaleplon"
]
],
[
[
"Primidone",
"{u} may decrease the metabolism of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may decrease the metabolism of {v}",
"Zaleplon"
]
]
] |
Primidone (Compound) binds GABRA1 (Gene) and GABRA1 (Gene) is bound by Zaleplon (Compound)
Primidone (Compound) causes Nystagmus (Side Effect) and Nystagmus (Side Effect) is caused by Zaleplon (Compound)
Primidone may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Zaleplon
Primidone may increase the central nervous system depressant activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Zaleplon
Primidone may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Zaleplon
Primidone may decrease the serum concentration of Cobicistat and Cobicistat may decrease the metabolism of Zaleplon
Primidone can increase the metabolism of Lopinavir and Lopinavir may decrease the metabolism of Zaleplon
Primidone may increase the severity of adverse effects when combined with Clemastine and Clemastine may decrease the metabolism of Zaleplon
Primidone may decrease the metabolism of Fluconazole and Fluconazole may decrease the metabolism of Zaleplon
|
DB00735
|
DB00774
| 827 | 1,072 |
Naftifine
|
Hydroflumethiazide
|
Naftifine is a synthetic, broad spectrum, antifungal agent and allylamine derivative for the topical treatment of tinea pedis, tinea cruris, and tinea corporis caused by the organisms Trichophyton rubrum, Trichophyton mentagrophytes, Trichophyton tonsurans and Epidermophyton floccosum.
|
A thiazide diuretic with actions and uses similar to those of hydrochlorothiazide. (From Martindale, The Extra Pharmacopoeia, 30th ed, p822)
|
The therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Naftifine.
| 69 |
[
[
[
827,
92,
1072
]
],
[
[
827,
92,
1049
],
[
1049,
82,
1072
]
],
[
[
827,
92,
1066
],
[
1066,
236,
1072
]
],
[
[
827,
92,
1045
],
[
1045,
1,
1072
]
],
[
[
827,
21,
28463
],
[
28463,
175,
1072
]
],
[
[
827,
249,
614
],
[
614,
42,
1072
]
],
[
[
827,
1,
828
],
[
828,
206,
1072
]
],
[
[
827,
51,
893
],
[
893,
225,
1072
]
],
[
[
827,
213,
1034
],
[
1034,
225,
1072
]
],
[
[
827,
249,
457
],
[
457,
225,
1072
]
]
] |
[
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Bendroflumethiazide"
],
[
"Bendroflumethiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Polythiazide"
],
[
"Polythiazide",
"{u} may increase the hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the therapeutic efficacy of {v}",
"Trichlormethiazide"
],
[
"Trichlormethiazide",
"{u} (Compound) resembles {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} (Compound) causes {v} (Side Effect)",
"Rash"
],
[
"Rash",
"{u} (Side Effect) is caused by {v} (Compound)",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may increase the serum concentration of {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} may increase the QTc prolonging activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} (Compound) resembles {v} (Compound)",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the diuretic activities of {v}",
"Etacrynic acid"
],
[
"Etacrynic acid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may decrease the antihypertensive activities of {v}",
"Esmolol"
],
[
"Esmolol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
],
[
[
"Naftifine",
"{u} may increase the serum concentration of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Hydroflumethiazide"
]
]
] |
Naftifine may decrease the therapeutic efficacy of Bendroflumethiazide and Bendroflumethiazide may increase the hypotensive activities of Hydroflumethiazide
Naftifine may decrease the therapeutic efficacy of Polythiazide and Polythiazide may increase the hypotensive activities of Hydroflumethiazide
Naftifine may decrease the therapeutic efficacy of Trichlormethiazide and Trichlormethiazide (Compound) resembles Hydroflumethiazide (Compound)
Naftifine (Compound) causes Rash (Side Effect) and Rash (Side Effect) is caused by Hydroflumethiazide (Compound)
Naftifine may increase the serum concentration of Dofetilide and Dofetilide may increase the QTc prolonging activities of Hydroflumethiazide
Naftifine (Compound) resembles Duloxetine (Compound) and Duloxetine may increase the orthostatic hypotensive activities of Hydroflumethiazide
Naftifine may decrease the diuretic activities of Etacrynic acid and Etacrynic acid may increase the severity of adverse effects when combined with Hydroflumethiazide
Naftifine may decrease the antihypertensive activities of Esmolol and Esmolol may increase the severity of adverse effects when combined with Hydroflumethiazide
Naftifine may increase the serum concentration of Digoxin and Digoxin may increase the severity of adverse effects when combined with Hydroflumethiazide
|
DB00564
|
DB00613
| 156 | 365 |
Carbamazepine
|
Amodiaquine
|
Carbamazepine, also known as Tegretol, is an anticonvulsant drug and analgesic drug used to control seizures and to treat pain resulting from trigeminal neuralgia. It was initially approved by the FDA in 1965. Aside from the above uses, this drug is also given to control the symptoms of bipolar 1. Interestingly, carbamazepine was the first anticonvulsant used to treat individuals with bipolar disorder.
|
A 4-aminoquinoquinoline compound with anti-inflammatory properties.
|
The metabolism of Amodiaquine can be increased when combined with Carbamazepine.
| 3 |
[
[
[
156,
26,
365
]
],
[
[
156,
26,
565
],
[
565,
155,
365
]
],
[
[
156,
6,
12846
],
[
12846,
160,
365
]
],
[
[
156,
18,
11100
],
[
11100,
172,
365
]
],
[
[
156,
180,
161
],
[
161,
26,
365
]
],
[
[
156,
251,
150
],
[
150,
26,
365
]
],
[
[
156,
180,
147
],
[
147,
249,
365
]
],
[
[
156,
97,
142
],
[
142,
26,
365
]
],
[
[
156,
135,
539
],
[
539,
209,
365
]
],
[
[
156,
97,
640
],
[
640,
223,
365
]
]
] |
[
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Flurazepam"
],
[
"Flurazepam",
"{u} (Compound) resembles {v} (Compound)",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C8"
],
[
"CYP2C8",
"{u} (Gene) is bound by {v} (Compound)",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} (Compound) downregulates {v} (Gene)",
"TIMM9"
],
[
"TIMM9",
"{u} (Gene) is downregulated by {v} (Compound)",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} may increase the serum concentration of {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} may decrease the serum concentration of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} can increase the metabolism of {v} and {u} may reduce the serum concentration of the active metabolites of {v}",
"Artemether"
],
[
"Artemether",
"{u} may increase the severity of QTc prolonging effects when combined with {v}",
"Amodiaquine"
]
],
[
[
"Carbamazepine",
"{u} may decrease the serum concentration of {v}",
"Quinine"
],
[
"Quinine",
"{u} may decrease the metabolism of {v}",
"Amodiaquine"
]
]
] |
Carbamazepine can increase the metabolism of Flurazepam and Flurazepam (Compound) resembles Amodiaquine (Compound)
Carbamazepine (Compound) binds CYP2C8 (Gene) and CYP2C8 (Gene) is bound by Amodiaquine (Compound)
Carbamazepine (Compound) downregulates TIMM9 (Gene) and TIMM9 (Gene) is downregulated by Amodiaquine (Compound)
Carbamazepine can increase the metabolism of Primidone and Primidone can increase the metabolism of Amodiaquine
Carbamazepine may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Amodiaquine
Carbamazepine can increase the metabolism of Rifampicin and Rifampicin may increase the serum concentration of Amodiaquine
Carbamazepine may decrease the serum concentration of Phenytoin and Phenytoin can increase the metabolism of Amodiaquine
Carbamazepine can increase the metabolism of Artemether and Carbamazepine may reduce the serum concentration of the active metabolites of Artemether and Artemether may increase the severity of QTc prolonging effects when combined with Amodiaquine
Carbamazepine may decrease the serum concentration of Quinine and Quinine may decrease the metabolism of Amodiaquine
|
DB01030
|
DB01229
| 1,168 | 292 |
Topotecan
|
Paclitaxel
|
An antineoplastic agent used to treat ovarian cancer. It works by inhibiting DNA topoisomerases, type I.
|
Paclitaxel is a chemotherapeutic agent marketed under the brand name Taxol among others. Used as a treatment for various cancers, paclitaxel is a mitotic inhibitor that was first isolated in 1971 from the bark of the Pacific yew tree which contains endophytic fungi that synthesize paclitaxel. It is available as an intravenous solution for injection and the newer formulation contains albumin-bound paclitaxel marketed under the brand name Abraxane.
|
The serum concentration of Paclitaxel can be increased when it is combined with Topotecan.
| 72 |
[
[
[
1168,
95,
292
]
],
[
[
1168,
5,
17066
],
[
17066,
159,
292
]
],
[
[
1168,
6,
8339
],
[
8339,
160,
292
]
],
[
[
1168,
7,
8945
],
[
8945,
160,
292
]
],
[
[
1168,
7,
1744
],
[
1744,
161,
292
]
],
[
[
1168,
18,
5353
],
[
5353,
161,
292
]
],
[
[
1168,
18,
1784
],
[
1784,
172,
292
]
],
[
[
1168,
7,
9320
],
[
9320,
172,
292
]
],
[
[
1168,
21,
28509
],
[
28509,
175,
292
]
],
[
[
1168,
251,
150
],
[
150,
26,
292
]
]
] |
[
[
[
"Topotecan",
"{u} may increase the serum concentration of {v}",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) treats {v} (Disease)",
"lung cancer"
],
[
"lung cancer",
"{u} (Disease) is treated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"ABCC10"
],
[
"ABCC10",
"{u} (Gene) is bound by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"PRKCQ"
],
[
"PRKCQ",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDC20"
],
[
"CDC20",
"{u} (Gene) is upregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) downregulates {v} (Gene)",
"CDK1"
],
[
"CDK1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) upregulates {v} (Gene)",
"GNPDA1"
],
[
"GNPDA1",
"{u} (Gene) is downregulated by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} (Compound) causes {v} (Side Effect)",
"Mediastinal disorder"
],
[
"Mediastinal disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Paclitaxel"
]
],
[
[
"Topotecan",
"{u} may decrease the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Paclitaxel"
]
]
] |
Topotecan (Compound) treats lung cancer (Disease) and lung cancer (Disease) is treated by Paclitaxel (Compound)
Topotecan (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Paclitaxel (Compound)
Topotecan (Compound) upregulates ABCC10 (Gene) and ABCC10 (Gene) is bound by Paclitaxel (Compound)
Topotecan (Compound) upregulates PRKCQ (Gene) and PRKCQ (Gene) is upregulated by Paclitaxel (Compound)
Topotecan (Compound) downregulates CDC20 (Gene) and CDC20 (Gene) is upregulated by Paclitaxel (Compound)
Topotecan (Compound) downregulates CDK1 (Gene) and CDK1 (Gene) is downregulated by Paclitaxel (Compound)
Topotecan (Compound) upregulates GNPDA1 (Gene) and GNPDA1 (Gene) is downregulated by Paclitaxel (Compound)
Topotecan (Compound) causes Mediastinal disorder (Side Effect) and Mediastinal disorder (Side Effect) is caused by Paclitaxel (Compound)
Topotecan may decrease the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Paclitaxel
|
DB00679
|
DB00334
| 653 | 992 |
Thioridazine
|
Olanzapine
|
A phenothiazine antipsychotic used in the management of psychoses, including schizophrenia, and in the control of severely disturbed or agitated behavior. It has little antiemetic activity. Thioridazine has a higher incidence of antimuscarinic effects, but a lower incidence of extrapyramidal symptoms, than chlorpromazine. (From Martindale, The Extra Pharmacopoeia, 30th ed, p618). Thioridazine was withdrawn worldwide in 2005 due to its association with cardiac arrythmias.
|
Olanzapine is a thienobenzodiazepine classified as an atypical or second-generation antipsychotic agent. The second-generation antipsychotics were introduced in the 90s and quickly gained traction due to their impressive efficacy, reduced risk for extrapyramidal side effects and reduced susceptibility to drug-drug interactions. Olanzapine very closely resembles [clozapine] and only differs by two additional methyl groups and the absence of a chloride moiety. It was discovered by scientists at Eli Lilly and approved to be marketed in the US in 1996.
|
The serum concentration of Olanzapine can be increased when it is combined with Thioridazine.
| 72 |
[
[
[
653,
95,
992
]
],
[
[
653,
95,
681
],
[
681,
42,
992
]
],
[
[
653,
225,
981
],
[
981,
225,
992
]
],
[
[
653,
95,
955
],
[
955,
155,
992
]
],
[
[
653,
6,
2914
],
[
2914,
160,
992
]
],
[
[
653,
7,
5046
],
[
5046,
161,
992
]
],
[
[
653,
18,
6945
],
[
6945,
161,
992
]
],
[
[
653,
10,
17016
],
[
17016,
164,
992
]
],
[
[
653,
18,
5170
],
[
5170,
172,
992
]
],
[
[
653,
184,
674
],
[
674,
30,
992
]
]
] |
[
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Clozapine"
],
[
"Clozapine",
"{u} may increase the QTc prolonging activities of {v}",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Loxapine"
],
[
"Loxapine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} may increase the serum concentration of {v}",
"Quetiapine"
],
[
"Quetiapine",
"{u} (Compound) resembles {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} (Compound) binds {v} (Gene)",
"ADRA2A"
],
[
"ADRA2A",
"{u} (Gene) is bound by {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} (Compound) upregulates {v} (Gene)",
"XBP1"
],
[
"XBP1",
"{u} (Gene) is upregulated by {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"GHR"
],
[
"GHR",
"{u} (Gene) is upregulated by {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} (Compound) palliates {v} (Disease)",
"schizophrenia"
],
[
"schizophrenia",
"{u} (Disease) is palliated by {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} (Compound) downregulates {v} (Gene)",
"TSPAN4"
],
[
"TSPAN4",
"{u} (Gene) is downregulated by {v} (Compound)",
"Olanzapine"
]
],
[
[
"Thioridazine",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Olanzapine"
]
]
] |
Thioridazine may increase the serum concentration of Clozapine and Clozapine may increase the QTc prolonging activities of Olanzapine
Thioridazine may increase the severity of adverse effects when combined with Loxapine and Loxapine may increase the severity of adverse effects when combined with Olanzapine
Thioridazine may increase the serum concentration of Quetiapine and Quetiapine (Compound) resembles Olanzapine (Compound)
Thioridazine (Compound) binds ADRA2A (Gene) and ADRA2A (Gene) is bound by Olanzapine (Compound)
Thioridazine (Compound) upregulates XBP1 (Gene) and XBP1 (Gene) is upregulated by Olanzapine (Compound)
Thioridazine (Compound) downregulates GHR (Gene) and GHR (Gene) is upregulated by Olanzapine (Compound)
Thioridazine (Compound) palliates schizophrenia (Disease) and schizophrenia (Disease) is palliated by Olanzapine (Compound)
Thioridazine (Compound) downregulates TSPAN4 (Gene) and TSPAN4 (Gene) is downregulated by Olanzapine (Compound)
Thioridazine can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Olanzapine
|
DB00996
|
DB01028
| 652 | 477 |
Gabapentin
|
Methoxyflurane
|
Gabapentin is a structural analogue of the inhibitory neurotransmitter gamma-aminobutyric acid ([GABA]) that was first approved for use in the United States in 1993. It was originally developed as a novel anti-epileptic for the treatment of certain types of seizures[A186277,A186143] - today it is also widely used to treat neuropathic pain.[A14097,A186179] Gabapentin has some stark advantages as compared with other anti-epileptics, such as a relatively benign adverse effect profile, wide therapeutic index, and lack of appreciable metabolism making it unlikely to participate in pharmacokinetic drug interactions.[A186143,A185981,L8717]. It is structurally and functionally related to another GABA derivative, [pregabalin].
|
An inhalation anesthetic. Currently, methoxyflurane is rarely used for surgical, obstetric, or dental anesthesia. If so employed, it should be administered with nitrous oxide to achieve a relatively light level of anesthesia, and a neuromuscular blocking agent given concurrently to obtain the desired degree of muscular relaxation. (From AMA Drug Evaluations Annual, 1994, p180) In the US, methoxyflurane is one of the products that have been withdrawn or removed from the market for reasons of safety or effectiveness.
|
The risk or severity of adverse effects can be increased when Gabapentin is combined with Methoxyflurane.
| 48 |
[
[
[
652,
71,
477
]
],
[
[
652,
249,
150
],
[
150,
26,
477
]
],
[
[
652,
225,
156
],
[
156,
26,
477
]
],
[
[
652,
251,
147
],
[
147,
26,
477
]
],
[
[
652,
71,
161
],
[
161,
26,
477
]
],
[
[
652,
246,
674
],
[
674,
30,
477
]
],
[
[
652,
38,
1262
],
[
1262,
192,
477
]
],
[
[
652,
192,
679
],
[
679,
38,
477
]
],
[
[
652,
54,
471
],
[
471,
208,
477
]
],
[
[
652,
225,
496
],
[
496,
223,
477
]
]
] |
[
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the serum concentration of {v}",
"Fosphenytoin"
],
[
"Fosphenytoin",
"{u} can increase the metabolism of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbamazepine"
],
[
"Carbamazepine",
"{u} can increase the metabolism of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may decrease the serum concentration of {v}",
"Rifampicin"
],
[
"Rifampicin",
"{u} can increase the metabolism of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may decrease the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydroxyzine"
],
[
"Hydroxyzine",
"{u} may increase the central nervous system depressant activities of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Methoxyflurane"
]
],
[
[
"Gabapentin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Ketoconazole"
],
[
"Ketoconazole",
"{u} may decrease the metabolism of {v}",
"Methoxyflurane"
]
]
] |
Gabapentin may increase the serum concentration of Fosphenytoin and Fosphenytoin can increase the metabolism of Methoxyflurane
Gabapentin may increase the severity of adverse effects when combined with Carbamazepine and Carbamazepine can increase the metabolism of Methoxyflurane
Gabapentin may decrease the serum concentration of Rifampicin and Rifampicin can increase the metabolism of Methoxyflurane
Gabapentin may increase the severity of adverse effects when combined with Primidone and Primidone can increase the metabolism of Methoxyflurane
Gabapentin may decrease the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Methoxyflurane
Gabapentin may increase the central nervous system depressant activities of Hydroxyzine and Hydroxyzine may increase the central nervous system depressant activities of Methoxyflurane
Gabapentin may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Methoxyflurane
Gabapentin may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Methoxyflurane
Gabapentin may increase the severity of adverse effects when combined with Ketoconazole and Ketoconazole may decrease the metabolism of Methoxyflurane
|
DB01247
|
DB00797
| 42 | 1,070 |
Isocarboxazid
|
Tolazoline
|
Isocarboxazid has the formula 1-benzyl-2-(5-methyl-3-isoxazolylcarbonyl)hydrazine-isocarboxazid. It is a monoamine oxidase inhibitor. It is used in the treatment of major depression, dysthymic disorder, atypical disorder, panic disorder and the phobic disorders. It was first introduced by Roche pharmaceuticals, further developed by Validus pharms Inc and first FDA approved as a prescription drug on July 1st, 1959.
|
A vasodilator that apparently has direct actions on blood vessels and also increases cardiac output. Tolazoline can interact to some degree with histamine, adrenergic, and cholinergic receptors, but the mechanisms of its therapeutic effects are not clear. It is used in treatment of persistent pulmonary hypertension of the newborn.
|
Isocarboxazid may increase the hypotensive activities of Tolazoline.
| 59 |
[
[
[
42,
82,
1070
]
],
[
[
42,
247,
707
],
[
707,
155,
1070
]
],
[
[
42,
155,
1591
],
[
1591,
1,
1070
]
],
[
[
42,
1,
1395
],
[
1395,
155,
1070
]
],
[
[
42,
247,
1335
],
[
1335,
1,
1070
]
],
[
[
42,
1,
1346
],
[
1346,
1,
1070
]
],
[
[
42,
71,
702
],
[
702,
32,
1070
]
],
[
[
42,
52,
828
],
[
828,
206,
1070
]
],
[
[
42,
225,
1353
],
[
1353,
71,
1070
]
],
[
[
42,
71,
1326
],
[
1326,
225,
1070
]
]
] |
[
[
[
"Isocarboxazid",
"{u} may increase the hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the hypertensive activities of {v}",
"Mephentermine"
],
[
"Mephentermine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} (Compound) resembles {v} (Compound)",
"Phenacemide"
],
[
"Phenacemide",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} (Compound) resembles {v} (Compound)",
"Phenylalanine"
],
[
"Phenylalanine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the hypertensive activities of {v}",
"Phentermine"
],
[
"Phentermine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} (Compound) resembles {v} (Compound)",
"Metamfetamine"
],
[
"Metamfetamine",
"{u} (Compound) resembles {v} (Compound)",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the antihypertensive activities of {v}",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Carbetocin"
],
[
"Carbetocin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
],
[
[
"Isocarboxazid",
"{u} may increase the severity of adverse effects when combined with {v}",
"Methyclothiazide"
],
[
"Methyclothiazide",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolazoline"
]
]
] |
Isocarboxazid may increase the hypertensive activities of Mephentermine and Mephentermine (Compound) resembles Tolazoline (Compound)
Isocarboxazid (Compound) resembles Phenacemide (Compound) and Phenacemide (Compound) resembles Tolazoline (Compound)
Isocarboxazid (Compound) resembles Phenylalanine (Compound) and Phenylalanine (Compound) resembles Tolazoline (Compound)
Isocarboxazid may increase the hypertensive activities of Phentermine and Phentermine (Compound) resembles Tolazoline (Compound)
Isocarboxazid (Compound) resembles Metamfetamine (Compound) and Metamfetamine (Compound) resembles Tolazoline (Compound)
Isocarboxazid may increase the severity of adverse effects when combined with Brimonidine and Brimonidine may increase the antihypertensive activities of Tolazoline
Isocarboxazid may increase the orthostatic hypotensive activities of Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Tolazoline
Isocarboxazid may increase the severity of adverse effects when combined with Carbetocin and Carbetocin may increase the severity of adverse effects when combined with Tolazoline
Isocarboxazid may increase the severity of adverse effects when combined with Methyclothiazide and Methyclothiazide may increase the severity of adverse effects when combined with Tolazoline
|
DB09117
|
DB01236
| 1,266 | 354 |
Paraldehyde
|
Sevoflurane
|
Paraldehyde was initially introduced into medical practice in the United Kingdom in 1882 by the Italian physician Vincenzo Cervello. It is classified as a central nervous system (CNS) depressant and has also been found to be an effective anticonvulsant, hypnotic and sedative agent due to its CNS depressant properties. Paraldehyde is used as an ingredient in some cough medicines as an expectorant, but its efficacy for this indication has not been confirmed and its use as an expectorant may possibly be due to a placebo effect.
|
Sevoflurane is an ether inhalation anesthetic agent used to induce and maintain general anesthesia. It is a volatile, non-flammable compound with a low solubility profile and blood/gas partition coefficient. Sevoflurane was patented in 1972, was approved for clinical use in Japan in 1990, and approved by the FDA in 1996. Sevoflurane is three times more potent than [desflurane], but has lower potency compared to [halothane] and [isoflurane]. Unlike other volatile anesthetics, sevoflurane has a pleasant odor and does not irritate the airway. The hemodynamic and respiratory depressive effects of sevoflurane are well tolerated, and most patients receiving this anesthetic agent present little toxicity. Therefore, it can be used for inhalational induction in adults and children for a wide variety of anesthetic procedures.
|
Paraldehyde may increase the central nervous system depressant (CNS depressant) activities of Sevoflurane.
| 15 |
[
[
[
1266,
38,
354
]
],
[
[
1266,
38,
171
],
[
171,
26,
354
]
],
[
[
1266,
38,
1257
],
[
1257,
192,
354
]
],
[
[
1266,
38,
679
],
[
679,
38,
354
]
],
[
[
1266,
192,
1083
],
[
1083,
38,
354
]
],
[
[
1266,
38,
245
],
[
245,
42,
354
]
],
[
[
1266,
71,
394
],
[
394,
42,
354
]
],
[
[
1266,
71,
828
],
[
828,
206,
354
]
],
[
[
1266,
54,
471
],
[
471,
208,
354
]
],
[
[
1266,
71,
411
],
[
411,
223,
354
]
]
] |
[
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Pentobarbital"
],
[
"Pentobarbital",
"{u} can increase the metabolism of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Thalidomide"
],
[
"Thalidomide",
"{u} may increase the central nervous system depressant activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Hydrocodone"
],
[
"Hydrocodone",
"{u} may increase the central nervous system depressant activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the central nervous system depressant activities of {v}",
"Haloperidol"
],
[
"Haloperidol",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Fluoxetine"
],
[
"Fluoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Duloxetine"
],
[
"Duloxetine",
"{u} may increase the orthostatic hypotensive activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the sedative activities of {v}",
"Rotigotine"
],
[
"Rotigotine",
"{u} may increase the sedative activities of {v}",
"Sevoflurane"
]
],
[
[
"Paraldehyde",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sertraline"
],
[
"Sertraline",
"{u} may decrease the metabolism of {v}",
"Sevoflurane"
]
]
] |
Paraldehyde may increase the central nervous system depressant activities of Pentobarbital and Pentobarbital can increase the metabolism of Sevoflurane
Paraldehyde may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Sevoflurane
Paraldehyde may increase the central nervous system depressant activities of Thalidomide and Thalidomide may increase the central nervous system depressant activities of Sevoflurane
Paraldehyde may increase the central nervous system depressant activities of Hydrocodone and Hydrocodone may increase the central nervous system depressant activities of Sevoflurane
Paraldehyde may increase the central nervous system depressant activities of Haloperidol and Haloperidol may increase the QTc prolonging activities of Sevoflurane
Paraldehyde may increase the severity of adverse effects when combined with Fluoxetine and Fluoxetine may increase the QTc prolonging activities of Sevoflurane
Paraldehyde may increase the severity of adverse effects when combined with Duloxetine and Duloxetine may increase the orthostatic hypotensive activities of Sevoflurane
Paraldehyde may increase the sedative activities of Rotigotine and Rotigotine may increase the sedative activities of Sevoflurane
Paraldehyde may increase the severity of adverse effects when combined with Sertraline and Sertraline may decrease the metabolism of Sevoflurane
|
DB00207
|
DB00675
| 645 | 568 |
Azithromycin
|
Tamoxifen
|
Azithromycin is a broad-spectrum macrolide antibiotic with a long half-life and a high degree of tissue penetration. It was initially approved by the FDA in 1991. It is primarily used for the treatment of respiratory, enteric and genitourinary infections and may be used instead of other macrolides for some sexually transmitted and enteric infections. It is structurally related to erythromycin. Azithromycin [9-deoxo-9a-aza-9a-methyl-9a-homoerythromycin] is a part of the _azalide_ subclass of macrolides, and contains a 15-membered ring, with a methyl-substituted nitrogen instead of a carbonyl group at the 9a position on the aglycone ring, which allows for the prevention of its metabolism. This differentiates azithromycin from other types of macrolides. In March 2020, a small
|
Tamoxifen is a non-steroidal antiestrogen used to treat estrogen receptor positive breast cancers as well as prevent the incidence of breast cancer in high risk populations.[A1025,L7799,L7802] Tamoxifen is used alone or as an adjuvant in these treatments.[L7799,L7802] Tamoxifen may no longer be the preferred treatment for these types of cancers as patients generally have better survival, side effect profiles, and compliance with [anastrozole]. Tamoxifen was granted FDA approval on 30 December 1977.
|
Azithromycin may increase the QTc-prolonging activities of Tamoxifen.
| 19 |
[
[
[
645,
42,
568
]
],
[
[
645,
196,
1315
],
[
1315,
155,
568
]
],
[
[
645,
223,
195
],
[
195,
155,
568
]
],
[
[
645,
6,
4590
],
[
4590,
160,
568
]
],
[
[
645,
18,
14449
],
[
14449,
172,
568
]
],
[
[
645,
21,
28937
],
[
28937,
175,
568
]
],
[
[
645,
180,
142
],
[
142,
26,
568
]
],
[
[
645,
249,
218
],
[
218,
26,
568
]
],
[
[
645,
223,
219
],
[
219,
28,
568
]
],
[
[
645,
249,
169
],
[
169,
28,
568
]
]
] |
[
[
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} may decrease the metabolism of {v}",
"Cyclobenzaprine"
],
[
"Cyclobenzaprine",
"{u} (Compound) resembles {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} (Compound) downregulates {v} (Gene)",
"IFRD2"
],
[
"IFRD2",
"{u} (Gene) is downregulated by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} (Compound) causes {v} (Side Effect)",
"Neutropenia"
],
[
"Neutropenia",
"{u} (Side Effect) is caused by {v} (Compound)",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} can increase the metabolism of {v}",
"Phenytoin"
],
[
"Phenytoin",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} may increase the serum concentration of {v}",
"Rifaximin"
],
[
"Rifaximin",
"{u} can increase the metabolism of {v}",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} may decrease the metabolism of {v}",
"Warfarin"
],
[
"Warfarin",
"{u} may increase the anticoagulant activities of {v}",
"Tamoxifen"
]
],
[
[
"Azithromycin",
"{u} may increase the serum concentration of {v}",
"Phenindione"
],
[
"Phenindione",
"{u} may increase the anticoagulant activities of {v}",
"Tamoxifen"
]
]
] |
Azithromycin may increase the QTc prolonging activities of Bedaquiline and Bedaquiline (Compound) resembles Tamoxifen (Compound)
Azithromycin may decrease the metabolism of Cyclobenzaprine and Cyclobenzaprine (Compound) resembles Tamoxifen (Compound)
Azithromycin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Tamoxifen (Compound)
Azithromycin (Compound) downregulates IFRD2 (Gene) and IFRD2 (Gene) is downregulated by Tamoxifen (Compound)
Azithromycin (Compound) causes Neutropenia (Side Effect) and Neutropenia (Side Effect) is caused by Tamoxifen (Compound)
Azithromycin can increase the metabolism of Phenytoin and Phenytoin can increase the metabolism of Tamoxifen
Azithromycin may increase the serum concentration of Rifaximin and Rifaximin can increase the metabolism of Tamoxifen
Azithromycin may decrease the metabolism of Warfarin and Warfarin may increase the anticoagulant activities of Tamoxifen
Azithromycin may increase the serum concentration of Phenindione and Phenindione may increase the anticoagulant activities of Tamoxifen
|
DB06789
|
DB00511
| 609 | 1,347 |
Hydroxyprogesterone caproate
|
Acetyldigitoxin
|
Hydroxyprogesterone caproate is a synthetic steroid hormone that is similar to medroxyprogesterone acetate and megestrol acetate. It is an ester derivative of 17α-hydroxyprogesterone formed from caproic acid (hexanoic acid). Hydroxyprogesterone caproate was previously marketed under the trade name Delalutin by Squibb, which was approved by the U.S. Food and Drug Administration (FDA) in 1956 and withdrawn from marketing in 1999. The U.S. FDA approved Makena from KV Pharmaceutical (previously named as Gestiva) on February 4, 2011 for prevention of preterm delivery in women with a history of preterm delivery, sparking a pricing controversy. In April 2023, the FDA withdrew its approval of Makena and its generics given an unfavorable risk-to-benefit assessment.
|
Cardioactive derivative of lanatoside A or of digitoxin used for fast digitalization in congestive heart failure.
|
Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Acetyldigitoxin.
| 57 |
[
[
[
609,
80,
1347
]
],
[
[
609,
80,
457
],
[
457,
155,
1347
]
],
[
[
609,
69,
461
],
[
461,
47,
1347
]
],
[
[
609,
225,
357
],
[
357,
80,
1347
]
],
[
[
609,
69,
1099
],
[
1099,
80,
1347
]
],
[
[
609,
191,
243
],
[
243,
80,
1347
]
],
[
[
609,
95,
1394
],
[
1394,
80,
1347
]
],
[
[
609,
251,
1080
],
[
1080,
80,
1347
]
],
[
[
609,
69,
1088
],
[
1088,
249,
1347
]
],
[
[
609,
80,
457
],
[
457,
1,
1348
],
[
1348,
155,
1347
]
]
] |
[
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the metabolism of {v}",
"Diltiazem"
],
[
"Diltiazem",
"{u} may increase the atrioventricular blocking activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may increase the severity of adverse effects when combined with {v}",
"Docetaxel"
],
[
"Docetaxel",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the metabolism of {v}",
"Idelalisib"
],
[
"Idelalisib",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may increase the cardiotoxic activities of {v}",
"Cyclophosphamide"
],
[
"Cyclophosphamide",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may increase the serum concentration of {v}",
"Palbociclib"
],
[
"Palbociclib",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the serum concentration of {v}",
"Mitotane"
],
[
"Mitotane",
"{u} may decrease the cardiotoxic activities of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the metabolism of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the serum concentration of {v}",
"Acetyldigitoxin"
]
],
[
[
"Hydroxyprogesterone caproate",
"{u} may decrease the cardiotoxic activities of {v}",
"Digoxin"
],
[
"Digoxin",
"{u} (Compound) resembles {v} (Compound)",
"Ouabain"
],
[
"Ouabain",
"{u} (Compound) resembles {v} (Compound)",
"Acetyldigitoxin"
]
]
] |
Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin and Digoxin (Compound) resembles Acetyldigitoxin (Compound)
Hydroxyprogesterone caproate may decrease the metabolism of Diltiazem and Diltiazem may increase the atrioventricular blocking activities of Acetyldigitoxin
Hydroxyprogesterone caproate may increase the severity of adverse effects when combined with Docetaxel and Docetaxel may decrease the cardiotoxic activities of Acetyldigitoxin
Hydroxyprogesterone caproate may decrease the metabolism of Idelalisib and Idelalisib may decrease the cardiotoxic activities of Acetyldigitoxin
Hydroxyprogesterone caproate may increase the cardiotoxic activities of Cyclophosphamide and Cyclophosphamide may decrease the cardiotoxic activities of Acetyldigitoxin
Hydroxyprogesterone caproate may increase the serum concentration of Palbociclib and Palbociclib may decrease the cardiotoxic activities of Acetyldigitoxin
Hydroxyprogesterone caproate may decrease the serum concentration of Mitotane and Mitotane may decrease the cardiotoxic activities of Acetyldigitoxin
Hydroxyprogesterone caproate may decrease the metabolism of Clarithromycin and Clarithromycin may increase the serum concentration of Acetyldigitoxin
Hydroxyprogesterone caproate may decrease the cardiotoxic activities of Digoxin and Digoxin (Compound) resembles Ouabain (Compound) and Ouabain (Compound) resembles Acetyldigitoxin (Compound)
|
DB01201
|
DB00280
| 177 | 589 |
Rifapentine
|
Disopyramide
|
Rifapentine is an antibiotic drug used in the treatment of tuberculosis. It inhibits DNA-dependent RNA polymerase activity in susceptible cells. Specifically, it interacts with bacterial RNA polymerase but does not inhibit the mammalian enzyme.
|
A class I anti-arrhythmic agent (one that interferes directly with the depolarization of the cardiac membrane and thus serves as a membrane-stabilizing agent) with a depressant action on the heart similar to that of guanidine. It also possesses some anticholinergic and local anesthetic properties.
|
The metabolism of Disopyramide can be increased when combined with Rifapentine.
| 3 |
[
[
[
177,
26,
589
]
],
[
[
177,
26,
289
],
[
289,
155,
589
]
],
[
[
177,
26,
44
],
[
44,
196,
589
]
],
[
[
177,
6,
4590
],
[
4590,
160,
589
]
],
[
[
177,
26,
161
],
[
161,
26,
589
]
],
[
[
177,
26,
555
],
[
555,
185,
589
]
],
[
[
177,
26,
326
],
[
326,
31,
589
]
],
[
[
177,
99,
1088
],
[
1088,
196,
589
]
],
[
[
177,
97,
1315
],
[
1315,
196,
589
]
],
[
[
177,
95,
1076
],
[
1076,
196,
589
]
]
] |
[
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} (Compound) resembles {v} (Compound)",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Primidone"
],
[
"Primidone",
"{u} can increase the metabolism of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Alogliptin"
],
[
"Alogliptin",
"{u} may increase the hypoglycemic activities of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} can increase the metabolism of {v}",
"Glipizide"
],
[
"Glipizide",
"{u} may increase the hypoglycemic activities of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} may increase the serum concentration of the active metabolites of {v}",
"Clarithromycin"
],
[
"Clarithromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} may decrease the serum concentration of {v}",
"Bedaquiline"
],
[
"Bedaquiline",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
]
],
[
[
"Rifapentine",
"{u} may increase the serum concentration of {v}",
"Fluconazole"
],
[
"Fluconazole",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
]
]
] |
Rifapentine can increase the metabolism of Levacetylmethadol and Levacetylmethadol (Compound) resembles Disopyramide (Compound)
Rifapentine can increase the metabolism of Tolterodine and Tolterodine may increase the QTc prolonging activities of Disopyramide
Rifapentine (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Disopyramide (Compound)
Rifapentine can increase the metabolism of Primidone and Primidone can increase the metabolism of Disopyramide
Rifapentine can increase the metabolism of Alogliptin and Alogliptin may increase the hypoglycemic activities of Disopyramide
Rifapentine can increase the metabolism of Glipizide and Glipizide may increase the hypoglycemic activities of Disopyramide
Rifapentine may increase the serum concentration of the active metabolites of Clarithromycin and Clarithromycin may increase the QTc prolonging activities of Disopyramide
Rifapentine may decrease the serum concentration of Bedaquiline and Bedaquiline may increase the QTc prolonging activities of Disopyramide
Rifapentine may increase the serum concentration of Fluconazole and Fluconazole may increase the QTc prolonging activities of Disopyramide
|
DB01062
|
DB08865
| 65 | 1,079 |
Oxybutynin
|
Crizotinib
|
Overactive bladder (OAB) is a common condition negatively impacting the lives of millions of patients worldwide. Due to its urinary symptoms that include nocturia, urgency, and frequency, this condition causes social embarrassment and a poor quality of life.[A185996,A185999] Oxybutynin, also marketed as Ditropan XL, is an anticholinergic medication used for the relief of overactive bladder symptoms that has been optimized for high levels of safety and efficacy since initial FDA approval in 1975.[A183782,L8648] This drug relieves undesirable urinary symptoms, increasing the quality of life for patients affected by OAB. It is often used as first-line therapy for OAB.
|
Crizotinib is a tyrosine kinase receptor inhibitor used for the treatment of anaplastic lymphoma kinase (ALK) or ROS1-positive non-small cell lung cancer (NSCLC) tumors, as well as ALK-positive anaplastic large cell lymphoma (ALCL) and inflammatory myofibroblastic tumor (IMT). By targeting the echinoderm microtubule-associated protein-like 4 (EML4)-ALK fusion protein, crizotinib offers robust effectiveness in treating NSCLC in patients with this type of rearrangement. Crizotinib was the first-in-class drug used to treat ALK-positive tumors. Second- and third-generation ALK-tyrosine kinase-inhibitors have overcome many of the pharmacodynamic and genetic resistance mechanisms crizotinib is prone to. Crizotinib was approved by the FDA in 2011, and its use is accompanied by FDA-approved tests used
|
The metabolism of Crizotinib can be decreased when combined with Oxybutynin.
| 46 |
[
[
[
65,
69,
1079
]
],
[
[
65,
6,
4590
],
[
4590,
160,
1079
]
],
[
[
65,
7,
5112
],
[
5112,
161,
1079
]
],
[
[
65,
21,
28445
],
[
28445,
175,
1079
]
],
[
[
65,
71,
237
],
[
237,
196,
1079
]
],
[
[
65,
69,
610
],
[
610,
196,
1079
]
],
[
[
65,
225,
59
],
[
59,
42,
1079
]
],
[
[
65,
225,
44
],
[
44,
196,
1079
]
],
[
[
65,
249,
653
],
[
653,
42,
1079
]
],
[
[
65,
246,
264
],
[
264,
196,
1079
]
]
] |
[
[
[
"Oxybutynin",
"{u} may decrease the metabolism of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} (Compound) binds {v} (Gene)",
"CYP3A4"
],
[
"CYP3A4",
"{u} (Gene) is bound by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} (Compound) upregulates {v} (Gene)",
"RNF167"
],
[
"RNF167",
"{u} (Gene) is upregulated by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} (Compound) causes {v} (Side Effect)",
"Skin disorder"
],
[
"Skin disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Mirabegron"
],
[
"Mirabegron",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may decrease the metabolism of {v}",
"Atomoxetine"
],
[
"Atomoxetine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may increase the severity of adverse effects when combined with {v}",
"Tolterodine"
],
[
"Tolterodine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may increase the serum concentration of {v}",
"Thioridazine"
],
[
"Thioridazine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
],
[
[
"Oxybutynin",
"{u} may decrease the therapeutic efficacy of {v}",
"Galantamine"
],
[
"Galantamine",
"{u} may increase the QTc prolonging activities of {v}",
"Crizotinib"
]
]
] |
Oxybutynin (Compound) binds CYP3A4 (Gene) and CYP3A4 (Gene) is bound by Crizotinib (Compound)
Oxybutynin (Compound) upregulates RNF167 (Gene) and RNF167 (Gene) is upregulated by Crizotinib (Compound)
Oxybutynin (Compound) causes Skin disorder (Side Effect) and Skin disorder (Side Effect) is caused by Crizotinib (Compound)
Oxybutynin may increase the severity of adverse effects when combined with Mirabegron and Mirabegron may increase the QTc prolonging activities of Crizotinib
Oxybutynin may decrease the metabolism of Atomoxetine and Atomoxetine may increase the QTc prolonging activities of Crizotinib
Oxybutynin may increase the severity of adverse effects when combined with Quinidine and Quinidine may increase the QTc prolonging activities of Crizotinib
Oxybutynin may increase the severity of adverse effects when combined with Tolterodine and Tolterodine may increase the QTc prolonging activities of Crizotinib
Oxybutynin may increase the serum concentration of Thioridazine and Thioridazine may increase the QTc prolonging activities of Crizotinib
Oxybutynin may decrease the therapeutic efficacy of Galantamine and Galantamine may increase the QTc prolonging activities of Crizotinib
|
DB00608
|
DB00691
| 588 | 650 |
Chloroquine
|
Moexipril
|
Chloroquine is an aminoquinolone derivative first developed in the 1940s for the treatment of malaria. It was the drug of choice to treat malaria until the development of newer antimalarials such as [pyrimethamine], [artemisinin], and [mefloquine]. Chloroquine and its derivative [hydroxychloroquine] have since been repurposed for the treatment of a number of other conditions including HIV, systemic lupus erythematosus, and rheumatoid arthritis. **The FDA emergency use authorization for [hydroxychloroquine] and chloroquine in the treatment of COVID-19 was revoked on 15 June 2020.** Chloroquine was granted FDA Approval on 31 October 1949.
|
Moexipril is a non-sulfhydryl containing precursor of the active angiotensin-converting enzyme (ACE) inhibitor moexiprilat. It is used to treat high blood pressure (hypertension). It works by relaxing blood vessels, causing them to widen. Lowering high blood pressure helps prevent strokes, heart attacks and kidney problems.
|
Chloroquine may increase the QTc-prolonging activities of Moexipril.
| 19 |
[
[
[
588,
42,
650
]
],
[
[
588,
225,
676
],
[
676,
225,
650
]
],
[
[
588,
223,
209
],
[
209,
155,
650
]
],
[
[
588,
225,
642
],
[
642,
155,
650
]
],
[
[
588,
42,
154
],
[
154,
32,
650
]
],
[
[
588,
95,
1318
],
[
1318,
42,
650
]
],
[
[
588,
223,
370
],
[
370,
42,
650
]
],
[
[
588,
196,
633
],
[
633,
42,
650
]
],
[
[
588,
69,
137
],
[
137,
42,
650
]
],
[
[
588,
42,
143
],
[
143,
42,
650
]
]
] |
[
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lisinopril"
],
[
"Lisinopril",
"{u} may increase the severity of adverse effects when combined with {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Donepezil"
],
[
"Donepezil",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Benazepril"
],
[
"Benazepril",
"{u} (Compound) resembles {v} (Compound)",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Vardenafil"
],
[
"Vardenafil",
"{u} may increase the antihypertensive activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the serum concentration of {v}",
"Propafenone"
],
[
"Propafenone",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Domperidone"
],
[
"Domperidone",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Cisapride"
],
[
"Cisapride",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may decrease the metabolism of {v}",
"Amiodarone"
],
[
"Amiodarone",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
],
[
[
"Chloroquine",
"{u} may increase the QTc prolonging activities of {v}",
"Erythromycin"
],
[
"Erythromycin",
"{u} may increase the QTc prolonging activities of {v}",
"Moexipril"
]
]
] |
Chloroquine may increase the severity of adverse effects when combined with Lisinopril and Lisinopril may increase the severity of adverse effects when combined with Moexipril
Chloroquine may decrease the metabolism of Donepezil and Donepezil (Compound) resembles Moexipril (Compound)
Chloroquine may increase the severity of adverse effects when combined with Benazepril and Benazepril (Compound) resembles Moexipril (Compound)
Chloroquine may increase the QTc prolonging activities of Vardenafil and Vardenafil may increase the antihypertensive activities of Moexipril
Chloroquine may increase the serum concentration of Propafenone and Propafenone may increase the QTc prolonging activities of Moexipril
Chloroquine may decrease the metabolism of Domperidone and Domperidone may increase the QTc prolonging activities of Moexipril
Chloroquine may increase the QTc prolonging activities of Cisapride and Cisapride may increase the QTc prolonging activities of Moexipril
Chloroquine may decrease the metabolism of Amiodarone and Amiodarone may increase the QTc prolonging activities of Moexipril
Chloroquine may increase the QTc prolonging activities of Erythromycin and Erythromycin may increase the QTc prolonging activities of Moexipril
|
DB00091
|
DB00673
| 198 | 191 |
Cyclosporine
|
Aprepitant
|
Cyclosporine is a calcineurin inhibitor known for its immunomodulatory properties that prevent organ transplant rejection and treat various inflammatory and autoimmune conditions. It is isolated from the fungus _Beauveria nivea_. Initially manufactured by Sandoz and approved for use by the FDA in 1983, cyclosporine is now available in various products by Novartis (previously known as Sandoz).[L11097,L3734,L11118]
|
Aprepitant, an antiemetic, is a substance P/neurokinin 1 (NK1) receptor antagonist which, in combination with other antiemetic agents, is indicated for the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly emetogenic cancer chemotherapy. Aprepitant is a selective high-affinity antagonist of human substance P/neurokinin 1 (NK1) receptors. Aprepitant has little or no affinity for serotonin (5-HT3), dopamine, and corticosteroid receptors, the targets of existing therapies for chemotherapy-induced nausea and vomiting (CI NV).
|
The serum concentration of Aprepitant can be increased when it is combined with Cyclosporine.
| 72 |
[
[
[
198,
95,
191
]
],
[
[
198,
6,
7128
],
[
7128,
160,
191
]
],
[
[
198,
169,
24710
],
[
24710,
15,
191
]
],
[
[
198,
21,
28419
],
[
28419,
175,
191
]
],
[
[
198,
90,
239
],
[
239,
180,
191
]
],
[
[
198,
79,
460
],
[
460,
180,
191
]
],
[
[
198,
249,
598
],
[
598,
180,
191
]
],
[
[
198,
71,
434
],
[
434,
180,
191
]
],
[
[
198,
180,
164
],
[
164,
26,
191
]
],
[
[
198,
223,
473
],
[
473,
180,
191
]
]
] |
[
[
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} (Compound) binds {v} (Gene)",
"CYP2C9"
],
[
"CYP2C9",
"{u} (Gene) is bound by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} (Compound) is included by {v} (Pharmacologic Class)",
"Cytochrome P450 3A4 Inhibitors"
],
[
"Cytochrome P450 3A4 Inhibitors",
"{u} (Pharmacologic Class) includes {v} (Compound)",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} (Compound) causes {v} (Side Effect)",
"Unspecified disorder of skin and subcutaneous tissue"
],
[
"Unspecified disorder of skin and subcutaneous tissue",
"{u} (Side Effect) is caused by {v} (Compound)",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} may increase the hyperkalemic activities of {v}",
"Valsartan"
],
[
"Valsartan",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} may increase the nephrotoxic activities of {v}",
"Etodolac"
],
[
"Etodolac",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} may increase the serum concentration of {v}",
"Pitavastatin"
],
[
"Pitavastatin",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Flunarizine"
],
[
"Flunarizine",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} can increase the metabolism of {v}",
"Phenobarbital"
],
[
"Phenobarbital",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
],
[
[
"Cyclosporine",
"{u} may decrease the metabolism of {v}",
"Glimepiride"
],
[
"Glimepiride",
"{u} can increase the metabolism of {v}",
"Aprepitant"
]
]
] |
Cyclosporine (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Aprepitant (Compound)
Cyclosporine (Compound) is included by Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) and Cytochrome P450 3A4 Inhibitors (Pharmacologic Class) includes Aprepitant (Compound)
Cyclosporine (Compound) causes Unspecified disorder of skin and subcutaneous tissue (Side Effect) and Unspecified disorder of skin and subcutaneous tissue (Side Effect) is caused by Aprepitant (Compound)
Cyclosporine may increase the hyperkalemic activities of Valsartan and Valsartan can increase the metabolism of Aprepitant
Cyclosporine may increase the nephrotoxic activities of Etodolac and Etodolac can increase the metabolism of Aprepitant
Cyclosporine may increase the serum concentration of Pitavastatin and Pitavastatin can increase the metabolism of Aprepitant
Cyclosporine may increase the severity of adverse effects when combined with Flunarizine and Flunarizine can increase the metabolism of Aprepitant
Cyclosporine can increase the metabolism of Phenobarbital and Phenobarbital can increase the metabolism of Aprepitant
Cyclosporine may decrease the metabolism of Glimepiride and Glimepiride can increase the metabolism of Aprepitant
|
DB00753
|
DB01618
| 347 | 1,006 |
Isoflurane
|
Molindone
|
A stable, non-explosive inhalation anesthetic, relatively free from significant side effects.
|
An indole derivative effective in schizophrenia and other psychoses and possibly useful in the treatment of the aggressive type of undersocialized conduct disorder. Molindone has much lower affinity for D2 receptors than most antipsychotic agents and has a relatively low affinity for D1 receptors. It has only low to moderate affinity for cholinergic and alpha-adrenergic receptors. Some electrophysiologic data from animals indicate that molindone has certain characteristics that resemble those of clozapine. (From AMA Drug Evaluations Annual, 1994, p283)
|
The risk or severity of adverse effects can be increased when Isoflurane is combined with Molindone.
| 48 |
[
[
[
347,
71,
1006
]
],
[
[
347,
21,
28562
],
[
28562,
175,
1006
]
],
[
[
347,
184,
674
],
[
674,
30,
1006
]
],
[
[
347,
192,
543
],
[
543,
38,
1006
]
],
[
[
347,
38,
1257
],
[
1257,
192,
1006
]
],
[
[
347,
54,
1365
],
[
1365,
208,
1006
]
],
[
[
347,
71,
980
],
[
980,
58,
1006
]
],
[
[
347,
225,
540
],
[
540,
71,
1006
]
],
[
[
347,
71,
917
],
[
917,
71,
1006
]
],
[
[
347,
71,
165
],
[
165,
225,
1006
]
]
] |
[
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} (Compound) causes {v} (Side Effect)",
"Agitation"
],
[
"Agitation",
"{u} (Side Effect) is caused by {v} (Compound)",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} can increase the therapeutic efficacy of {v}",
"Pregabalin"
],
[
"Pregabalin",
"{u} can increase the therapeutic efficacy of {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the central nervous system depressant activities of {v}",
"Perampanel"
],
[
"Perampanel",
"{u} may increase the central nervous system depressant activities of {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Amisulpride"
],
[
"Amisulpride",
"{u} may increase the antipsychotic activities of {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Morphine"
],
[
"Morphine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prilocaine"
],
[
"Prilocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Molindone"
]
],
[
[
"Isoflurane",
"{u} may increase the severity of adverse effects when combined with {v}",
"Brompheniramine"
],
[
"Brompheniramine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Molindone"
]
]
] |
Isoflurane (Compound) causes Agitation (Side Effect) and Agitation (Side Effect) is caused by Molindone (Compound)
Isoflurane can increase the therapeutic efficacy of Pregabalin and Pregabalin can increase the therapeutic efficacy of Molindone
Isoflurane may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may increase the central nervous system depressant activities of Molindone
Isoflurane may increase the central nervous system depressant activities of Perampanel and Perampanel may increase the central nervous system depressant activities of Molindone
Isoflurane may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Molindone
Isoflurane may increase the severity of adverse effects when combined with Amisulpride and Amisulpride may increase the antipsychotic activities of Molindone
Isoflurane may increase the severity of adverse effects when combined with Morphine and Morphine may increase the severity of adverse effects when combined with Molindone
Isoflurane may increase the severity of adverse effects when combined with Prilocaine and Prilocaine may increase the severity of adverse effects when combined with Molindone
Isoflurane may increase the severity of adverse effects when combined with Brompheniramine and Brompheniramine may increase the severity of adverse effects when combined with Molindone
|
DB00370
|
DB00771
| 543 | 941 |
Mirtazapine
|
Clidinium
|
Mirtazapine is a tetracyclic _piperazino-azepine_ antidepressant agent that was initially approved for the treatment of major depressive disorder (MDD) in the Netherlands in 1994. This drug was first manufactured by Organon Inc., and received FDA approval in 1997 for the treatment of major depressive disorder.[T595, L6157] The effects of this drug may be observed as early as 1 week after beginning therapy.[A178144,L6160] In addition to its beneficial effects in depression, mirtazapine has been reported to be efficacious in the off-label management of various other conditions. It may improve the symptoms of neurological disorders, reverse weight loss caused by medical conditions, improve sleep, and prevent nausea and vomiting after surgery.
|
Clidinium is a synthetic anticholinergic agent which has been shown in experimental and clinical studies to have a pronounced antispasmodic and antisecretory effect on the gastrointestinal tract. It inhibits muscarinic actions of acetylcholine at postganglionic parasympathetic neuroeffector sites. It is used for the treatment of peptic ulcer disease and also to help relieve abdominal or stomach spasms or cramps due to colicky abdominal pain, diverticulitis, and irritable bowel syndrome.
|
Mirtazapine may increase the central nervous system depressant (CNS depressant) activities of Clidinium.
| 15 |
[
[
[
543,
38,
941
]
],
[
[
543,
38,
959
],
[
959,
225,
941
]
],
[
[
543,
38,
918
],
[
918,
1,
941
]
],
[
[
543,
38,
289
],
[
289,
71,
941
]
],
[
[
543,
192,
287
],
[
287,
38,
941
]
],
[
[
543,
38,
1265
],
[
1265,
192,
941
]
],
[
[
543,
213,
702
],
[
702,
192,
941
]
],
[
[
543,
38,
587
],
[
587,
38,
941
]
],
[
[
543,
54,
1365
],
[
1365,
208,
941
]
],
[
[
543,
211,
997
],
[
997,
71,
941
]
]
] |
[
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Fexofenadine"
],
[
"Fexofenadine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Difenoxin"
],
[
"Difenoxin",
"{u} (Compound) resembles {v} (Compound)",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Levacetylmethadol"
],
[
"Levacetylmethadol",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Zolpidem"
],
[
"Zolpidem",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Nabilone"
],
[
"Nabilone",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may decrease the antihypertensive activities of {v}",
"Brimonidine"
],
[
"Brimonidine",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the central nervous system depressant activities of {v}",
"Ethanol"
],
[
"Ethanol",
"{u} may increase the central nervous system depressant activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the sedative activities of {v}",
"Pramipexole"
],
[
"Pramipexole",
"{u} may increase the sedative activities of {v}",
"Clidinium"
]
],
[
[
"Mirtazapine",
"{u} may increase the neurotoxic activities of {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the severity of adverse effects when combined with {v}",
"Clidinium"
]
]
] |
Mirtazapine may increase the central nervous system depressant activities of Fexofenadine and Fexofenadine may increase the severity of adverse effects when combined with Clidinium
Mirtazapine may increase the central nervous system depressant activities of Difenoxin and Difenoxin (Compound) resembles Clidinium (Compound)
Mirtazapine may increase the central nervous system depressant activities of Levacetylmethadol and Levacetylmethadol may increase the severity of adverse effects when combined with Clidinium
Mirtazapine may increase the central nervous system depressant activities of Zolpidem and Zolpidem may increase the central nervous system depressant activities of Clidinium
Mirtazapine may increase the central nervous system depressant activities of Nabilone and Nabilone may increase the central nervous system depressant activities of Clidinium
Mirtazapine may decrease the antihypertensive activities of Brimonidine and Brimonidine may increase the central nervous system depressant activities of Clidinium
Mirtazapine may increase the central nervous system depressant activities of Ethanol and Ethanol may increase the central nervous system depressant activities of Clidinium
Mirtazapine may increase the sedative activities of Pramipexole and Pramipexole may increase the sedative activities of Clidinium
Mirtazapine may increase the neurotoxic activities of Lithium cation and Lithium cation may increase the severity of adverse effects when combined with Clidinium
|
DB00281
|
DB00320
| 611 | 530 |
Lidocaine
|
Dihydroergotamine
|
Ever since its discovery and availability for sale and use in the late 1940s, lidocaine has become an exceptionally commonly used medication. In particular, lidocaine's principal mode of action in acting as a local anesthetic that numbs the sensations of tissues means the agent is indicated for facilitating local anesthesia for a large variety of surgical procedures [F4349, L5930, L5948]. It ultimately elicits its numbing activity by blocking sodium channels so that the neurons of local tissues that have the medication applied on are transiently incapable of signaling the brain regarding sensations [F4349, L5930, L5948]. In doing so, however, it can block or decrease muscle contractile, resulting in effects like vasodilation, hypotension, and irregular heart rate, among others [F4349, L5930, L5948]. As a result, lidocaine is also considered a class Ib anti-arrhythmic agent [L
|
A 9,10alpha-dihydro derivative of [ergotamine]. Dihydroergotamine is used as an abortive therapy for migraines. Its use has largely been supplanted by triptans in current therapy due to the class's greater selectivity and more favourable side effect profile. Recent improvements have been made in the design of intranasal delivery devices allowing for greater delivery of dihydroergotamine solution to the vasculature-rich upper nasal cavity. The recently approved Precision Olfactory Delivery technology developed by Impel Neuropharma technology has correlated with an increase of 3-fold in Cmax and 4-fold in AUC despite the solution formulated at 75% of the strength of the existing intranasal product.
|
The metabolism of Dihydroergotamine can be decreased when combined with Lidocaine.
| 46 |
[
[
[
611,
69,
530
]
],
[
[
611,
6,
8339
],
[
8339,
160,
530
]
],
[
[
611,
21,
28512
],
[
28512,
175,
530
]
],
[
[
611,
180,
173
],
[
173,
26,
530
]
],
[
[
611,
95,
1028
],
[
1028,
195,
530
]
],
[
[
611,
95,
1038
],
[
1038,
201,
530
]
],
[
[
611,
223,
486
],
[
486,
213,
530
]
],
[
[
611,
192,
543
],
[
543,
213,
530
]
],
[
[
611,
225,
453
],
[
453,
69,
530
]
],
[
[
611,
69,
59
],
[
59,
69,
530
]
]
] |
[
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} (Compound) binds {v} (Gene)",
"ABCB1"
],
[
"ABCB1",
"{u} (Gene) is bound by {v} (Compound)",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} (Compound) causes {v} (Side Effect)",
"Dizziness"
],
[
"Dizziness",
"{u} (Side Effect) is caused by {v} (Compound)",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} can increase the metabolism of {v}",
"Nevirapine"
],
[
"Nevirapine",
"{u} can increase the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may increase the serum concentration of {v}",
"Metipranolol"
],
[
"Metipranolol",
"{u} may increase the vasoconstricting activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may increase the serum concentration of {v}",
"Nadolol"
],
[
"Nadolol",
"{u} may increase the atrioventricular blocking activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Doxepin"
],
[
"Doxepin",
"{u} may decrease the antihypertensive activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may increase the central nervous system depressant activities of {v}",
"Mirtazapine"
],
[
"Mirtazapine",
"{u} may decrease the antihypertensive activities of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may increase the severity of adverse effects when combined with {v}",
"Risperidone"
],
[
"Risperidone",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
]
],
[
[
"Lidocaine",
"{u} may decrease the metabolism of {v}",
"Quinidine"
],
[
"Quinidine",
"{u} may decrease the metabolism of {v}",
"Dihydroergotamine"
]
]
] |
Lidocaine (Compound) binds ABCB1 (Gene) and ABCB1 (Gene) is bound by Dihydroergotamine (Compound)
Lidocaine (Compound) causes Dizziness (Side Effect) and Dizziness (Side Effect) is caused by Dihydroergotamine (Compound)
Lidocaine can increase the metabolism of Nevirapine and Nevirapine can increase the metabolism of Dihydroergotamine
Lidocaine may increase the serum concentration of Metipranolol and Metipranolol may increase the vasoconstricting activities of Dihydroergotamine
Lidocaine may increase the serum concentration of Nadolol and Nadolol may increase the atrioventricular blocking activities of Dihydroergotamine
Lidocaine may decrease the metabolism of Doxepin and Doxepin may decrease the antihypertensive activities of Dihydroergotamine
Lidocaine may increase the central nervous system depressant activities of Mirtazapine and Mirtazapine may decrease the antihypertensive activities of Dihydroergotamine
Lidocaine may increase the severity of adverse effects when combined with Risperidone and Risperidone may decrease the metabolism of Dihydroergotamine
Lidocaine may decrease the metabolism of Quinidine and Quinidine may decrease the metabolism of Dihydroergotamine
|
DB00490
|
DB01063
| 254 | 1,378 |
Buspirone
|
Acetophenazine
|
Buspirone is a novel anxiolytic agent with a unique structure and a pharmacological profile. Belonging to the azaspirodecanedione drug class, buspirone is a serotonin 5-HT<sub>1A</sub> receptor agonist that is not chemically or pharmacologically related to benzodiazepines, barbiturates, and other sedative/anxiolytic drugs. Unlike many drugs used to treat anxiety, buspirone does not exhibit anticonvulsant, sedative, hypnotic, and muscle-relaxant properties. Due to these characteristics, buspirone been termed 'anxioselective'. First synthesized in 1968 then patented in 1975, it is commonly marketed under the brand name Buspar®. Buspirone was first approved in 1986 by the FDA and has been used to treat anxiety disorders, such as generalized anxiety disorder (GAD), and relieve symptoms of anxiety
|
Acetophenazine is an antipsychotic drug of moderate-potency. It is used in the treatment of disorganized and psychotic thinking. It is also used to help treat false perceptions (e.g. hallucinations or delusions). It primarily targets the dopamine D2 receptor.
|
The risk or severity of adverse effects can be increased when Buspirone is combined with Acetophenazine.
| 48 |
[
[
[
254,
71,
1378
]
],
[
[
254,
71,
973
],
[
973,
155,
1378
]
],
[
[
254,
71,
525
],
[
525,
1,
1378
]
],
[
[
254,
225,
270
],
[
270,
155,
1378
]
],
[
[
254,
69,
392
],
[
392,
1,
1378
]
],
[
[
254,
240,
175
],
[
175,
71,
1378
]
],
[
[
254,
249,
379
],
[
379,
155,
1378
]
],
[
[
254,
6,
7309
],
[
7309,
160,
1378
]
],
[
[
254,
71,
997
],
[
997,
57,
1378
]
],
[
[
254,
71,
18
],
[
18,
58,
1378
]
]
] |
[
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Aceprometazine"
],
[
"Aceprometazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Perphenazine"
],
[
"Perphenazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Prochlorperazine"
],
[
"Prochlorperazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may decrease the metabolism of {v}",
"Chlorpromazine"
],
[
"Chlorpromazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the serotonergic activities of {v}",
"Trazodone"
],
[
"Trazodone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the serum concentration of {v}",
"Ranolazine"
],
[
"Ranolazine",
"{u} (Compound) resembles {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} (Compound) binds {v} (Gene)",
"DRD2"
],
[
"DRD2",
"{u} (Gene) is bound by {v} (Compound)",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Lithium cation"
],
[
"Lithium cation",
"{u} may increase the neurotoxic activities of {v}",
"Acetophenazine"
]
],
[
[
"Buspirone",
"{u} may increase the severity of adverse effects when combined with {v}",
"Sulpiride"
],
[
"Sulpiride",
"{u} may increase the antipsychotic activities of {v}",
"Acetophenazine"
]
]
] |
Buspirone may increase the severity of adverse effects when combined with Aceprometazine and Aceprometazine (Compound) resembles Acetophenazine (Compound)
Buspirone may increase the severity of adverse effects when combined with Perphenazine and Perphenazine (Compound) resembles Acetophenazine (Compound)
Buspirone may increase the severity of adverse effects when combined with Prochlorperazine and Prochlorperazine (Compound) resembles Acetophenazine (Compound)
Buspirone may decrease the metabolism of Chlorpromazine and Chlorpromazine (Compound) resembles Acetophenazine (Compound)
Buspirone may increase the serotonergic activities of Trazodone and Trazodone may increase the severity of adverse effects when combined with Acetophenazine
Buspirone may increase the serum concentration of Ranolazine and Ranolazine (Compound) resembles Acetophenazine (Compound)
Buspirone (Compound) binds DRD2 (Gene) and DRD2 (Gene) is bound by Acetophenazine (Compound)
Buspirone may increase the severity of adverse effects when combined with Lithium cation and Lithium cation may increase the neurotoxic activities of Acetophenazine
Buspirone may increase the severity of adverse effects when combined with Sulpiride and Sulpiride may increase the antipsychotic activities of Acetophenazine
|
DB00014
|
DB00412
| 1,187 | 514 |
Goserelin
|
Rosiglitazone
|
Goserelin is a synthetic hormone. In men, it stops the production of the hormone testosterone, which may stimulate the growth of cancer cells. In women, goserelin decreases the production of the hormone estradiol (which may stimulate the growth of cancer cells) to levels similar to a postmenopausal state. When the medication is stopped, hormone levels return to normal.
|
Rosiglitazone is an anti-diabetic drug in the thiazolidinedione class of drugs. It is marketed by the pharmaceutical company GlaxoSmithKline as a stand-alone drug (Avandia) and in combination with metformin (Avandamet) or with glimepiride (Avandaryl). Like other thiazolidinediones, the mechanism of action of rosiglitazone is by activation of the intracellular receptor class of the peroxisome proliferator-activated receptors (PPARs), specifically PPARγ. Rosiglitazone is a selective ligand of PPARγ, and has no PPARα-binding action. Apart from its effect on insulin resistance, it appears to have an anti-inflammatory effect: nuclear factor kappa-B (NFκB) levels fall and inhibitor (IκB) levels increase in patients on rosiglitazone. Recent research has suggested that rosiglitazone may also be
|
The therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Goserelin.
| 69 |
[
[
[
1187,
92,
514
]
],
[
[
1187,
196,
614
],
[
614,
1,
514
]
],
[
[
1187,
21,
28488
],
[
28488,
175,
514
]
],
[
[
1187,
42,
354
],
[
354,
182,
514
]
],
[
[
1187,
196,
784
],
[
784,
182,
514
]
],
[
[
1187,
196,
884
],
[
884,
185,
514
]
],
[
[
1187,
42,
878
],
[
878,
185,
514
]
],
[
[
1187,
92,
526
],
[
526,
31,
514
]
],
[
[
1187,
196,
589
],
[
589,
31,
514
]
],
[
[
1187,
42,
1018
],
[
1018,
31,
514
]
]
] |
[
[
[
"Goserelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Dofetilide"
],
[
"Dofetilide",
"{u} (Compound) resembles {v} (Compound)",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} (Compound) causes {v} (Side Effect)",
"Eye disorder"
],
[
"Eye disorder",
"{u} (Side Effect) is caused by {v} (Compound)",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Sevoflurane"
],
[
"Sevoflurane",
"{u} may increase the anticoagulant activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Anagrelide"
],
[
"Anagrelide",
"{u} may increase the anticoagulant activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Levofloxacin"
],
[
"Levofloxacin",
"{u} may increase the hypoglycemic activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Paroxetine"
],
[
"Paroxetine",
"{u} may increase the hypoglycemic activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may decrease the therapeutic efficacy of {v}",
"Glyburide"
],
[
"Glyburide",
"{u} may increase the hypoglycemic activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Disopyramide"
],
[
"Disopyramide",
"{u} may increase the hypoglycemic activities of {v}",
"Rosiglitazone"
]
],
[
[
"Goserelin",
"{u} may increase the QTc prolonging activities of {v}",
"Sunitinib"
],
[
"Sunitinib",
"{u} may increase the hypoglycemic activities of {v}",
"Rosiglitazone"
]
]
] |
Goserelin may increase the QTc prolonging activities of Dofetilide and Dofetilide (Compound) resembles Rosiglitazone (Compound)
Goserelin (Compound) causes Eye disorder (Side Effect) and Eye disorder (Side Effect) is caused by Rosiglitazone (Compound)
Goserelin may increase the QTc prolonging activities of Sevoflurane and Sevoflurane may increase the anticoagulant activities of Rosiglitazone
Goserelin may increase the QTc prolonging activities of Anagrelide and Anagrelide may increase the anticoagulant activities of Rosiglitazone
Goserelin may increase the QTc prolonging activities of Levofloxacin and Levofloxacin may increase the hypoglycemic activities of Rosiglitazone
Goserelin may increase the QTc prolonging activities of Paroxetine and Paroxetine may increase the hypoglycemic activities of Rosiglitazone
Goserelin may decrease the therapeutic efficacy of Glyburide and Glyburide may increase the hypoglycemic activities of Rosiglitazone
Goserelin may increase the QTc prolonging activities of Disopyramide and Disopyramide may increase the hypoglycemic activities of Rosiglitazone
Goserelin may increase the QTc prolonging activities of Sunitinib and Sunitinib may increase the hypoglycemic activities of Rosiglitazone
|
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.